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1. KIDNEY TRANSPLANTATION
Kidney transplantation is the preferred treatment of choice for almost all categories of patients 
with end-stage-renal disease (ESRD) including those with hypertension, glomerulonephritis, 
diabetes mellitus and genetic causes as polycystic renal disease. Transplanted patients will 
live approximately 10-15 years longer than patients that remain on dialysis. In light of the 
increased donor shortage and the increasing waiting time, the number of kidney transplants 
from living donors enormously increased during the last decade. Complete matching for 
major Human Leucocyte Antigen (HLA) molecules between donor and recipients is preferable, 
but due to the high degree of polymorphism of HLA, only some recipients with a suitable 
living-related sibling donor receive a fully HLA-identical donor kidney.1
1.1 HLA-mismatched kidney transplantation
After HLA-mismatched deceased or living kidney donation, the primary targets of the immune 
response of the transplant recipient are the major HLA molecules present on the donor 
kidney. Mismatches in major HLA molecules between donor and recipient may provoke strong 
immune responses resulting in graft rejection when not treated with immunosuppressive 
medication.2
Allorecognition may occur via the direct or indirect recognition pathway (Figure 
1).2, 3 The direct allorecognition pathway involves recipient T cells recognising intact major 
HLA molecules presented by donor antigen presenting cells (APC). The most potent APC 
are dendritic cells (DC).4 The indirect allorecognition pathway refers to the recognition of 
recipient T cells recognising peptides from donor origin presented by self-HLA molecules on 
recipient APC. In both recognition pathways, recipient CD4+ and CD8+ T cells may contribute 
to graft rejection. The frequency of responding T cells is high in the direct allorecognition 
pathway, whereas in the indirect allorecognition pathway the frequency of responding T cells 
is low.5 The direct allorecognition pathway plays an important role in the early phase after 
organ transplantation, and is thought to play a significant role during acute rejection. Donor 
cells migrate to recipient lymph nodes for presentation to recipient T cells.2, 6 The indirect 
allorecognition pathway plays a role in the late phase after transplantation, and it has been 
proposed to be responsible for the development of chronic allograft rejection.2, 7
Figure 1: Direct and indirect allorecognition pathway after kidney transplantation. During direct al-
lorecognition, recipient T cells recognize intact HLA molecules presented by donor antigen pre-
senting cells (APC). During indirect recognition, recipient T cells recognize donor peptides af-
ter they have been processed and presented by self-HLA molecules on the surface of recipient APC.
donor HLA 
Donor peptide 
Direct allorecognition 
pathway
Indirect allorecognition 
pathway
recipient HLA
donor 
APC
Recipient 
APC 
T cell T cell
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1.2 HLA-identical living-related kidney transplantation
After HLA-identical living-related (LR) kidney transplantation, all major HLA molecules (HLA-
A, B, C, DR, DP and DQ) from recipient and donor are identical, only mismatches in non-HLA 
antigens, like minor histocompatibility antigens (mHAgs) may exist. mHAgs are genetic 
inherited peptides derived from polymorphic intracellular proteins presented in the context 
of HLA class I and II molecules, which can be recognized by recipient T cells.8 In humans, the 
number of identified mHAgs has been expanded, reaching 17 autosomally encoded mHAgs 
and 10 Y-chromosome encoded antigens (Table 1).9, 10 The expression of mHAgs is broad or 
restricted, e.g. specific for proximal tubular epithelial cells of the kidney or haematopoietic 
cells.8, 10 In contrast to the strong immune responses directed to major HLA molecules, 
responses to mHAgs do not provoke strong immune responses in cellular tests.8
In humans, the clinical relevance of mHAgs has almost exclusively been shown after 
bone marrow transplantation (BMT).10 The first indication that mHAgs could be important 
for transplant outcome was observed in a female patient, who had aplastic anaemia, 
transplanted with bone marrow from her HLA-identical brother. This patient had cytotoxic 
T-lymphocytes (CTL), which recognised structures restricted to male cells encoded by the 
structures on the Y chromosome.11, 12
The clinical relevance of mHAgs after solid organ transplantation is yet not clear. 
After HLA-identical LR kidney transplantation, mismatches in mHAgs13 and other non-HLA 
antigens14 between donor and recipient may induce an immune response that may result 
into rejection of the donor kidney. Krishnan et al.15 reported an association between HA-1 
mismatches in HLA-A2 matched donor-recipient pairs and chronic allograft nephropathy 
(CAN) evidenced by increased graft failure.In contrast, Heinold et al.16 reported that 
mismatches in mHAgs between donor and recipient had no influence on the 5-years graft 
survival.
One report showed that mHAgs could be relevant after HLA-identical LR sibling 
kidney transplantation. Despite treatment of azathioprine (AZA) and prednisone, a female 
patient who received a donor kidney from her HLA-identical brother, experienced acute 
rejection within 3 weeks.17 In this report was demonstrated in cell-mediated lympholysis 
(CML) that cytotoxic T cells from the patient were directed to male-specific HY mHAg. 
We showed that donor immune reactivity can also be determined by IFN-g Elispot 
assay in the first period after HLA-identical LR kidney transplantation.18 
1.3 Organ allograft rejection and immunosuppressive medication
Renal allograft rejection can be classified into hyperacute rejection, acute rejection, and 
CAN. Hyperacute rejection occurs rapidly within 24 hours after transplantation due to pre-
existing humoral antibodies against donor cells, while acute rejection may occur in the first 
three months after kidney transplantation.19 CAN is a main cause of late renal failure and 
limits the long-term outcome of organ transplantation.20 Clinically, CAN is characterised by a 
decrease in renal function and the development of proteinuria, but also chronic damage, e.g. 
atherosclerosis, glomerulosclerosis, interstitial fibrosis and tubular atrophy, demonstrated in 
renal biopsies.20, 21
To prevent graft rejection, transplant recipients receive immunosuppressive 
medication to suppress the immune response directed to the foreign organ. In 1954, the 
first kidney transplantation was performed between HLA-identical twins to prevent problems 
of an immune rejection.22 The first successful kidney transplantation between non-twins 
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was performed five years later.23 The latter recipient received total body radiation pre-
transplantation to decrease the strength of the immune system.
Nowadays, kidney transplantation is the preferred renal replacement therapy. 
Patients with chronic renal failure who have a living donor available are able to receive 
a renal transplant before dialysis is needed. In our transplant center, the 1-, 5- and 10-
years unadjusted (not censored for death) renal graft survival is 78%, 56% and 39%, 
respectively, in deceased donors. The graft survival at 1-, 5- and 10-years in recipients of 
LR not HLA-identical donor is 89%, 78% and 61%, respectively, and is 93%, 84% and 70%, 
respectively, in recipients of a LR HLA-identical sibling donors (Figure 2).
The development of immunosuppressive drugs, to inhibit the reaction of the immune 
system, improved the prevention and treatment of acute rejection.24 For the last 50 
years, corticosteroids and azathioprine (AZA) have been used in organ transplantation 
as immunosuppressive medication. Corticosteroids influences genes involving in priming 
the innate immune response, suppresses pro-inflammatory cytokines and promote anti-
inflammatory cytokines.25 AZA inhibits the proliferation of activated immune cells by 
interfering with DNA synthesis.25, 26 In the early 1980s, cyclosporine A (CsA) was introduced 
as a new immunosuppressive drug, and the number of acute rejections significantly 
decreased. CsA is a calcineurin inhibitor (CNI), which binds to cyclophilin resulting into 
inactive calcineurin. Consequently, calcineurin is unable to dephosphorylate nuclear factor of 
activated T cells (NFAT), and therefore, IL-2 production is prevented.25, 26 In the last decade, 
also other immunosuppressive agents became available, including tacrolimus (another CNI), 
mycophenolate mofetil (MMF), sirolimus and everolimus, daclizumab and basiliximab, and 
leflunomide.25, 26
Despite successful treatment of transplant recipients with immunosuppressive 
drugs to prevent allograft rejection, life-long administration of immunosuppressive drugs 
after transplantation is deemed necessary. However, long-term use of immunosuppression 
is associated with severe side-effects, such as malignancies, infections, nephrotoxicity, 
hypertension, diabetes mellitus and osteoporosis.26-28 Consequently, tapering or withdrawal 
of immunosuppression is warranted, provided this is not accompanied with transplant 
rejection. Therefore, it is important to identify patients in whom the immunosuppressive 
load can be tapered or even withdrawn to reduce the side-effects of immunosuppression.
Figure 2: The unadjusted (not censored for death) graft survival after kidney transplantation in Erasmus 
Medical Center, Rotterdam, The Netherlands. Recipients of a deceased donor kidney are presented as dotted 
line, recipients of a living-related not HLA-identical donor kidney are presented as dashed line (HLA-mm LR), 
and recipients of a living-related HLA-identical sibling donor kidney are presented as solid line (HLA-id LR).
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2. IMMUNE MONITORING BEFORE AND AFTER KIDNEY TRANSPLANTATION
Monitoring for the presence of immunological activity directed to the graft is necessary 
to identify patients in whom the immunosuppressive medication can be safely tapered. 
Biopsies taken from the donor kidney may provide valuable information. Unfortunately, this 
is an invasive technique and unpleasant for the transplant recipient. Therefore, it should be 
avoided for routine diagnoses. Immune monitoring in peripheral blood would be preferred.
There are several non-invasive assays using PBMC to determine immune reactivity 
to donor antigens, e.g. mixed lymphocyte reaction (MLR), cell-mediated lympholysis (CML), 
CTL precursor frequency (CTLpf), helper T-lymphocyte precursor frequency (HTLpf), Elispot 
assay, flow cytometry, tetramer staining, measurement of donor-specific alloantibodies and 
cytokine mRNA quantification.29 Here, the focus was only on donor-specific assays in PBMC: 
proliferative capacity of PBMC in MLR, cytotoxic and helper reactivity in CTLpf and HTLpf, 
respectively, and the frequency of cytokine producing cell in Elispot assay.
In an one-way mixed lymphocyte culture or MLR, the proliferative capacity of 
recipient cells to donor cells is determined. Using CML, the capacity of recipients’ cytotoxic 
T-lymphocytes (CTL) to kill donor cells can be determined. The number of recipients’ CTL 
responding to donor antigens can be measured in limiting dilution assays (LDA).30-32 The 
supernatant of the LDA in combination with an IL-2-dependent murine CTLL-2 cell line can 
be used to determine the number of helper T-lymphocytes (HTLpf).33-35 The Elispot assay 
(Enzyme-Linked ImmunoSpot assay) is designed to enumerate cytokine secreting cells 
directed to donor cells.18, 36
2.1 Immune monitoring of alloreactivity before kidney transplantation
Pretransplant determination of HLA and anti-HLA antibodies [panel-reactive antibodies (PRA) 
and cross match] has been in practice during the last 4 decennia to prevent hyperacute 
rejection.
The percentage PRA is the percentage of cells from a panel of blood donors against 
which potential recipients’ serum reacts. The higher the PRA, the more sensitized a patient is 
to the general donor pool, and thus more difficult to find a suitable donor. When a potential 
suitable donor is available, a cross match is performed to detect possible preformed antibodies 
in a potential recipients’ blood against antigens on the surface of a potential donor cells. In 
our center, both current and historic serum had to be cross match negative with the potential 
donor cells to prevent hyperacute rejection after renal transplantation.
Before kidney transplantation it is important to identify those patients who are 
at risk for future allograft rejection.30, 35-41 Poggio et al.38 and Andree et al.41 described the 
humoral response in combination with the cellular response as screening method before 
transplantation. The cellular response was based on T-cell alloreactivity to a panel of allogeneic 
stimulator PBMC from healthy individuals by analysing the number of IFN-g producing cells 
using Elispot assays, creating a Panel of Reactive T-cell (PRT) assay. The percentage PRT 
is the percentage of stimulators that stimulated memory T cells, i.e. IFN-g producing cells. 
Haemodialysis patients had higher PRT values than healthy individuals.41 T-cell alloreactivity 
based on PRT can be independent of positive PRA, and vice versa.38 Increased number of 
patients have to be tested to assess the pretransplant risk for acute rejection by PRT.
Several studies demonstrated that pretransplant CTLpf30, 35, 42 and MLR42 failed to 
predict the clinical outcome after renal transplantation. Nevertheless, we demonstrated 
that both high HTLpf and MLR determined before kidney transplantation were predictive 
Chapter 1
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for patients who developed acute rejection in the first year after kidney transplantation.35 
Patients with low or undetectable donor-specific HTLpf and MLR remained free from acute 
rejection.35
Also, the number of IFN-g producing cells determined by Elispot assays has been 
correlated with posttransplantation outcomes.36, 37, 39, 43 Increased pretransplant frequency of 
donor-specific IFN-g producing cells was related with posttransplant risk for acute rejections36, 
39, and impaired posttransplant renal function.37
2.2 Immune monitoring of alloreactivity after tapering or withdrawal of 
immunosuppression in HLA-mismatched kidney transplant recipients
After kidney transplantation, patients receive a maintenance dose of immunosuppression 
to prevent graft rejection. Chronic use of immunosuppression is associated with severe 
side-effects.26-28 Therefore, nowadays, an important goal after kidney transplantation is to 
identify those patients in whom the immunosuppressive load can be safely reduced. Most of 
these studies were performed in the HLA-mismatched kidney transplant setting.31, 32, 44-56 
Some studies described the withdrawal or avoidance of steroids after kidney 
transplantation.48, 49 Other studies reported good results by withdrawal of CNI45 or converting 
from CNI to AZA or MMF50-53, or halving the AZA or MMF dose.47, 54
Most of the studies did not correlate the ability of successfully tapering the 
immunosuppressive drugs with in vitro immune function. Some studies evaluated the 
MLR and others the CML assay.45, 55, 56 However, because of small number of patients, a 
limited prognostic factor was found between MLR or CML reactivity of patients’ cells to 
donor antigens and acute graft rejection. A study from Beik et al.44 suggested that donor-
specific hyporeactivity was associated with a lower incidence of acute rejection after steroid 
withdrawal in a small cohort of kidney transplant recipients.
Our group studied stable renal transplant recipients, who were routinely converted 
from CsA and prednisone to either AZA or MMF in combination with prednisone at 1-year 
after kidney transplantation. Thereafter, the AZA or MMF dose was tapered to 50% of their 
original dose.31, 46, 51 Clinically, conversion of CsA to AZA or MMF improved serum creatinine 
levels. After conversion, less acute rejection occurred in the MMF group (4/34) compared 
to the AZA group (11/30). Tapering of AZA or MMF was possible in most of the patients, 
only three acute rejections occurred in both groups during tapering of AZA (3/25) or MMF 
(3/26).51 We demonstrated that donor-specific CTLpf determined before conversion to AZA 
or MMF was higher in patients who experienced acute rejection after conversion compared 
to patients who remained free from acute rejection (Figure 3), while no difference was 
observed in third-party reactivity. No relation was found with tetanus toxoid responses, 
donor-specific and third-party responses in MLR and HTLpf. Because a donor-specific CTLpf 
of <10 CTL/106 PBMC had a positive predictive value of 100% for not developing rejection 
after conversion from CsA to AZA or MMF, we suggest that renal transplant recipients with no 
or low numbers of donor-specific CTLpf could be safely tapered in their immunosuppressive 
load.31 Subsequently, the T-cell reactivity was determined before and after tapering of AZA 
or MMF.46 Donor and third-party reactivity determined in MLR, CTLpf and HTLpf was not 
affected after tapering of AZA or MMF, while tetanus toxoid reactivity was increased.
Recently, we showed that withdrawal of CNI in kidney transplant recipients at least 2 
years after kidney transplantation was associated with a significant decrease in donor-specific 
CTLpf, while third-party reactive CTLpf, donor and third-party reactive MLR and IFN-g Elispot 
remained unaffected. Moreover, the percentage of CD4+CD25brightCTLA-4+ T cells (regulatory 
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Figure 3: Frequencies of donor-speci-
fic CTLp before conversion of CsA to AZA 
or MMF from patients who remained free 
from acute rejection and from patients who 
experienced acute rejection after conver-
sion. The significance of difference was 
calculated with the Mann-Whitney U-test.
T cells) was increased.32 Regulatory cells have the ability to regulate alloresponses. These 
cells may also regulate effector CTLp. Therefore, we speculate that CNI inhibits regulatory 
mechanism that could downregulate donor responses. Consequently, after CNI withdrawal, 
the immunosuppression could be tapered further. Thereafter, we indeed demonstrated that 
patients, who had donor-specific CTLpf below 10/106 PBMC, can be tapered to 50% of their 
AZA or MMF dose without affecting their serum creatinine.47, 54
Nowadays, changes in number of circulating regulatory T cells are a hype in models 
of tolerance. An increased number of CD4+CD25high in tolerant liver transplant recipients 
is reported.57 In small cohort of kidney transplant recipients it was shown that clinically 
tolerant patients did not differ in their number of CD4+CD25high from healthy individuals, 
while chronic allograft nephropathy is associated with a decrease in CD4+CD25high.58 To our 
knowledge controlled studies on tolerance and regulatory cells are not yet described.
The group of Soulillou59 showed that five tolerant kidney transplant patients have a 
for transplant recipients unique blood T-cell repertoire of T-cell receptor Vβ and CDR3 usage 
compared to patients with CAN and stable patients with immunosuppression. This assay 
using polymerase chain reaction (PCR) and TcLandscape analyses does not need donor cells, 
but the importance of this assay had to be confirmed in larger series.
DC are APC that may initiate and regulate immune responses.4 DC can be divided into myeloid 
DC (mDC) and plasmacytoid DC (pDC). mDC produce high levels of IL-12 and induce T-helper 
1 and CTL responses. In contrast, pDC produce IFN-a and seems to play a role induction 
of T-helper 2 responses.60 Moreover, Kuwana et al.61 suggested that pDC can be involved 
in the induction of peripheral T-cell tolerance after organ transplantation. Several studies 
showed that immunosuppression in transplant recipients influence DC subset numbers.62-64 
After liver transplantation, patients who were completely off immunosuppression had higher 
pDC/mDC ratio compared to patients on maintenance therapy.65 These results indicate that 
without using donor cells tolerant transplant recipients can be identified.
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2.3 Immune monitoring after HLA-identical LR kidney transplantation
In the HLA-identical LR kidney transplant setting, no donor-reactive T-cell responses directed 
to non-HLA antigens, i.e. mHAgs, can be determined by MLR, CTLpf and HTLpf.18 However, in 
the IFN-g Elispot assay significant responses were found after stimulation with donor cells.18 
Recently, we found that HLA-identical LR kidney transplant recipients had significantly lower 
numbers of donor-reactive IFN-g producing cells two years after transplantation than at a 
stable period 3 months after transplantation (Figure 4). However, some patients had detectable 
numbers of donor-reactive IFN-g producing cells even long after kidney transplantation. No 
literature is known about the necessity of long-term use of immunosuppression in HLA-
identical LR kidney transplant recipients, and whether withdrawal of immunosuppression 
influenced donor-reactive T-cell responses.
2.4 Immune monitoring of chronic rejection
The long-term outcome after kidney transplantation remains still a problem due to CAN20. It 
has been suggested that the indirect recognition pathway plays a role in CAN.2, 20
A report from Ciubotariu et al.66 showed that the indirect recognition pathway 
contributes to the development of coronary artery vasculopathy (CAV) in heart transplant 
recipients. Hornick et al.67 could detect in 5 out of 7 heart transplant recipients with CAV, 
elevated frequencies of T cells with indirect anti-donor specificity, while no indirect anti-
donor reactivity was detected in patients without CAV. Recently, we found increased donor-
reactivity via the indirect recognition pathway during late acute rejection episodes after 
clinical heart transplantation.68
Baker et al.69 showed in renal transplant recipients (with and without CAN), long 
after kidney transplantation, donor-specific hyporesponsiveness via the direct recognition 
pathway according to proliferation, CTLpf and cytokine secretion of IFN-g, IL-2 and IL-5. 
Remarkable was that anti-donor proliferative response via the indirect recognition pathway 
was higher in patients with CAN compared to patients without CAN. Recently, Poggio et 
al.7 reported that renal transplant recipients with CAN had higher IFN-g Elispot responses 
compared to those without CAN. These results suggest that the indirect recognition pathway 
play is a relevant tool to monitor late acute rejection and chronic rejection long after organ 
transplantation.
Figure 4: Number of donor-reactive IFN-
g producing cell (pc) determined in PBMC 
from HLA-identical living-related kidney 
transplant recipients 3 months after kid-
ney transplantation and 2 years after kidney 
transplantation. The Mann-Whitney U-test 
was used to compare the patient groups.
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The aim of this thesis is to clarify the clinical relevance of donor-reactive T-cell responses 
directed to minor histocompatibility antigens (mHAgs) after HLA-identical living-related (LR) 
kidney transplantation. The thesis is divided in two parts: (1) ‘Donor-reactive T-cell responses 
after HLA-identical LR kidney transplantation’ and (2) ‘Tapering of immunosuppression after 
HLA-identical LR kidney transplantation’.
 In Chapter 1 we describe non-invasive cell mediated immune assays to determine 
donor-reactive T-cell responses in peripheral blood from transplant recipients taken before 
transplantation and during tapering or withdrawal of immunosuppression. Those donor-
reactive T-cell responses could be helpful to identify transplant recipients in whom the 
immunosuppressive load can be safely reduced.
After HLA-identical sibling donor bone marrow transplantation (BMT), graft-versus-
host disease may occur which is likely due to alloantigens known as mHAgs.1 However, the 
clinical relevance of mHAgs after HLA-identical LR kidney transplantation is yet unknown. 
Given the existence of possibly hundreds of mHAgs2, it is reasonable to suggest that 
transplant outcome might be influenced by mHAg disparities between HLA-identical donor-
recipient pairs. Therefore, theoretically, if immune reactivity occurs after HLA-identical 
LR kidney transplantation, it should be directed to mismatched mHAgs or other non-HLA 
antigens present on the donor kidney. 
It has been reported that donor-reactive T-cell responses may decrease during the first 
year after HLA-mismatched organ transplantation.3-7 Chapter 3 describes whether donor-
reactive IFN-g and granzyme B (GrB) producing cells also decreases during the first year after 
HLA-identical LR kidney transplantation. Donor-recipient couples were typed for 11 known 
mHAgs in an endeavour to relate the number of known mHAg mismatches between donor 
and recipient with the number of donor-reactive cytokine producing cells. Chapter 4 studies 
the number of donor-reactive cytokine producing cells (IFN-g, IL-10, GrB, IL-13) after HLA-
identical LR kidney transplantation and after HLA-mismatched LR kidney transplantation to 
investigate whether donor reactivity in the HLA-identical setting was different from the HLA-
matched setting during immunological quiescence. Healthy individuals served as controls. 
Chapter 5 describes the expression profile of 42 cytokines in donor-stimulated mixed 
lymphocyte cultures from peripheral blood mononuclear cells (PBMC) of HLA-identical LR 
kidney transplant recipients using a novel protein array. 
Monitoring of myeloid dendritic cells (mDC) and plasmacytoid DC (pDC) in peripheral 
blood following liver transplantation might identify patients in whom the immunosuppressive 
dose can be safely tapered.8 Since it is less time consuming and more accurate to measure 
sequential blood samples of one patient in one flow cytometric session, we examined the 
effect of cryopreservation of PBMC from kidney transplant recipients on mDC and pDC 
percentages and the expression of maturation markers in comparison to fresh blood cells as 
described in Chapter 6. In addition, PBMC from kidney transplant recipients were compared 
with heart failure patients, who received no immunosuppressive medication, to study the 
influence of immunosuppression on the DC subsets.
In general, recipients of an HLA-identical LR kidney transplant receive the same 
immunosuppressive medication as those of an HLA-mismatched kidney transplant. Because 
the necessity of long-term use of immunosuppression in HLA-identical LR kidney transplant 
recipients is yet unknown, we questioned whether these patients could be tapered in their 
immunosuppressive load despite mismatches in mHAgs between donor and recipient. 
Theoretically, tapering or withdrawal of immunosuppression in organ transplant recipients may 
Aim and outline of the thesis
25
result into increased alloreactivity.9-12 Therefore, immunological monitoring of donor reactivity 
in those patients could be helpful to identify patients in whom the immunosuppressive load 
can be safely reduced or even withdrawal. Previously, we demonstrated that donor reactivity 
can be determined after HLA-identical LR kidney transplantation.13
Chapter 7 and 8 studies the effect of halving the azathioprine (AZA) dose in HLA-
identical LR kidney transplant recipients on renal function and on T-cell reactivity determined 
by the number of IFN-g, IL-13 and GrB producing cells against donor, 3rd-party and tetanus 
toxoid. 
Thereafter, in patients on mycophenolate mofetil (MMF) or AZA in combination with 
prednisolone therapy the AZA and MMF dose was withdrawal. Chapter 9 describes the clinical 
results after discontinuation of AZA or MMF and the two years follow-up of these patients on 
prednisolone monotherapy. In the same patient group, the effect of discontinuation of MMF 
and AZA on T-cell reactivity and DC subsets is described in Chapter 10. T-cell reactivity was 
determined using IFN-g, IL-10 and GrB Elispot assays, and circulating DC subset numbers 
and their maturation status were determined by flow cytometry. In Chapter 11, the effect 
of MMF or AZA withdrawal on 17 soluble cytokines from supernatant of donor-stimulated 
mixed lymphocyte reactions determined by multiplex bead array technique was analysed. 
Finally, the results described in this thesis are summarized and discussed in Chapter 
12.
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Abstract
Background: It has been reported that donor-reactive T-cell responses may decrease during 
the first year after HLA-mismatched organ transplantation. We wondered whether donor-
reactive T-cell responses directed to minor histocompatibility antigens (mHAgs) or other non-
HLA antigens also decrease after HLA-identical living-related (LR) kidney transplantation.
Methods: We studied donor-reactive T-cell responses by IFN-g and granzyme B (GrB) 
Elispot assays in 15 HLA-identical LR kidney transplant recipients before, 6-months and 
one year after transplantation. Third-party reactivity was used as control. Patient and donor 
peripheral blood mononuclear cells were typed for 11 known mHAgs.
Results: During the study period, 60% and 36% of the patients demonstrated donor-
reactive IFN-g and GrB producing cells (pc), respectively. The number of donor-reactive 
IFN-g and GrB pc was significantly lower than the number of third-party reactive IFN-g and 
GrB pc. After transplantation, donor-reactivity and third-party reactivity were comparable 
to pretransplant values. No relation was found in mHAg mismatches between donor and 
recipient and donor-reactive T-cell response.
Conclusions: Donor-reactivity could be detected before and after HLA-identical LR kidney 
transplantation, but was not related with the number of mHAg mismatches, and did not 
decrease after transplantation. 
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INTRODUCTION
Kidney transplantation is the preferred treatment of choice for patients with end-stage-renal 
disease. In case of kidney transplantation, complete matching for major HLA molecules 
between donor and recipients is preferable. However, due to the high degree of polymorphism 
of HLA, only recipients with a suitable living-related (LR) sibling donor can receive a fully 
HLA-identical donor kidney.1 
Apart from major HLA molecules, also other antigens may elicit an immune response 
after transplantation, for example, minor histocompatibility antigens (mHAgs). mHAgs are 
peptides derived from polymorphic proteins which can be presented in HLA class I or II 
molecules and are inherited independently of HLA.2 In humans, the clinical relevance of 
mHAgs has been shown after bone marrow transplantation (BMT).3 Therefore, theoretically, 
immune responses after HLA-identical LR kidney transplantation could be directed to the 
mismatched mHAgs or other non-HLA antigens. Indeed, a role of non-HLA antigens was 
suggested after solid organ transplantation.4, 5
After HLA-mismatched organ transplantation, several studies reported a decrease in 
donor-reactive T-cell response during the first year after kidney, liver and lung transplantation 
using mixed lymphocyte culture (MLC), cytotoxic T-lymphocyte precursor frequency (CTLpf), 
helper T-lymphocyte precursor frequency (HTLpf) and IFN-g Elispot assays.6-10
Recently, we demonstrated that donor-reactive responses can be found after HLA-
identical LR kidney transplantation.11 In the present study, we questioned whether in these 
patients donor-reactive cytokine responses may also decrease within the first year after 
transplantation. Therefore, we used IFN-g and granzyme B (GrB) Elispot assays, which 
reflect the Th1 response and the activity of cytotoxic T lymphocytes (CTL), respectively.
PATIENTS AND METHODS
HLA-identical living-related (LR) kidney transplant recipients
The Ethical Review Committee of our center approved the protocol, which was conducted 
according to local requirements. After informed consent, 35 ml peripheral blood was taken 
from 15 HLA-identical LR kidney transplant recipients before transplantation, 6-months and 
one year after transplantation, and from their related donors. The characteristics of the 
patient group are described in Table 1.
Peripheral blood mononuclear cell sampling
Peripheral blood mononuclear cell (PBMC) from both recipient and donor was isolated 
from heparinized blood by density gradient centrifugation using Ficoll-Paque (Amersham 
Biosciences, Uppsala, Sweden). PBMC were collected from the interphase, washed twice 
with RPMI-1640-DM (Cambrex, Verviers, Belgium) supplemented with 100 IU/ml of penicillin 
(Cambrex) and 100 µg/ml of streptomycin (Cambrex). PBMC were stored in RPMI-1640-DM 
containing 15% foetal calf serum (FCS) and 10% dimethyl sulphoxide (MERCK, Hohenbrunn, 
Germany) at –140oC until use.
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IFN-g and GrB Elispot assays
The viability of PBMC was tested in the phytohemagglutinin (PHA; Murex Biotech, Kent, 
UK) proliferation assay as described before.11 The stimulation index (SI) was calculated by 
the ratio of the counts per minute (cpm) obtained in the presence of PHA to the cpm in the 
absence of PHA. Only data of viable cells (SI ≥ 50) are presented.
The donor-reactive T-cell response was determined using IFN-g and GrB Elispot 
assays (U-CyTech biosciences, Utrecht, The Netherlands) as described before.11, 12 In a 
96-wells round bottom plate (Nunc, Roskilde, Denmark), six replicates of 2x105 patients’ 
PBMC were preincubated with 100 µL of 2x105 irradiated (40 Gy) donor PBMC, irradiated 
patients’ PBMC (autologous response used as negative control to control the influence of 
irradiation), or  third-party PBMC, which were completely HLA-mismatched with donor and 
recipient. After 40 h of incubation, the non-adherent cells were harvested and resuspended 
in culture medium. The non-adherent cells were transferred in triplicate to a flat-bottom 
plate (Nunc, Roskilde, Denmark) precoated with IFN-g or GrB monoclonal antibodies (U-
CyTech biosciences) and post-coated with phosphate-buffered saline (PBS) supplemented 
with blocking stock solution B (U-CyTech biosciences). Cells were incubated for 5 hours at 
37oC at the IFN-g and GrB Elispot plate. After incubation, the cells were lysed with ice-cold 
milli-Q water and washed extensively. Subsequently, the wells were incubated overnight at 
4oC with 100 µL of diluted biotinylated goat anti-human cytokine (IFN-g or GrB) polyclonal 
antibody (U-CyTech biosciences) followed by incubation with 50 µL phi-labelled goat anti-
biotine antibodies (U-CyTech biosciences) for 1 hour at 37oC. After washing the wells, 30 
Gender Immunosuppressive therapy after
transplantation (mg/day) (6-mo)
Immunosuppressive therapy after
transplantation (mg/day) (one year)
Patient
R D #Tx RRT
Yrs
on
RRT
PRA
(%) Tacro MMF Pred AZA CsA Tacro MMF Pred AZA Primary disease
Time of
recurrence
after Tx (yrs)
1 M M 1 CAPD 1.3 0 4 1000 4 1000 Focal segmental
glomerulosclerosis
No
2 F M 1 HD 4.0 0 5 125 2.5 100 AL-amyloïdose No
3 M F 1 HD 1.3 4 6 500 6 500 IgA nephropathy No
4 M F 2 HD 13.0 4 10 1500 10 1000 Focal segmental
glomerulosclerosis
No
5 F F 2 HD 1.1 41 500 2.5 Membranous proliferative
glomerulonephritis
No
6 M F 1 CAPD 0.1 0 4 2000 4 1500 Membranous proliferative
glomerulonephritis
1.0
7 M F 1 HD 4.0 0 1000 5 1000 5 Polycystic kidney disease No
8 F F 1 CAPD 1.5 78 6 1500 6 1500 Membranous proliferative
glomerulonephritis
2.4
9 F M 1 None 0 0 10 2000 20 10 2000 20 Polycystic kidney disease No
10 M M 1 CAPD 1.0 6 10 400 10 175 IgA nephropathy No
11 M M 1 CAPD 1.0 0 4 1000 3 Polycystic kidney disease No
12 M F 1 HD 1.4 0 4 750 5 6 500 Focal segmental
glomerulosclerosis
0.3
13 M F 1 None 0 0 2 1000 2 1000 5 Pauci-immune
glomerulonephritis
No
14 F F 1 None 0 0 5 1000 2 500 Tubular interstitial
nephritis
No
15 F F 1 CAPD 1.0 0 1000 5 Hypertension No
median 1 1.3 0 5 1000 5 5 1000 7.5 137.5
Table 1: Demographics of the HLA-identical LR kidney transplant recipients
R, recipient; D, donor; M, male; F, female; #Tx, number of kidney transplantations; RRT, renal replacement 
therapy before kidney transplantation; CAPD, continuous ambulatory peritoneal dialysis; HD, haemodialysis; 
PRA, panel reactive antibodies before transplantation; mo, months; Tacro, tacrolimus; MMF, mycophenolate 
mofetil; Pred, prednisone; AZA, azathioprine; CsA, cyclosporine A; -, no immunosuppressive medication.
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µL of reagent (activator I + II, U-CyTech biosciences), that activates phi, was added and 
incubated for 15 to 30 minutes at room temperature in the dark. The reaction was stopped 
by adding milli-Q water to the wells. The spots were counted automatically by using a 
Bioreader 3000 Elispot reader (BioSys, GmbH, Karben, Germany).
The autologous response was subtracted from the donor and third-party response. 
The autologous response was significantly lower than the donor-reactive response (IFN-g, 
p=0.01; GrB, p=0.04). 
mHAgs typing after HLA-identical LR kidney transplantation
Patient and donor PBMC were typed for 11 known mHAgs: HA-1, HA-2, HA-3, HA-8, HB-
1, ACC-1, ACC-2, HwA-9, HwA-10, UGT2B17, and HY. DNA from donor and recipient were 
isolated using the QIAamp® DNA Mini Kit.13 The PCR-SSP (sequence specific primers) 
technique was used as typing method. This is a PCR based technique with the use of SSPs, 
which shortens the post-amplification processing time to a simple gel electrophoresis 
detection step. Each tested mHAgs is part of a di-allelic system. This means that each locus 
contains two alleles, and a specific primer combination for each allele was used to test the 
presence of this allele. 
Statistical analysis
The Wilcoxon signed rank test was used to compare the number of IFN-g pc and GrB pc before, 
6-months and one year after HLA-identical LR kidney transplantation. The Spearman’s rank 
correlation coefficient (rs) was used to correlate the number of IFN-g pc and GrB pc reactive 
to donor and third-party cells. Two sided P-values ≤0.05 were considered significant. For 
statistical analysis, SPSS 11.5 for Windows was used (SPSS, Inc., Chicago, IL, USA).
RESULTS
Clinical results
At one year after HLA-identical LR kidney transplantation, 12 from the 15 patients had stable 
serum creatinine levels (median, 98 µmol/L; range, 68-139) and no proteinuria (<0.5 g/L). 
Patient 6, 8 and 12 developed recurrence of their original disease, membranous proliferative 
glomerulonephritis (MPGN) and focal segmental glomerulosclerosis (FSGS), at 1.0, 2.4 and 
0.3 years after transplantation, respectively (Table 1). None of the 15 patients experienced 
acute rejection episodes, or infections with cytomegalovirus or Epstein-Barr virus.
The frequency of IFN-g and GrB producing cells
We found in 53% (8/15), 60% (9/15) and 67% (10/15) of the patients detectable (≥1 
cytokine producing cells (pc)/2x105 PBMC) donor-reactive IFN-g pc before, 6-months and 
one year after transplantation, respectively (Table 2). Before transplantation (median, 2 IFN-
g pc/2x105 PBMC; range, 0-129), the number of donor-reactive IFN-g producing cells (pc) 
was comparable to the number of IFN-g pc at 6-months (median, 1 IFN-g pc/2x105 PBMC; 
range, 0-58; p=0.75) and one year (median, 2 IFN-g pc/2x105 PBMC; range, 0-64; p=0.31; 
Figure 1A) after transplantation. No change was observed in the reactivity against third-
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party antigens before transplantation (median, 67 IFN-g pc/2x105 PBMC; range, 0-283) and 
after transplantation (6-months: median, 86 IFN-g pc/2x105 PBMC; range, 0-166; p=0.28; 
one year: median, 82 IFN-g pc/2x105; range, 3-173; p=0.94; Figure 1B). The donor-reactive 
response was at all time points significantly lower than the third-party reactive response 
(before, p=0.001; 6-months, p=0.001; one year, p=0.002).
From 13 of the 15 HLA-identical patients, we were able to perform GrB Elispot assays. 
In 31% (4/13) of the patients detectable responses to donor antigens were found before 
transplantation, and 38% (5/13) of the patients had detectable responses both at 6-months 
and one year after transplantation (Table 2). The number of donor-reactive GrB pc was 
comparable before transplantation (median, 0 GrB pc/2x105 PBMC; range, 0-192), 6-
months (median, 0 GrB pc/2x105 PBMC; range, 0-131; p=0.73) and one year (median, 0 
GrB pc/2x105 PBMC; range, 0-54; p=0.69; Figure 1C) after transplantation. The third-party 
reactive response before transplantation (median, 76 GrB pc/2x105 PBMC; range, 3-231) 
was comparable with 6-months (median, 56 GrB pc/2x105 PBMC; range, 4-177; p=0.58) 
and one year (median, 33 GrB pc/2x105 PBMC; range, 0-151; p=0.21; Figure 1D) after 
transplantation. At all time points, the donor-reactivity was always lower compared to the 
third-party reactivity (before, p=0.001; 6-months, p=0.001; one year, p=0.01). 
Overall, the number of donor-reactive and third-party reactive IFN-g pc correlated 
with the number of donor-reactive and third-party reactive GrB pc (donor: rs=0.71; n=39; 
p<0.0001; third-party: rs=0.55; n=39; p=0.0003; Figure 2A and B).
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Figure 1: The number of IFN-g (n=15) and granzyme B (GrB) (n=13) producing cells reactive to donor 
cells (A, C) and third-party cells (B, D) before, 6-months (mo) and 1-year after HLA-identical living-rela-
ted kidney transplantation. (KTx, kidney transplantation)
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Relation between the number of donor-reactive cytokine pc and known mHAg mismatches 
after HLA-identical LR kidney transplantation
We analysed whether donor-reactive responses (≥1 cytokine pc/2x105 PBMC) found after 
HLA-identical LR kidney transplantation were directed to known mismatched mHAgs between 
donor and recipient (Table 2).
 From the 15 patient-donor combinations, nine couples (patient 1, 2, 6, 7, 8, 9, 11, 
12, 14) demonstrated at least one mismatch for known mHAgs between donor and recipient. 
Seven out of nine couples had a mHAg mismatch in combination with the correct HLA-
restriction molecule in which the donor mHAgs could be presented to T cells. Those seven 
patient-donor combinations demonstrated no differences in cytokine producing cells with 
the other eight patient-donor combinations (IFN-g: p=0.54; GrB: p=0.75; Fischer’s Exact 
test).
Figure 2: Correlation between the number of IFN-g (n=39) and granzyme (GrB) (n=39) producing cells 
reactive to donor cells (A) or third-party cells (B) (squares, pretransplant values; triangles, 6-mo values; 
circles, 1-year values).
DISCUSSION
After HLA-identical LR kidney transplantation, immune responses could be directed 
to the mismatched mHAgs or other non-HLA antigens between donor and recipient. In 
contrast to immune responses against major HLA molecules, mHAgs do not induce strong 
immune responses in cellular assays.14 In our study, donor-reactive cytokine responses 
(≥1 cytokine pc/2x105 PBMC) could be detected even before and after HLA-identical LR 
kidney transplantation. Those donor-reactive T-cell responses before transplantation could 
be a result of paternal or maternal mHAg priming of fetal T cells.15 They could provide a 
continuous source of those mHAgs that may maintain during adult life.16
During the study period, we found that 60% (27/45) and 36% (14/39) of the PBMC 
samples responded to donor antigens in IFN-g and GrB Elispot assays, respectively. The 
frequency of donor-reactive IFN-g pc and GrB pc in PBMC from stable HLA-identical LR kidney 
transplant recipients in our study was comparable with the frequency of donor-reactive IFN-g 
pc and GrB pc in PBMC from stable HLA-mismatched kidney transplant recipients in other 
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studies, who were 3 to 18 months after transplantation.17-19 Additionally, the number of 
donor-reactive GrB pc from our previous study were comparable with the number of donor-
reactive GrB pc at 6-months (p=0.83) and one year (p=0.83) after transplantation.20 Thus, 
low numbers of donor-reactive IFN-g pc and GrB pc can be found during immunological 
quiescence and are independent from HLA matching.
The clinical relevance of mHAgs in HLA-identical LR kidney transplantation is yet 
unknown. A study from Krishnan et al.21 reported in a small cohort of patients an association 
between HA-1 mismatch and chronic allograft nephropathy. In contrast to this study, we 
found no relation between known mHAg mismatches in combination with the correct HLA-
restriction molecule and the number of donor-reactive cytokine producing cells. In our previous 
studies, we were also unable to find an association between known mHAgs mismatches and 
donor-reactive responses.20, 22 Additionally, Heinold et al.23 reported that mHAg mismatches 
between donor and recipient after cadaveric and living-related kidney transplantation had no 
significant influence on the five years death-censored allograft survival.
Several studies reported a decrease in T-cell response during the first year after 
organ transplantation.6-10 To our knowledge, there are no reports describing donor-reactive 
cytokine responses during the first year after HLA-identical LR renal transplantation. In the 
present study, we found that the numbers of donor-reactive and third-party reactive IFN-g 
pc and GrB pc in PBMC from HLA-identical LR kidney transplant recipients remained stable 
during the first year after transplantation. The number of donor-reactive IFN-g pc increased in 
some patients and decreased in others in the first six months after transplantation, while no 
IFN-γ
(cytokine pc/2x105 PBMC)
GrB1
(cytokine pc/2x105 PBMC)
Patient Mismatched mHAgs
between donor and
recipient
HLA-restriction
molecule
present before 6-mo 1-year before 6-mo 1-year
1 HA-2M 0 1 8 0 0 2
2 HB-1H, HY3 B44, DQ5 5 0 6 0 0 0
3 no difference 35 30 11 0 23 10
4 no difference 26 31 23 0 8 13
5 no difference 2 10 0 0 0 0
6 HA-1R 2 0 2 8 0 0
7 HA-2M, ACC1-Y, ACC2-D,
HwA-9R, HwA-10
A3 0 1 1 nd2 nd nd
8 HA-8R A2 17 41 10 28 131 54
9 HA-1H, HY A2, DQ5 5 0 0 0 0 0
10 no difference 0 0 3 nd nd nd
11 HwA-9R A3 0 3 2 0 0 0
12 HA-1H B60(40) 129 58 64 192 44 48
13 no difference 0 0 0 1 0 0
14 HA-1H, HA-2V, HA-8R, ACC-
1Y, ACC-2D, HwA-9G, HwA-
10
A2, B44 0 15 0 0 2 0
15 no difference 0 0 0 0 0 0
1GrB, Granzyme B; 2nd, not enough cells were available to perform also GrB Elispot as-
says; 3Mismatched mHAgs with the known HLA-restriction molecule are presented as cursive.
Table 2: Known mismatched minor histocompatibility antigens and donor-reactive IFN-g and 
granzyme B producing cells after HLA-identical LR kidney transplantation
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further increase was found at one year after transplantation. These results were comparable 
with our previous data.11 Apparently, during immunological quiescence, reactivity directed 
to non-HLA antigens do not have to be actively downregulated. Therefore, no decrease in 
donor-reactive IFN-g pc and GrB pc was observed.
In the HLA-mismatched setting, studies demonstrated that pre- and posttransplant 
numbers of IFN-g pc were associated with impaired serum creatinine levels.18, 24 In the 
present study, we found no correlation between pre- and posttransplant numbers of cytokine 
pc and serum creatinine levels. Recent studies suggested that use of dialysis and even time 
on dialysis results in higher numbers of alloreactive IFN-g pc compared to short-term use 
of dialysis.25, 26 In our study, we observed no relation between the number of cytokine pc 
and time on renal replacement therapy. We also found no relation between the number of 
cytokine pc and PRA in HLA-identical LR kidney transplant recipients.
In the present study, still 67% and 38% of the patients had detectable donor-reactive 
responses in IFN-g and GrB Elispot assays, respectively, at one year after transplantation. 
Remarkably, in five HLA-identical LR kidney transplant recipients donor-reactivity was not 
detectable in both IFN-g and GrB Elispot assays at one year after transplantation. We suggest 
that HLA-identical LR kidney transplant recipients without any detectable donor-reactive IFN-
g pc and GrB pc should already be tapered in their immunosuppressive medication within the 
first year posttransplantation. This is probably too early for those patients with detectable 
numbers of donor-reactive cytokine producing cells. In some reports a small number of HLA-
identical LR kidney transplant recipients are described during complete discontinuation of 
immunosuppression with stable graft function.27-29
It has been suggested that natural killer (NK) cells could also play a role in solid 
organ transplantation.30, 31 NK cells are able to produce pro-inflammatory cytokines as IFN-g 
and GrB.31, 32 However, in our Elispot assays, no difference in response was found between 
PBMC depleted for NK cells and PBMC not depleted for NK cells (data not shown). Therefore, 
we assume that NK cells play not a role in our test system.
In conclusion, in peripheral blood, non-HLA reactivity can be detected before 
and after HLA-identical LR kidney transplantation. The height of the donor-reactivity was 
not related with the number of known mHAgs mismatches. We observed no decrease in 
reactivity against those donor antigens during the first year after HLA-identical LR kidney 
transplantation. In 67% of HLA-identical LR kidney transplant recipients, donor-reactivity 
is detectable even at one year after transplantation, and in 33% of the patients no donor-
reactivity was found.
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ABSTRACT
Background: After HLA-identical living-related (LR) kidney transplantation, only non-
HLA antigen mismatches between donor and recipient may exist. We questioned whether 
donor-reactive responses against non-HLA antigens could be found after HLA-identical LR 
kidney transplantation, and wondered whether donor-reactivity in the HLA-identical setting 
was different from the HLA-mismatched setting during immunological quiescence. Healthy 
individuals served as controls.
Methods: Elispot assays were performed to determine the number of alloreactive IFN-g 
producing cells (pc), IL-10 pc, granzyme B (GrB) pc and IL-13 pc from peripheral blood 
mononuclear cells (PBMC) of HLA-identical, HLA-mismatched LR kidney transplant recipients 
and healthy individuals.
Results: The frequency of alloreactive IFN-g pc, IL-13 pc and GrB pc was higher in healthy 
individuals compared to both transplant patient groups. In the HLA-identical group, 
significantly higher numbers of donor-reactive IL-10 pc were found compared to their 
autologous control. These frequencies were also higher compared to the HLA-mismatched 
and healthy control group. The number of donor-reactive GrB pc was higher in the HLA-
mismatched group than in the HLA-identical group. Donor-reactive IFN-g pc and IL-13 pc 
were comparable in both transplant groups.
Conclusions: In recipients of HLA-identical LR kidney transplant, high donor-reactive IL-10 
pc, in combination with low donor-reactive IFN-g pc, IL-13 pc and GrB pc, suggests active 
downregulation of reactivity against non-HLA molecules.
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INTRODUCTION
After HLA-identical LR kidney transplantation, all major HLA molecules are identical (HLA-
A, B, C, DR, DQ) with the donor, and only mismatches may exist in non-HLA antigens or 
minor histocompatibility antigens (mHAgs). Minor HAgs are HLA-restricted peptides derived 
from cellular proteins that differ in amino acid sequence between donor and recipient due 
to genetic polymorphisms.1-3 After HLA-identical allogeneic bone marrow transplantation 
(BMT), immune responses are caused by mHAg mismatches between donor and recipient.3 
Theoretically, after HLA-identical LR kidney transplantation, both mismatches in mHAgs4 and 
mismatches in other non-HLA antigens5, may induce rejection of the kidney transplant.
Cytokines are important mediators in regulating lymphocyte activation, proliferation, 
differentiation, and survival.6 Pro-inflammatory cytokines, such as interleukin (IL)-2, 
interferon (IFN)-g and tumor necrosis factor (TNF)-a, have been postulated to promote 
allograft rejection. In contrast, anti-inflammatory cytokines, such as IL-4, IL-5, IL-10 and 
IL-13, have been associated with downregulation of the immune response.7-9 Some studies 
also reported that anti-inflammatory cytokines, such as IL-4, were present during rejection 
after clinical heart transplantation.10, 11
Recently, studies reported a beneficial role for IL-10 after BMT and after HLA-
mismatched kidney transplantation.12-15 After BMT with HLA-identical sibling donors, donor-
stimulated peripheral blood mononuclear cells (PBMC) showed significantly higher numbers 
of IL-10 producing cells (pc) in Elispot assays and higher levels of IL-10 mRNA expression 
levels in the absence of graft-versus-host disease (GVHD) compared to samples taken during 
GVHD.13, 14 After HLA-mismatched kidney transplantation, higher numbers of donor-reactive 
IL-10 pc in PBMC were found by Elispot assays in the absence of rejection compared to 
during acute rejection.15 In addition, high levels of IL-10 determined in supernatants from 
unstimulated PBMC by enzyme-linked immunosorbent assay (ELISA) was associated with 
stable graft function.12
Cytotoxic T-lymphocytes (CTL) play a crucial role in allograft rejection.16, 17 CTLs 
are capable of inducing apoptotic cell death via the death receptor pathway, such as FAS-
FAS ligand, or via the exocytosis pathway, which involves perforin and granzyme B (GrB). 
The number of CTL responding to donor antigens can be measured by determining the 
CTL precursor frequency (CTLpf) in limiting dilution assays.18 After HLA-identical LR kidney 
transplantation, no donor-reactive responses can be measured by CTLpf. An alternative for 
cytotoxicity is to determine the activity of CTL by using the IFN-g or GrB Elispot assay.19-21
In the present study, we questioned whether we could detect donor-reactivity 
against non-major HLA molecules after HLA-identical LR kidney transplantation. Autologous 
responses were used as negative controls. Furthermore, we wondered whether the donor-
reactive response in the HLA-identical setting was different from the HLA-mismatched setting 
during immunological quiescence.
SUBjECTS AND METHODS
Kidney transplant recipients and healthy individuals
Both the transplant recipients and kidney donors visited our out clinic regularly to control 
their renal function. After informed consent, 35 ml heparinized blood was taken from both 
recipients and their specific donors of a HLA-identical (n=13) and HLA-mismatched (n=12) LR 
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kidney transplants, and healthy individuals (n=10: n=5 male and n=5 female blood donors). 
The characteristics of HLA-identical and HLA-mismatched LR kidney transplant recipients 
are described in Table 1A and B, respectively. We included 10 healthy individuals (n=5 male 
and n=5 female blood donors). From the HLA-identical recipients, one patient received his 
second graft and two patients their third graft (Table 1A). In the HLA-mismatched group, 
two patients received their second graft. After HLA-identical LR kidney transplantation, none 
of the patients experienced an acute rejection episode. In the HLA-mismatched group, only 
one patient developed an acute rejection period within 1 week after transplantation (Table 
1B).
Peripheral Blood Mononuclear Cells (PBMC) sampling
PBMC from transplant recipients, their specific kidney donors and healthy individuals were 
isolated from heparinized blood by density gradient centrifugation using Ficoll-Paque (density 
1.0777 g/ml; Amersham Biosciences, Uppsala, Sweden). PBMC were collected from the 
interphase, washed twice with RPMI-1640-DM (Cambrex, Verviers, Belgium) supplemented 
with 100 IU/ml of penicillin (Cambrex) and 100 µg/ml of streptomycin (Cambrex). Thereafter, 
PBMC were stored in RPMI-1640-DM containing 15% foetal calf serum (FCS) and 10% 
dimethyl sulfoxide (MERCK, Germany) at –140oC until use.
Elispot assay: IFN-g, IL-10, IL-13, and granzyme B (GrB)
The phytohemagglutinin (PHA) proliferation assay was performed to control the viability of 
the PBMC as described before.18 The stimulation index (SI) was calculated by the ratio of 
the cpm obtained in the presence of PHA to the cpm in the absence of PHA. Only results of 
viable cells (SI ≥ 50) were analyzed in the described results.
Alloreactivity was determined in an IFN-g, IL-10, IL-13 and GrB Elispot assays. In a 
96-well round bottom plate (Nunc, Roskilde, Denmark), six replicates of 1x105 PBMC from 
healthy individuals were stimulated with 100 µl of 1x105 irradiated (40 Gy) PBMC derived 
from another healthy individual. In the HLA-mismatched setting, 1x105 patients’ PBMC were 
stimulated with 100 µl of 1x105 irradiated (40 Gy) donor-specific PBMC. Because we expected 
low frequencies of cytokine pc in the HLA-identical setting, 100 µl of 2x105 patients’ PBMC 
was added to 100 µl of 2x105 irradiated donor-specific PBMC to increase the sensitivity of 
the Elispot assays. Additionally, irradiated stimulator cells alone were incubated in culture 
media [if cytokine producing cells (pc) were detected, <5 spots/2x105 PBMC in IFN-g, IL-13 
and GrB Elispot assays, and <20 spots/2x105 PBMC in IL-10 Elispot assays were found]. To 
control the influence of irradiation on cytokine production, responder cells were incubated 
with irradiated responder (40 Gy) cells (autologous response). The autologous response 
was substracted from the alloresponse. Responder PMBC in the culture medium alone were 
used as a negative control (Figure 1A-D). As a positive control, PBMC were stimulated with 
1 µg/ml PHA (Murex Biotech, Kent, UK) (Figure 1A-D). After 40 h of incubation at 37oC and 
5% CO2, the non-adherent cells were collected, washed, and resuspended in 300 µl culture 
medium. The non-adherent cells were transferred in 3 wells of a flat-bottom 96-well plate 
(Nunc, Roskilde, Denmark) pre-coated with either mouse anti-human IFN-g, IL-10, IL-13 
or GrB monoclonal antibody (U-CyTech Biosciences, Utrecht, The Netherlands) and post-
coated with phosphate-buffered saline (PBS) supplemented with 1% bovine serum albumin 
(BSA; U-CyTech Biosciences). The cells were incubated for 5 hours at 37oC and 5% CO2 for 
IFN-g, IL-13 and GrB Elispot assays, and overnight for IL-10 Elispot assay. After incubation, 
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Gender Age
(years)
Time
after KTxe
(years)
PRAf
(%)
Immunosuppresive regimen
(mg/day)
IDb Patc Dond CsAg Tacroh MMFi AZAj Predk
1 Female Male 35 2.7 2 50 7.5
2 Male Female 54 2.1 2 4 1500
3 Female Female 58 1.0 27 500 10
4 Male Female 45 0.5 37 350 10
5 Male Male 49 0.3 5 450 15
6 Female Male 32 6.4 83 7.5
7 Male Female 30 0.6 31 300 10
8 Male Male 29 3.5 0 200 10
9 Male Female 53 0.5 2 400 10
10 Female Male 48 1.0 0 50 2.5
11 Male Male 49 0.9 0 4 5
12 Male Female 54 0.9 0 4 1000
13 Male Female 58 0.8 0 2 1000 5
median 49 0.9 2 375 4 1000 125 10
Table 1A: Characteristics of HLA-identical living-related kidney transplant recipientsa
aHLA-identical LR kidney transplantation, identical at the HLA-A, B, C, DR, and 
DQ loci; bID, identification number; cPat, patient; dDon, donor; eKTx, kidney 
transplantation; fPRA, panel-reactive antibodies; gCsA, cyclosporine A; hTacro, 
tacrolimus; iMMF, mycophenolate mofetil; jAZA, azathioprine; kPred, prednisone.
Gender Age
(years)
Time
after
KTxd
(years)
PRAe
(%)
HLA-mmf Immunosuppresive regimen
(mg/day)
IDa Patb Donc CsAg Tacroh MMFi AZAj Predk
1 Male Male 47 0.2 4 0-1-1 350 2000 7.5
2 Male Female 38 8.1 0 1-1-1 125 10
3 Male Female 36 2.1 0 0-1-1 175 10
4 Male Female 62 0.7 0 2-2-2 2 1000 10
5 Female Female 23 4.3 0 1-0-0 125 10
6 Female Male 19 0.4 14 1-1-0 200 7.5
7 Male Female 54 0.7 5 0-2-1 200 2000 7.5
8 Female Male 43 7.7 0 1-1-1 100 7.5
9 Male Female 32 1.5 2 1-1-1 200 2000 10
10 Male Male 61 0.9 2 1-1-1 350 1500 10
11 Female Male 40 1.1 4 1-1-0 200 1500
12 Male Male 48 2.0 9 1-2-2 300 15
median 41 1.3 2 1-1-1 200 2 1750 125 10
Table 1B: Characteristics of HLA-mismatched living-related kidney transplant recipients
aID, identification number; bPat, patient; cDon, donor; dKTx, kid-
ney transplantation; ePRA, panel-eactive antibodies; fHLA-mm, mismat-
ches at the HLA-A, B, and DR loci; gCsA, cyclosporine A; hTacro, tacroli-
mus; iMMF, mycophenolate mofetil; jAZA, azathioprine; kPred, prednisone.
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the cells were lysed with ice-cold milli-Q water and washed extensively. Subsequently, the 
wells were incubated overnight at 4oC with 100 µl of diluted biotinylated goat anti-human 
cytokine (IFN-g, IL-10, IL-13 or GrB) polyclonal antibody (U-CyTech Biosciences) followed by 
incubation with 50 µl phi-labelled goat anti-biotine antibodies (U-CyTech Biosciences) for 1 
h at 37oC. After washing the wells, 30 µl of reagent (activator I + II, U-CyTech Biosciences), 
that activates phi, was added and incubated for 15 to 30 minutes at room temperature in the 
dark. The reaction was stopped by adding milli-Q water to the wells. The spots were counted 
automatically by using a Bioreader 3000 Elispot reader (BioSys, GmbH, Karben, Germany).
mHAg typing after HLA-identical living-related kidney transplantation
PBMC of the patient and the donor were typed for 11 known mHAgs: HA-1, HA-2, HA-3, 
HA-8, HB-1, ACC-1, ACC-2, HwA-9, HwA-10, UGT2B17 and HY (Table 2). From the 13 HLA-
identical donor-recipient couples, 10 couples (ID1, 2, 3, 4, 6, 8, 10, 11, 12, 13) were typed 
for 11 known mHAgs, and 3 couples (ID5, 7, 9) were not typed for HwA-10. As described, 
DNA from donor and recipient was isolated using the QIAamp® DNA Mini Kit.22
Statistical analysis
The Kruskal-Wallis Test was used to compare age and gender between healthy individuals, 
and HLA-mismatched and HLA-identical LR kidney transplant recipients. We used the 
Mann-Whitney U-test to compare time after kidney transplantation, serum creatinine, and 
proteinuria between HLA-mismatched and HLA-identical LR kidney transplant recipients. 
To compare the frequencies of cytokine pc between healthy individuals, HLA-mismatched 
and HLA-identical LR kidney transplant recipients the Mann-Whitney U-test was used. The 
Wilcoxon signed rank test was used to compare the number of donor-reactive cytokine pc 
with the number of their autologous control in PBMC from HLA-identical LR kidney transplant 
recipients, and the frequencies of IFN-g pc, IL-10 pc, IL-13 pc and GrB pc within PBMC from 
healthy individuals, HLA-mismatched LR kidney transplant recipients, and HLA-identical 
LR kidney transplant recipients. Two sided P-values ≤0.05 were considered significant. For 
statistical analysis, SPSS 11.5 for Windows was used (SPSS, Inc., Chicago, IL, USA).
RESULTS
Clinical results
At time of blood collection, all patients were in a clinical stable period, none of the patients had 
acute rejection or infections. There was no difference in time after transplantation (p=0.54) 
and panel-reactive antibodies (PRA) (p=0.60) between both patient groups (Table 1A and 
B). Serum creatinine levels were comparable between the HLA-identical group and the HLA-
mismatched group (p=0.54). None of the HLA-identical and HLA-mismatched recipients had 
proteinuria (<0.5 g/l). Median age of the HLA-identical and HLA-mismatched recipients and 
healthy individuals was 49 years (range: 29-58), 41 years (range: 19-62) and 40 years 
(range: 26-61), respectively. No difference in age (p=0.82) and gender (p=0.61) was found 
between kidney transplant recipients and healthy individuals.
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Alloreactivity in PBMC from healthy individuals, HLA-mismatched and HLA-identical LR 
kidney transplant recipients
The frequency of IFN-g producing cells (pc) directed to alloantigens in PBMC from healthy 
individuals (median, 17 IFN-g pc/2x105 PBMC; range, 0-176) was significantly higher than 
in PBMC from HLA-mismatched (median, 4 IFN-g pc/2x105 PBMC; range, 0-36; p=0.03) and 
HLA-identical recipients (median, 1 IFN-g pc/2x105 PBMC; range, 0-22; p=0.003; Figure 
2A). The number of donor-reactive IFN-g pc was comparable between the HLA-mismatched 
and HLA-identical group (p=0.27).
The healthy control group showed low numbers of alloreactive IL-10 pc (median, 0 
IL-10 pc/2x105 PBMC; range, 0-20), which was comparable to the number of donor-reactive 
IL-10 pc of the HLA-mismatched group (median, 0 IL-10 pc/2x105 PBMC; range, 0-142; 
p=0.97, Figure 2B). Remarkably, PBMC from the HLA-identical group (median, 13 IL-10 
pc/2x105 PBMC; range, 0-145) demonstrated higher frequencies of donor-reactive IL-10 pc 
compared to the number of alloreactive IL-10 pc in PBMC from the healthy control group 
(p=0.03) and HLA-mismatched group (p=0.04). 
Additionally, we analysed whether increased numbers of IL-10 pc were directed 
to donor antigens or to auto-antigens. Therefore, we compared the number of IL-10 pc of 
the uncorrected donor-reactive response with the number of IL-10 pc of the autologous 
response. The donor-reactive IL-10 pc (median, 20 IL-10 pc/2x105 PBMC; range, 3-185) 
was significantly higher than the autologous reactive IL-10 pc (median, 12 IL-10 pc/2x105 
PBMC; range, 2-40; p=0.03; Figure 2B), suggesting that the donor-reactive response was 
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Figure 1: Cytokine responses in culture medium alone and PHA responses in PBMC from healthy indi-
viduals (HI), HLA-mismatched (HLA-mm) and HLA-identical (HLA-id) living-related (LR) kidney trans-
plant recipients determined in IFN-g (A), IL-10 (B), IL-13 (C) and granyzme B (GrB) (D) Elispot assay.
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directed to donor antigens and not reflecting autoreactivity. Also, in the other Elispot assays, 
the number of cytokine pc was higher after donor stimulation than in the autologous control 
(Figure 2A, C, D).
 The number of alloreactive IL-13 pc (median, 7 IL-13 pc/2x105 PBMC; range 2-22) 
and GrB pc (median, 8 GrB pc/2x105 PBMC; range, 0-20) in PBMC from healthy individuals 
was higher compared to the number of donor-reactive IL-13 pc and GrB pc in PBMC from 
HLA-mismatched (IL-13: median, 1 IL-13 pc/2x105 PBMC; range, 0-12; p=0.03; GrB: 
median, 5 GrB pc/2x105 PBMC; range, 0-28, p=0.56) and HLA-identical recipients (IL-13: 
median, 0 IL-13 pc/2x105 PBMC; range, 0-2; p<0.001; Figure 2C; GrB: median, 1 GrB 
pc/2x105 PBMC; range, 0-4; p=0.001; Figure 2D). The number of IL-13 pc was comparable 
between both patient groups (p=0.37), but the number of GrB pc was higher in PBMC from 
HLA-mismatched group compared to HLA-identical group (p=0.02).
In the healthy control group, allostimulated PBMC demonstrated higher numbers 
of IFN-g pc compared to the numbers of IL-10 pc (p=0.01), IL-13 pc (p=0.07) and GrB pc 
(p=0.03; Figure 2). Also, the number of IL-13 pc was higher than the number of IL-10 pc 
(p=0.05). 
The number of donor-reactive IFN-g pc, IL-10 pc, IL-13 pc and GrB pc was comparable 
within the HLA-mismatched group (Figure 2).
It has been suggested that the balance between IFN-g and IL-10 reflects the immune 
status of transplant recipients in relation to their donor graft.15 Therefore, we compared 
the frequency of allospecific IFN-g pc with the frequency of IL-10 pc. In PBMC from healthy 
individuals, high numbers of IFN-g pc were observed in combination with low numbers of 
IL-10 pc (p=0.01). No relation was found between the number of donor-reactive IFN-g pc 
and IL-10 pc in PBMC from HLA-mismatched recipients (p=0.64). Interestingly, PBMC from 
HLA-identical recipients showed low numbers of donor-reactive IFN-g pc in combination with 
high numbers of donor-reactive IL-10 pc (p=0.01; Figure 3). 
Minor histocompatibility antigens typing after HLA-identical LR kidney transplantation
We analysed whether donor-reactive responses (≥ 1 cytokine pc) found after HLA-identical 
LR kidney transplantation were directed to known mismatched mHAgs between donor and 
recipient (Table 2). The cytomegalovirus (CMV) and Epstein-Barr virus (EBV) serological 
status had no influence on donor-reactive IFN-g, IL-10, IL-13 and GrB responses.
All numbers of IL-13 pc and GrB pc were low, and consequently, no relation could be 
found between the number of IL-13 pc and GrB pc and the number of mHAg mismatches.
From the 13 donor-recipient combinations, 10 couples (ID1, 2, 3, 4, 6, 8, 9, 10, 
11, 12) demonstrated mismatches for known mHAgs. Three couples (ID5, 7, 13) had no 
mismatches for mHAgs. Those 3 patients had no IFN-g pc directed to donor antigens, but 
had significant numbers of IL-10 pc.
Five of the 10 patients had the correct HLA-restriction molecule for donor mHAg 
presentation to recipient T-cells.23 One of those patients (ID2) had the highest frequency 
of IFN-g pc. Unfortunately, not enough cells were available to perform IL-10 Elispot assay. 
Two other patients (ID1, ID10) demonstrated high numbers of IL-10 pc in combination with 
significantly lower numbers of IFN-g pc. On the other hand, two other patients (ID6, ID11) 
had detectable numbers of IFN-g pc in combination with no IL-10 pc. 
From the five couples (ID3, 4, 8, 9, 12) without the correct HLA-restriction molecule, 
four patients (ID3, 4, 9, 12) showed high numbers of IL-10 pc and 1 patient (ID8) had no 
IL-10 pc, all in combination with low numbers of IFN-g pc (≤ 2 IFN-g pc/2x105 PBMC). 
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Figure 2: Alloreactivity in PBMC from healthy individuals (HI), and donor-reactive response in pa-
tients with an HLA-mismatched (HLA-mm) or HLA-identical (HLA-id) living-related (LR) kid-
ney transplant using IFN-g (A), IL-10 (B), IL-13 (C), and granzyme B (GrB) (D) Elispot assay. 
The donor-reactive responses in HLA-identical LR kidney transplant recipients (dotted circles) 
were further analysed for their autologous responses and uncorrected donor-reactive responses.
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Two patients (ID6, ID8) tested more than 3 years after transplantation had no IL-10 pc 
directed to donor antigens.
DISCUSSION
In humans, mHAg disparities between donor and recipient may influence transplant outcome 
after BMT.23 Also, after HLA-identical LR kidney transplantation, theoretically, mismatches 
in mHAgs between donor and recipient and in combination with the presence of the correct 
HLA-restriction molecule may trigger T-cell responses.23 Nowadays, the number of identified 
human mHAgs have been expanded to a total of 14 autosomally mHAgs and 10 Y-chromosome 
encoded mHAgs.22 However, it is yet not known how many mHAgs exist, but is expected 
to be much more.3, 24 In our study, during immunological quiescence, we found only in 2 
out of 13 patients high donor-reactive IFN-g pc (>5 IFN-g pc/2x105 PBMC). We observed no 
donor-reactive IFN-g pc, IL-13 pc and GrB pc in the absence of known mHAg mismatches. In 
contrast, high numbers of donor-reactive IL-10 pc were detected in combinations with and 
without known mHAg mismatches.
Recently, Perez-Garcia et al.25 demonstrated an increased risk for acute GVHD after 
HA-8 mismatched HLA-identical sibling donor allogeneic BMT, which could cause high T-cell 
responsiveness directed to donor HA-8. In our study, one couple had an HA-8 mismatch, 
which could be presented in HLA-A2. This patient had high numbers of donor-directed IFN-
g pc, which suggests a potential risk for graft failure, because HA-8 is also expressed on 
epithelial cells of the kidney.26
IL-10 is a cytokine that has suppressive effects on the production of proinflammatory 
cytokines and T-cell responses.27 Several cells produce IL-10, such as activated Th2 cells, 
monocytes, and T-regulatory type 1 (Tr1) cells.27, 28 In our experiments, we only used non-
adherent cells. Therefore, monocytes do not interfere in the presented Elispot assays. Th2 
cells and Tr1 cells can be activated by donor cells.27 Both Th2 and Tr1 cells mainly produce 
IL-10. Tr1 cells also produce transforming growth factor (TGF)-β29, and activated Th2 cells 
also produce IL-4, IL-5 and IL-13.28 We found high numbers of donor-reactive IL-10 pc in 
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Figure 3: The number of IFN-g pc and IL-10 pc in PBMC from healthy individuals (HI) after allosti-
mulation. The number of IFN-g pc and IL-10 pc in PBMC from HLA-mismatched (HLA-mm) and HLA-
identical (HLA-id) living-related (LR) kidney transplant recipients after stimulation with donor cells.
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combination with no or low numbers of IFN-g pc, IL-13 pc and GrB pc after HLA-identical LR 
kidney transplantation. Because we did not detect donor-reactive IL-13 pc, we assume that 
Tr1 cells play an important role in those patients. Unfortunately, we have not determined 
TGF-β. After BMT with HLA-identical sibling donors, Tr1 cells may play a role via the secretion 
of IL-10 in preventing GVHD.13, 14 High frequencies of donor-reactive IL-10 pc determined 
by Elispot assay were found in PBMC from recipients who did not developed GVHD, while 
recipients who developed GVHD had low numbers of IL-10 pc.14 Petersen et al.13 showed 
high levels of donor-directed IL-10 mRNA in PBMC from recipients who did not developed 
GVHD, while low IL-10 mRNA levels were found in recipients who developed GVHD. In the 
HLA-identical LR kidney transplant setting, VanBuskirk et al.30 showed, using a trans-vivo 
delayed-type hypersensitivity (DTH)-analysis, a possible role for Tr1 cells by secretion of 
IL-10 and TGF-β. Moreover, Rodriguez et al.31 demonstrated, also using a trans-vivo DTH-
analysis, that matching for HLA molecules resulted in enhanced immune regulation in kidney 
transplant recipients. In HLA-identical LR kidney transplant recipients, the latter group also 
found regulated DTH responses, suggesting of the induction of mHAg-specific regulatory 
T-cell responses. Additionally, Cai et al.32 showed the existence of HA-1-specific T-cells with 
suppressive function, which was dependent of IL-10, TGF-β and cytotoxic T lymphocyte-
associated 4 (CTLA-4), following HLA-identical LR kidney transplantation. In our study, this 
could suggest that HLA-identical LR kidney transplant recipients are developing peripheral 
tolerance against non-HLA antigens by Tr1 cells through the secretion of IL-10. Therefore, 
we propose that HLA-identical LR kidney transplant recipients with stable renal function and 
high numbers of donor-reactive IL-10 pc in combination with low numbers of IFN-g pc should 
be tapered in their immunosuppressive load.
It has been suggested that the presence of PRA reactivity was associated with long-
term graft loss in kidney transplants from HLA-identical sibling donors4, which could reflect 
immune reactivity directed to non-HLA antigens or mHAgs. In the present study, we found 
Gender Donor-reactive cytokine pc/2x105 PBMCIDa
Patient Donor
Mismatched mHAgs in the
HLA-identical donor
HLA-restriction
molecule
present
IFN-γ IL-10 IL-13 GrBb
1 female male HA-2M, HYd B8, DQ5 1 23 0 4
2 male female HA-8R, ACC-1Y, ACC-2D, HwA-9G A2 22 xxc 1 1
3 female female HA-8R 0 7 xx xx
4 male female HwA-9R 1 145 0 1
5 male male No difference 0 8 0 xx
6 female male HY B7, B60 1 0 xx xx
7 male female No difference 0 14 0 1
8 male male HwA-9G 2 0 0 0
9 male female HwA-9G 2 14 2 1
10 female male HB-1H, HY B44, DQ5 7 11 xx 0
11 male male HwA-9R A3 3 0 xx 0
12 male female HA-1R 2 40 xx 0
13 male female No difference 0 24 Xx 0
Table 2: Known mismatched minor histocompatibility antigens and donor-reactive IFN-g pc, IL-10 
pc, IL-13 pc, and granzyme B pc after HLA-identical LR kidney transplantation.
aID, identification number; bGrB, Granzyme B; cxx, not enough cells to determine 4 cytokines; dMis-
matched mHAgs with the known HLA-restriction molecule are presented as cursive and underlined.
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no correlation between PRA before HLA-identical LR kidney transplantation and the number 
of IFN-g pc, IL-10 pc and GrB pc. Also, in the HLA-mismatched group, no relation was found 
between PRA before kidney transplantation and the number of cytokine producing cells.
After HLA-mismatched kidney transplantation, high donor-reactive IL-10 pc was 
associated with stable graft function, and low IL-10 was related with rejection.15 In our 
study, 3 HLA-mismatched LR kidney transplant recipients with excellent renal function 
had high numbers of IL-10 pc in combination with low numbers of IFN-g pc. Because we 
assume that donor-reactive IL-10 pc could be derived from Tr1 cells, we suggest to reduce 
the immunosuppressive load in patients with stable graft function and high numbers of 
donor-reactive IL-10 pc in combination with low numbers of IFN-g pc. Whether the 
immunosuppressive medication influences the balance between IFN-g and IL-10 should be 
investigated by e.g. in vitro addition of immunosuppressive drugs, or by discontinuation the 
immunosuppressive medication in these transplant recipients. Furthermore, the autologous 
response was comparable between healthy individuals and transplant recipients (data not 
shown), suggesting that immunosuppression has no influence on the autologous response.
Studies reported that CD4+CD25bright regulatory T cells might play a beneficial role in 
mediating peripheral tolerance after kidney transplantation.33, 34 Unfortunately, not enough 
cells were available to determine the percentage CD4+CD25bright regulatory T cells by flow 
cytometry.
 In conclusion, high numbers of donor-reactive IL-10 pc in combination with low 
reactivity in autologous control, low numbers of donor-reactive IFN-g pc, IL-13 pc and GrB 
pc, after HLA-identical LR kidney transplantation, may reflect active downregulation of 
reactivity against non-HLA molecules.
Acknowledgment: This study was supported by grant C02.2002 from the Dutch Kidney 
Foundation.
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ABSTRACT
Background: In the present pilot study, we investigated which proteins are produced after 
donor stimulation of peripheral blood mononuclear cells from recipients of HLA-identical 
living-related kidney transplant. 
Methods: We used a protein-array analysis to determine cytokines, chemokines, and 
growth factors in supernatant from donor-stimulated mixed lymphocyte reaction cultures. 
Autologous cultures were considered to be negative control. 
Results: In 38 out of 42 proteins (90%), the donor response was higher compared with the 
autologous response. 
Conclusion: Therefore, we concluded that even after HLA-identical LR kidney transplantation 
we could measure a donor-reactive response, which we assumed was directed toward minor 
histocompatibility antigens or to non-HLA antigens.
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INTRODUCTION
In HLA-identical living-related (LR) kidney transplantation, all major HLA molecules of the 
recipient are identical to those of the donor. Nevertheless, minor histocompatibility antigen 
(mHAg) mismatches may exist. mHAgs are genetically inherited peptides derived from 
polymorphic intracellular proteins presented in the context of HLA molecules, which can be 
recognized by the immune system.1 The expression of mHAgs is ubiquitous or specific on 
haematopoietic cells.2 Beside mHAg mismatches, differences in other non-HLA antigens may 
exist between donor and recipient.3
A key problem after HLA-identical LR kidney transplantation is that no donor-reactive 
responses can be measured by methods as mixed lymphocyte reaction (MLR), cytotoxic T 
lymphocyte (CTL) precursor frequency, or helper T lymphocyte precursor frequency assays. 
Recently, we demonstrated that after HLA-identical LR kidney transplantation, responses 
against donor antigens may be measured by a sensitive method, interferon (IFN)-g4 (or 
granzyme B5) Elispot assay. We questioned whether other donor-reactive cytokines can be 
produced in the HLA-identical LR kidney transplantation setting. Recently, a protein-array 
system became available to determine protein expression levels of cytokines, chemokines, 
and growth factors in cell culture supernatants. In this array it is possible to detect multiple 
cytokine expression levels simultaneously. In the present pilot study, we screened the 
expression profiles of 42 cytokines in donor-stimulated MLR cultures from peripheral blood 
mononuclear cells (PBMC) of HLA-identical LR kidney transplant recipients.
MATERIALS AND METHODS
Patients and PBMC sampling
Two stable HLA-identical LR kidney transplant recipients (without proteinuria) participated 
in this study. Both recipients suffered from membranous glomerulonephritis before 
transplantation. Recipient 1 was 2.1 years after kidney transplantation and had received 
mycophenolate mofetil (1000 mg/day) in combination with tacrolimus (4 mg/day). Recipient 
2 was 0.5 year after kidney transplantation and received cyclosporine A (350 mg/day) and 
prednisone (10 mg/day). PBMC were isolated from heparinized blood by density gradient 
centrifugation using Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden) as described 
before.4 Thereafter, PBMC were stored in RPMI-1640-DM (Cambrex, Verviers, Belgium) 
containing 15% foetal calf serum and 10% dimethyl sulfoxide (MERCK, Germany) at –140 
oC.
MLR
Into a 96-well round bottom plate (Nunc, Roskilde, Denmark), we added 100 µl of 5 x 104 
patient PBMC in complete culture medium [RPMI-1640-DM (Cambrex) supplemented with 
2 mmol/l of L-glutamine (GibcoBRL, Scotland, United Kingdom), 100 IU/ml of penicillin 
(Cambrex), 100 µg/ml of streptomycin (Cambrex), and 10% heat-inactivated and filtered 
(0.20-µm sterile syringe filter, Corning Incorporated, Corning, NY) human male serum that 
was pre-tested for adequate cell growth support in MLR] to 100 µl of 5 x 104 irradiated 
(40 Gy) donor PBMC. To control the influence of irradiation on cytokine production, 5 x 104 
patient PBMC were incubated with 5 x 104 irradiated (40 Gy) patient PBMC (autologous 
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response). After incubation of 7 days at 37 oC and 5% CO2, 200 µl cell culture supernatant 
was obtained and stored at –20 oC until use.
Human Cytokine Antibody Array
RayBio® Human Cytokine Antibody Array III (RayBiotech Inc, Norcross, GA, USA) was used 
to assay cell culture supernatants from the above mentioned MLR to determine 42 proteins, 
including cytokines, IL-1a, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40p70, 
IL-13, IL-15, IFN-g, TGF-β1, TNF-α, TNF-β; chemokines, GRO, CXCL1 (GRO-a), CXCL5 
(ENA-78), CXCL9 (MIG), CXCL12 (SDF-1), CCL1 (I-309), CCL2 (MCP-1), CCL5 (RANTES), 
CCL7 (MCP-3), CCL8 (MCP-2), CCL15 (MIP-1δ), CCL17 (TARC), CCL22 (MDC); and growth 
factors, GCSF, GM-CSF, MCSF, SCF, EGF, IGF-1, Angiogenin, oncostatin M, Thrombopoietin, 
VEGF, PDGF-BB, Leptin. As positive controls a biotin-conjugated IgG was provided by the 
manufacturer. The intensity of this positive signal (100%) was used to determine the relative 
protein expression levels of all samples measured. Small changes in the manufacturer’s 
recommended protocol were made: the membrane was treated for 6 hours with blocking 
buffer instead of 30 minutes, and the samples were diluted 1:10 in blocking buffer. To 
determine the relative protein expression levels, we used a MultiImage® Light Cabinet 
(Alpha Innotech Corporation, San Leandro, California, USA).
RESULTS
Inflammatory proteins are a group of proteins that act as mediators of cell communication. 
Based on this definition, inflammatory proteins include cytokines, chemokines, and growth 
factors. Therefore, we presented our data in three groups: cytokines, chemokines, and 
growth factors. The results are expressed as relative expression compared to a positive 
control included in the membrane of the array. The relative increase in cytokines (Figure 
1, 1A and 2A), chemokines (Figure 1, 1B and 2B), and growth factors (Figure 1, 1C and 
2C) was determined in culture supernatants from donor-stimulated MLRs compared to 
autologous control supernatants.
The donor response was higher than the autologous response for 15 of 17 (88%) 
cytokines in supernatant from recipient 1 (Figure 1, 1A), and 14 out of 17 (82%) cytokines in 
recipient 2’s supernatant (Figure 1, 2A). We also observed a greater donor than autologous 
response for 13 out of 13 (100%) chemokines in supernatant from recipient 1 (Figure 1, 
1B), and 12 out of 13 (92%) chemokines in supernatant from recipient 2 (Figure 1, 2B). In 
addition, for 10 out of 12 (83%) growth factors determined in a supernatant from recipient 
1 (Figure 1, 1C) and 12 out of 12 (100%) growth factors in the supernatant from recipient 
2, the donor response was higher than the autologous response  (Figure 1, 2C).
DISCUSSION
Advantages of the protein-array method include high sensitivity, simultaneous detection 
of multiple protein expression levels simultaneously, and easy performance. The array is 
a screening method. Thereafter, the exact concentration of proteins or cytokine producing 
cells of interest should be determined in ELISA or Elispot, respectively.
Recently, we demonstrated frequencies of IFN-g and granzyme B producing cells 
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Figure 1: Relative expression profile of cytokines (1A: recipient 1, 2A: recipient 2), chemokines (1B: 
recipient 1, 2B: recipient 2), and growth factors (1C: recipient 1, 2C: recipient 2) determined in do-
nor-stimulated MLR cultures from PBMC of HLA-identical LR kidney transplant recipients (black bars). 
Autologous stimulated cultures were considered as negative control (white bars). The intensity of a po-
sitive control (100%) was used to determine the relative expression levels of the inflammatory proteins.
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specific for donor antigens as determined by Elispot assay in recipients of HLA-identical 
LR kidney transplantation.4, 5 In addition, we found detectable numbers of IL-10 and IL-13 
producing cells in PBMC from some recipients of an HLA-identical LR kidney transplant, 
suggesting a T-helper 2-skewed alloreactivity directed to donor mHAgs or to non-HLA 
antigens.6 In the present study, we demonstrate that donor-reactive cytokine responses can 
even be observed for 90% (38/42) of the cytokines determined by a protein-array method. 
These results confirm our earlier results of donor-reactive cytokine producing cells directed 
toward donor antigens as detected by Elispot after HLA-identical LR kidney transplantation.4, 
5 We assume that the donor responses are directed toward donor mHAgs or toward non-HLA 
antigens.
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ABSTRACT
Background: It has been postulated that the plasmacytoid/myeloid dendritic cell ratio (pDC/
mDC) reflects immune reactivity, and can therefore be used to monitor transplant recipients. 
We investigated the influence of Ficoll-Paque separation and PBMC cryopreservation on the 
pDC/mDC ratio and the expression of maturation markers, e.g. chemokine receptors (CKR) 
CCR7, CXCR4, and CCR5, in comparison to fresh blood cells.
Methods: Fractions of pDC and mDC, and CKR expression were measured by flow cytometry 
in fresh blood, in Ficoll-isolated PBMC and in cryopreserved PBMC from healthy individuals 
and kidney transplant recipients.
Results: Ficoll-isolation of PBMC resulted in higher pDC/mDC ratios in both groups compared 
to fresh blood cells resulting from a relatively large increase in pDC compared to mDC. The 
pDC/mDC ratio increased further after cryopreservation of PBMC from kidney transplant 
recipients. Ficoll-isolation and cryopreservation of PBMC affected the proportion of mDC and 
pDC positive for CKR, and their expression levels resulting in a more mature phenotype.
Conclusions: The pDC/mDC ratio and pDC or mDC maturation status based on CKR 
expression, is dependent on manipulation of PBMC. Therefore, fresh blood is preferable for 
monitoring purposes in transplant patients, as only these cells reflect the in vivo immune-
status of patients accurately.
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INTRODUCTION
Dendritic cells (DC) are professional antigen presenting cells that play a critical role in the 
induction and regulation of immune responses. During their lifetime, DC are not only found in 
lymphoid tissues, but also in blood and in non-lymphoid tissues, where they act as sentinels 
for antigen capture. DC have different functions at various stages of maturation. Immature 
DC capture antigens by endocytosis, phagocytosis and pinocytosis, and differentiate into 
mature DC.1 Immature DC express chemokine receptors (CKR) CCR1, CCR2, CCR5, CXCR3 
and CXCR4, low levels of MHC class I and II molecules, and do not express CD83, CD54, 
CD80/CD86.2-6 Mature DC are highly specialised to activate T cells in the lymphoid organs 
and are characterised by high expression of CD83, CD54, CD80/86, and MHC class I and II 
molecules. Besides the upregulation of costimulatory molecules, the expression of CCR7 is 
enhanced, whereas CCR5 and CXCR4 is downregulated compared to immature DC.5, 7-10
In human peripheral blood, at least two DC subsets have been described: the 
CD11c+CD123low myeloid DC (mDC) and the CD11c-CD123high plasmacytoid DC (pDC).11 
Whereas mDC produce large amounts of IL-12 and induce strong T-helper 1 and cytotoxic T 
lymphocyte (CTL) responses, pDC induce T-helper 2 responses and produce lower amounts 
of IL-12. Additionally, pDC express the IL-3 receptor chain α (CD123), which is necessary for 
survival and differentiation, and are the main producers of IFN-a in response to viruses.12
The absolute number of pDC and mDC or their ratio (pDC/mDC) in peripheral 
blood could be useful for immunological monitoring in disease and organ transplantation.13-
18 Several studies have shown that the numbers of mDC and pDC in peripheral blood vary 
according to conditions such as exercise, stress, surgery, cancer, and leukemia, and lower 
mDC and pDC numbers have been reported in acquired immunodeficiency syndrome.13-16, 
18-20 In patients with acute myeloid leukemia, higher percentages of both pDC and mDC 
were observed in comparison to healthy individuals.15 In contrast, mDC were higher during 
end stage heart failure and had a partially mature phenotype based on their CCR7 and 
CD83 expression.21 After clinical heart transplantation, the absolute number of pDC and 
mDC in peripheral blood is strongly reduced21, and the number of mDC decreased further 
during acute rejection.20 Mazariegos et al.17 showed that the ratio between pDC and mDC 
in peripheral blood of stable liver transplant patients was higher in patients who could be 
successfully weaned from immunosuppression. 
Most of the aforementioned studies used a cocktail of DC Lineage (Lin1 method) 
negative monoclonal antibodies (mAbs), which includes mAbs for T cells, B cells, NK cells, and 
monocytes, in combination with HLA-DR, CD123 and CD11c mAbs.14, 15, 17, 18, 20, 21 Upham et 
al.13 used CD33 mAbs for identifying mDC, and Ho et al.19 used CMRF-44 mAbs for identifying 
peripheral blood DC. Recently, a new set of mAbs became available for identifying mDC and 
pDC: the blood dendritic cell antigen (BDCA)-1 mAbs are used for mDC, and BDCA-3 mAbs 
for a very small fraction of mDC which lack the expression of BDCA-1. BDCA-2 mAbs and 
BDCA-4 mAbs are used for identifying pDC.22 With the BDCA antibodies, it became possible 
to determine pDC and mDC without the use of a large number of Lineage-negative markers 
and anti-HLA-DR. Therefore, determination of the maturation status of both DC subsets is 
easier and more efficient compared to the Lin1-method.
In the described studies, variable cell-preparations were used. Most authors used 
PBMC isolated by Ficoll-Paque separation, with or without subsequent cryopreservation.14, 15, 
17, 19 Only Upham et al.13 and Athanassopoulos et al.20, 21 used fresh blood samples. However, 
in PBMC samples it is impossible to determine the absolute number of DC/µl blood. In 
addition, it is also unknown whether Ficoll-Paque separation alters the ratio between pDC 
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and mDC, or affects the maturation status of both DC subsets.
Objective
Since, it is practical and probably more accurate to measure sequential blood samples of one 
patient in one flow cytometric session, we investigated the influence of PBMC cryopreservation 
and storage on the pDC/mDC ratio and maturation status of DC subsets. Therefore, we 
compared the pDC/mDC ratio and the maturation status of the DC subsets in fresh blood, 
and in the same sample after Ficoll-Paque separation or subsequent cryopreservation. All 
tests were performed with the BDCA antibodies. In addition, we assessed the reproducibility 
of the BDCA method. Finally, in order to control the effect of immunosuppression, DC subsets 
were measured in fresh blood cells and cryopreserved PBMC from heart failure patients, who 
did not receive immunosuppression, by using the Lin1 method. 
MATERIALS AND METHODS
Study group
The study population consisted of healthy individuals (n=10), kidney transplant (KTx) 
recipients (n=9), and heart failure (HF) patients (n=5). Informed consent was obtained 
from each individual. Seven of the KTx recipients received a living-related donor kidney 
(KTx 1, 3, 4, 5, 6, 7, 9), and 2 recipients received a cadaveric donor kidney (KTx 2, 8). All 
KTx patients were selected at least 2 years after kidney transplantation (median, 5.9 years; 
range, 2.7-9.4). Median age of the healthy individuals, KTx recipients and HF patients was 
31.4 years (range, 24.4-55.6), 40.8 years (range, 26.4-51.3) and 57.8 years (range, 39.2-
62.4), respectively. Healthy individuals were significantly younger than KTx (p=0.002) and 
HF patients (p=0.003). No difference in age was found between KTx recipients and HF 
patients (p=0.90). Healthy individual and patient characteristics are described in Table 1.
Peripheral Blood Mononuclear Cells Sampling
From healthy individuals, KTx recipients and HF patients, 35 ml heparinized blood was 
obtained. 2 ml was used for fresh blood measurements, and 33 ml was used for isolation 
of peripheral blood mononuclear cells (PBMC) and subsequent cryopreservation. All blood 
samples were processed and measured within 1-3 h after collection.
PBMC were isolated from heparinized blood by density gradient centrifugation using 
Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden). PBMC were collected from 
the interphase, washed twice with RPMI-1640-DM (GibcoBRL, Scotland, United Kingdom) 
supplemented with 100 IU/ml of penicillin (Cambrex, Verviers, Belgium) and 100 µg/ml of 
streptomycin (Cambrex). To determine the ratio pDC/mDC, approximately 10x106 PBMC 
were used for direct flow cytometry.
Approximately 2x107 PBMC (PBMC-CRYO) were frozen in 2 ml RPMI-1640-DM 
containing 15% foetal calf serum (FCS) and 10% dimethyl sulfoxide (MERCK, Darmstadt, 
Germany) and stored at –80oC for at least 7 days. For successful cryopreservation of PBMC, 
Nalgene® Cryo Freezing containers (Nalgene Nunc International, Rochester, New York) were 
used, achieving a –1oC/minute rate of cooling when placed at –80oC. After thawing of the 
PBMC, cell viability was >95%.
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Antibodies for staining
For the BDCA method the following mouse anti-human monoclonal antibodies (mAbs) were 
used: allophycocyanin (APC)-conjugated BDCA-1 (clone: AD5-8E7) and APC-conjugated 
BDCA-2 (clone: AC144) (both purchased from Miltenyi Biotec, GmbH, Germany), peridinin 
chlorophyll protein (PerCP)-conjugated CD14 (clone: mφP9) and PerCP-conjugated CD19 
(clone: 4G7; both purchased from Becton Dickinson Biosciences, San Jose, CA, USA), 
fluorescein isothiocyanate (FITC)-conjugated CCR5 (CD195; clone: 2d7) and phycoerythrin 
(PE)-conjugated CXCR4 (CD184; clone: 12G5; both purchased from Becton Dickinson 
Pharmingen, San Diego, CA, USA), PE-conjugated CCR7 (clone: 150503; purchased from RD 
Systems, Minneapolis, USA). For the Lin1 method the following mouse anti-human mAbs were 
used: FITC-conjugated CD34 (clone 8G12), FITC-conjugated Lineage cocktail 1 (containing 
CD3 (clone: SK7), CD14 (clone: MφP9), CD16 (clone: 3G8), CD19 (clone: SJ25C1), CD20 
(clone: L27), and CD56 (clone: NCAM16.2)), PE-conjugated anti-IL-3 receptor α chain 
(CD123) (9F5), APC-conjugated CD11c (clone: S-HCL.3), PerCP-conjugated anti-HLA-DR 
(clone: L243) (all purchased from Becton-Dickinson Biosciences, San Jose, CA, USA).
Immunofluorescence staining and flow cytometric analysis – BDCA method
Analysis of mDC and pDC was performed by four-colour flow cytometry. BDCA-1 and BDCA-
2 were used to identify mDC and pDC, respectively. Another marker for identifying pDC is 
BDCA-4. However, staining with BDCA-2 mAbs results in a more compact cluster of cells 
Sex1
M/F
Age
(years)
Time after
Tx9 (years)
Immunosuppression (per day)
HI2 1 M 26.0 -
2 F 52.2 -
3 M 28.1 -
4 M 30.5 -
5 F 24.4 -
6 F 35.7 -
7 M 55.6 -
8 F 32.3 -
9 M 25.7 -
10 F 38.8 -
KTx3 1 M 38.6 9.4 150 mg AZA5 + 10 mg pred
2 M 45.4 7.9 2 mg Tacro6 + 1000 mg MMF7 + 2.5 mg pred
3 M 40.8 5.3 50 mg AZA + 5 mg pred8
4 M 45.1 5.9 50 mg AZA + 10 mg pred
5 M 30.8 6.1 75 mg AZA + 7.5 mg pred
6 M 51.3 6.7 1500 mg MMF + 5 mg pred
7 M 29.3 4.3 100 mg AZA + 10 mg pred
8 F 26.4 2.7 4 mg Tacro + 5 mg pred
9 F 50.2 3.9 8 mg Tacro + 500 mg MMF
HF4 1 M 62.4 Statines, Becotide
2 F 39.2 -
3 F 57.8 -
4 M 59.0 Statines
5 M 56.3 Pulmicort
Table 1: Healthy individual and patient characteristics  
1M, male; F, female; 2HI, healthy individuals; 3KTx, kidney transplant recipients; 4HF, heart failure 
patients; 5AZA, azathioprine; 6Tacro, tacrolimus; 7MMF, mycophenolate mofetil; 8pred, prednisone; 
9Tx, transplantation.
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Figure 1: Identification of peripheral blood dendritic cells (DC) phenotype (in healthy individu-
als and kidney transplant recipients). DC were identified in CD14 negative and CD19 negative po-
pulation (A). Myeloid DC (mDC) and plasmacytoid DC (pDC) were further analysed by high expres-
sion of BDCA-1 and BDCA-2, respectively (B). Characterization of the maturation status for both DC 
subsets was achieved by analysis of the chemokine receptor markers CCR7, CCR5 and CXCR4 (C).
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than BDCA-4 mAbs 22, thus only BDCA-2 mAbs was used in this study.    
In tubes 1 and 2, 300 µl fresh blood cells were incubated with 10 µl BDCA-1-APC mAbs, 15 
µl CD14-PerCP mAbs, and 30 µl CD19-PerCP mAbs. In tubes 3 and 4, 300 µl fresh blood cells 
were incubated with 10 µl BDCA-2-APC mAbs, 15 µl CD14-PerCP mAbs, and 30 µl CD19-
PerCP mAbs. In tubes 1 and 3 also 15 µl CCR7-PE mAbs were added, whereas in tubes 2 
and 4, 30 µl CCR5-FITC mAbs and 30 µl CXCR4-PE mAbs were added. Cells were incubated 
for 30 min in the dark at room temperature. Thereafter, erythrocytes were lysed with 2 ml 
FACS lysing solution (Becton Dickinson) for 10 minutes in the dark at room temperature. 
Subsequently, cells were centrifuged for 5 min at 2000 rpm and supernatant was discarded. 
Cells were washed twice in 2 ml FACSflow (Becton Dickinson) and centrifuged for 5 min at 
2000 rpm. Thereafter, cells were resuspended in at least 300 µl FACSflow. 
Ten million Ficoll-isolated PBMC were washed with 2 ml FACSflow and centrifuged for 
5 min at 2000 rpm. Thereafter, PBMC were resuspended in 1.5 ml FASCflow. Subsequently, 
300 µl cell suspension was added to the mAb cocktails as described for fresh blood cells, and 
incubated for 30 min in the dark at room temperature. After incubation, cells were washed 
twice with FACSflow, and at least 300 µl FACSflow was added to PBMC. 
After cryopreservation, PBMC were thawed, and 10x106 cells were used to determine 
the pDC and mDC fractions. First, PBMC were washed in 2 ml FACSflow and resuspended 
in 1.5 ml FASCflow. 300 µl cell suspension was added to the mAb cocktails as described 
for fresh blood cells, and incubated for 30 min in the dark at room temperature. After 
incubation, cells were washed twice with FACSflow and resuspended in 300 µl FACSflow.
 From each tube, 500 000 events were acquired on a FACScalibur flow cytometer 
using CELLQUEST PRO software (Becton Dickinson). As illustrated in Figure 1, CD14- and 
CD19- gated cells were analysed for BDCA-1 or BDCA-2 expression (Figure 1A). mDC and 
pDC were identified as CD14-CD19-BDCA-1+ cells and CD14-CD19-BDCA-2+ cells, respectively 
(Figure 1B). In 6 healthy individuals and 4 KTx patients, the proportion of mDC and pDC 
positive for CCR7, CCR5 and CXCR4 (Figure 1C) and their geometric Mean Fluorescence 
Intensity (gMFI) was determined.
Immunofluorescence staining and flow cytometric analysis – Lineage 1 method
Analysis of mDC and pDC with the Lin1 method was performed as described recently by 
Athanassopoulos.21 Briefly, 200 µl of fresh blood samples were incubated with 5 µl Lin1-FITC 
and 5 µl CD34-FITC mAbs, 5 µl HLA-DR-PerCP mAbs, 10 µl CD11c-APC mAbs (1:20 diluted 
in FACSflow), and 10 µl CD123-PE mAbs (1:5 diluted in FACSflow) for 30 min in the dark at 
room temperature. Subsequently, erythrocytes were lysed with 2 ml FACS lysing solution 
for 10 min in the dark at room temperature. Next, cells were centrifuged for 5 min at 2000 
rpm, and supernatant was discarded. Cells were washed twice with 2 ml FACSflow, and 
resuspended in 300 µl FACSflow.
Cryopreserved PBMC were thawed, washed in 2 ml FACSflow and resuspended in 
1.5 ml FASCflow at a concentration of 5x106 PBMC/ml. 300 µl cell suspension was added to 
the same amount of mAbs as described for fresh blood cells, and incubated for 30 min in 
the dark at room temperature. After incubation, cells were washed twice with FACSflow, and 
resuspended in 300 µl FACSflow.
From each tube, 300 000 events were acquired on a FACScalibur flow cytometer 
using CELLQUEST PRO software. Cells that stained negative for Lin1-cocktail and positive for 
HLA-DR expression were gated, and further defined for the expression of CD11c and CD123, 
which represents mDC and pDC, respectively.
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Biovariability and intra-assay reproducibility of the BDCA method
Biovariability of the BDCA method was performed in 5 healthy individuals (C1, C7, C8, C9, 
C10; Table 2). 7 ml of fresh blood cells from each individual was collected and the mDC and 
pDC fractions were measured at week 1, week 2, and week 3. 
Intra-assay reproducibility of the BDCA method was performed in 4 healthy individuals 
(C2, C7, C8, C9; Table 3). The staining as described in Section ‘Immunofluorescence staining 
and flow cytometric analysis - BDCA method’ was performed 5 times separately using the 
same blood sample to measure the pDC and mDC fractions.
Statistical analysis
The Wilcoxon signed rank test was used to compare the pDC/mDC ratio between fresh blood 
samples, PBMC, and PBMC-CRYO in healthy individuals, KTx recipients, and HF patients. The 
Wilcoxon signed rank test was also used to compare the percentage positive and expression 
levels of CCR7, CCR5, and CXCR4 on DC subsets between fresh blood samples, PBMC, and 
PBMC-CRYO in healthy individuals and KTx recipients. The Mann-Whitney U-test was used to 
compare the age of healthy individuals, KTx recipients and HF patients. Two sided p-values 
≤ 0.05 were considered significant. The coefficient of variation (CV) was used to measure 
biovariability and intra-assay reproducibility. For statistical analysis, SPSS 11.5 for Windows 
was used (SPSS, Inc., Chicago, IL, USA).
BDCA method
Individual Week % pDC % mDC pDC/mDC ratio
1 1 28 72 0.38
2 33 67 0.50
3 37 63 0.58
Mean
SD
CV %
32.7
4.5
13.8
67.3
4.5
6.7
0.49
0.10
2 1 31 69 0.45
2 26 74 0.35
3 26 74 0.35
Mean
SD
CV %
27.7
2.9
10.4
72.3
2.9
4.0
0.38
0.06
3 1 46 54 0.86
2 32 68 0.46
3 40 60 0.67
Mean
SD
CV %
39.3
7.0
17.9
60.7
4.0
11.6
0.67
0.20
4 1 38 62 0.61
2 40 60 0.68
3 38 62 0.62
Mean
SD
CV %
38.7
1.2
3.0
61.3
1.2
1.9
0.64
0.04
5 1 24 76 0.31
2 20 80 0.24
3 17 83 0.21
Mean
SD
CV %
20.3
3.5
17.3
79.7
3.5
4.4
0.25
0.05
Table 2: Biovariability of the BDCA method
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RESULTS
Biovariability and intra-assay reproducibility of the BDCA method
Blood from healthy individuals were taken on 3 consecutive weeks (Table 2). Within 3 weeks 
less than 18% variation (CV: range, 3.0-17.9%) existed between the percentage of pDC, 
and less than 12% variation for the mDC (CV: range, 1.9-11.6%).
Table 3 shows the intra-assay reproducibility of the BDCA method. In all controls, 
the CV for the pDC (range, 7.7-13.1%) and mDC (range, 1.6-6.8%) fractions was at all 
times lower than 14%.
Influence of Ficoll-Paque separation and subsequent cryopreservation on dendritic cell 
subset ratio in healthy individuals and kidney transplant recipients
Proportion of mDC and pDC was determined by flow cytometry from all healthy individuals 
and KTx recipients.
After Ficoll-isolation (PBMC), the pDC/mDC ratio was higher (median, 0.66; range, 
0.36-1.1) than in corresponding fresh blood samples (median 0.54; range, 0.17-0.86; 
p=0.02; Figure 2A) from healthy individuals. In PBMC-CRYO samples, the pDC/mDC ratio 
BDCA method
Individual measurement %pDC %mDC pDC/mDC ratio
1 1 26 74 0.35
2 29 71 0.40
3 31 69 0.44
4 29 71 0.40
5 26 74 0.34
Mean
SD
CV %
28.2
2.2
7.7
71.8
2.2
3.0
0.39
0.04
2 1 20 80 0.25
2 29 71 0.41
3 26 74 0.35
4 21 79 0.27
5 20 80 0.25
Mean
SD
CV %
24.4
3.2
13.1
75.6
3.2
4.2
0.32
0.06
3 1 14 86 0.16
2 11 89 0.13
3 14 86 0.16
4 12 88 0.14
5 14 86 0.17
Mean
SD
CV %
13.0
1.4
10.9
87.0
1.4
1.6
0.15
0.02
4 1 45 55 0.83
2 42 58 0.72
3 45 55 0.81
4 47 53 0.88
5 37 63 0.58
Mean
SD
CV %
43.2
3.9
9.0
56.8
3.9
6.8
0.77
0.12
Table 3: Intra-assay reproducibility of the BDCA method
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(median, 0.70; range, 0.28-1.1) was comparable to PBMC (p=0.51), but higher (p=0.007) 
than in corresponding unmanipulated fresh blood samples.
 Also in KTx recipients, the pDC/mDC ratio was higher in PBMC (median, 0.51; 
range, 0.23-0.89) than in corresponding fresh blood samples (median, 0.31; range, 0.15-
0.83; p=0.008) (Figure 2B). In PBMC-CRYO samples, the pDC/mDC ratio (median, 0.68; 
range, 0.40-1.2) increased further in comparison to Ficoll-isolated PBMC (p=0.09).
To investigate whether the increase in pDC/mDC ratio after cryopreservation in 
KTx recipients was due to immunosuppressive drugs, pDC/mDC ratio was also determined 
in HF patients, not treated with immunosuppression. The pDC/mDC ratio in PBMC-CRYO 
of HF patients was also higher (median, 1.5; range, 0.55-3.97) than the corresponding 
unmanipulated blood samples (median, 0.77; range, 0.18-1.69; p=0.04; Figure 2C).
Analysis of proportion mDC and pDC in unmanipulated cells, Ficoll-isolated and 
cryopreserved PBMC showed that manipulation of PBMC resulted in higher proportion of both 
mDC and pDC compared to unmanipulated cells in both groups (Table 4). After Ficoll-isolation 
of PBMC in healthy individuals, we found approximately 3-fold increase in proportion of both 
mDC and pDC compared to fresh blood cells. However, cryopreservation of PBMC resulted 
in a 5-fold increase in proportion of both mDC and pDC in comparison to unmanipulated 
cells. In KTx recipients, we found a 4-fold increase in proportion of both mDC and pDC after 
Ficoll-isolation of PBMC in comparison to fresh blood cells. Cryopreserved PBMC resulted 
in a 6-fold and 8-fold increase in proportion of mDC and pDC, respectively, compared to 
unmanipulated cells.
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Figure 2:  Dendritic cell subset ratio deter-
mined in fresh blood cells (FB), in PBMC se-
parated by Ficoll-Paque (PBMC), and in cry-
opreserved PBMC (PBMC-CRYO). The ratio of 
pDC/mDC was measured in healthy individu-
als (n=10; A), kidney transplant recipients 
(n=9; B), and heart failure patients (n=5; C).
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Effect of Ficoll-Paque separation and cryopreservation of PBMC on percentage dendritic cell 
subsets positive maturation markers
From 6 out of 10 healthy individuals and 4 out of 9 KTx recipients, percentage (%) of mDC 
and pDC positive for CKR were determined (Figure 3). Because of the low numbers, the 
healthy individuals (n=6) and KTx recipients (n=4) were combined in one group. 
In PBMC samples (median, 54.6%; range 15.2-99.87), %CCR7+ mDC was higher than in both 
corresponding fresh blood samples (median, 15.0%; range, 8.3-46.0; p=0.03) and PBMC-
CRYO samples (median, 11.6%; range, 1.3-94.2; p=0.005; Figure 3A). After PBMC-CRYO, 
%CCR5+ mDC (median, 76.8%; range, 60.0-98.1) was lower compared to unmanipulated 
blood samples (median, 97.9; range, 82.4-99.4; p=0.03) and PBMC samples (median, 
93.9%; range, 85.6-99.6; p=0.02; Figure 3B). For %CXCR4+ mDC, comparable results were 
found as for CCR5+ mDC (Figure 3C). Comparable results were found between %CCR5+ mDC 
and CXCR4+ mDC, because both CKR were analysed in the same dotplot (Figure 1C).
As for mDC, %CCR7+ pDC was also higher in PBMC samples (median, 98.4%; 
range, 93.7-99.9) than in unmanipulated blood samples (median, 96.7%; range, 92.5-98.7; 
p=0.04) and in PBMC-CRYO (median, 96.7; range 93.5-98.3; p=0.03; Figure 3D). As shown 
Proportion mDC (%) Proportion pDC (%) n-fold increase in
mDC compared to
FB
n-fold increase in
pDC compared to
FB3FB
4P
B
M
C
5C
R
Y
O
FB PB
M
C
C
R
Y
O
P
B
M
C
:F
B
C
R
Y
O
:FB
P
B
M
C
:F
B
C
R
Y
O
:FB
HI11 0.26 0.81 0.91 0.06 0.37 0.37 3.1 3.5 6.2 6.2
HI2 0.19 0.78 0.77 0.11 0.69 0.71 4.1 4.1 6.3 6.5
HI3 0.22 1.06 1.35 0.11 0.85 0.89 4.8 6.1 7.7 8.1
HI4 0.26 1.09 1.31 0.05 0.59 0.56 4.2 5.0 11.8 11.2
HI5 0.15 0.79 0.92 0.09 0.85 0.86 5.3 6.1 9.4 9.6
HI6 0.17 0.52 0.57 0.10 0.45 0.45 3.1 3.4 4.5 4.5
HI7 0.29 0.84 0.62 0.13 0.45 0.45 3.0 2.1 3.5 3.5
HI8 0.07 0.43 0.43 0.06 0.28 0.47 6.1 6.1 4.7 7.8
HI9 0.32 0.95 1.13 0.10 0.34 0.32 3.0 3.5 3.4 3.2
HI10 0.31 1.08 1.19 0.19 0.72 0.77 3.5 3.8 3.8 4.1
median 3.8 4.0 5.5 6.4
KTx12 0.12 0.75 0.61 0.10 0.66 0.73 6.3 5.1 6.6 7.3
KTx2 0.08 0.37 0.33 0.03 0.19 0.24 4.6 4.1 6.3 8.0
KTx3 0.20 0.93 0.72 0.03 0.21 0.29 4.7 3.6 7.0 9.7
KTx4 0.10 0.46 0.52 0.03 0.41 0.46 4.6 5.2 13.7 15.3
KTx5 0.16 0.70 0.63 0.05 0.36 0.43 4.4 3.9 7.2 8.6
KTx6 0.14 0.45 0.57 0.18 0.38 0.43 3.2 4.1 2.1 2.4
KTx7 0.24 0.85 0.88 0.07 0.32 0.39 3.5 3.7 4.6 5.6
KTx8 0.16 0.50 0.35 0.03 0.20 0.24 3.1 2.2 6.7 8.0
KTx9 0.31 0.97 1.40 0.13 0.72 0.87 3.1 4.5 5.5 6.7
median 4.4 4.1 6.6 8.0
Table 4: Influence of Ficoll-Paque separation and PBMC cryopreservation on proportion pDC and mDC in 
comparison to fresh blood cells
1HI, healthy individual; 2KTx, kidney transplant recipient; 3FB, fresh blood cells; 4PBMC, Ficoll-isolated 
PBMC; 5CRYO, cryopreserved PBMC.
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in Figure 3E, %CCR5+ pDC in fresh blood samples was higher (median, 99.8%, range, 99.4-
100) than the corresponding PBMC (median, 98.6%; range, 93.3-99.4; p=0.005) and PBMC-
CRYO (median, 97.7%; range, 89.6-99.3; p=0.005). Comparable results were observed for 
%CXCR4+ pDC (Figure 3F).
Effect of Ficoll-Paque separation and cryopreservation of PBMC on chemokine receptor 
expression levels on dendritic cell subsets
The expression levels (gMFI) of CKR on DC subsets were also determined in 6 healthy 
individuals and 4 KTx recipients.
The expression of CCR7 on mDC was comparable between PBMC, PBMC-CRYO, and 
fresh blood samples (Figure 4A). In contrast, the expression of CCR5 on mDC was lower after 
cryopreservation (median, 56.6 gMFI; range, 8.6-95.4) compared to fresh blood samples 
(median, 69.9 gMFI; range, 36.5-114.9; p=0.01) and PBMC (median, 70.6 gMFI; range, 
44.8-108.1; p=0.05; Figure 4B). In comparison to unmanipulated fresh blood samples, 
expression of CXCR4 on mDC showed no differences between PBMC samples and PBMC-
CRYO (Figure 4C).
The expression of CCR7 on pDC was higher in PBMC samples (median, 45.4 gMFI; 
range, 18.6-76.5; p=0.005) and PBMC-CRYO (median, 43.0; range, 22.6-67.5; p=0.005) 
compared to unmanipulated blood samples (median, 26.7; range, 11.6-40.2; Figure 4D). A 
decrease in CCR5 expression on pDC was observed in PBMC samples (median, 53.8 gMFI; 
range, 28.2-85.1) compared to fresh blood samples (median 72.8 gMFI; range, 39.0-131.4; 
p=0.005; Figure 4E). CCR5 expression on pDC decreased even further after cryopreservation 
compared to PBMC (median, 27.8 gMFI; range, 16.8-61.7; p=0.005). Also, CXCR4 expression 
on pDC showed lower expression in PBMC samples (median, 46.9 gMFI; range, 12.3-62.5; 
p=0.005) and PBMC-CRYO (median, 39.1 gMFI; range, 6.0-236.1; p=0.007) compared to 
unmanipulated samples (median, 183.4 gMFI; range, 95.3-238.4; Figure 4F).
 
Some differences in the pDC population between the KTx recipients and healthy individuals 
were found. The percentage (%; Figure 3) pDC positive for CCR7 and expression (gMFI; 
Figure 4) of CCR7 on pDC were higher in fresh blood cells from KTx recipients than healthy 
individuals. The percentage pDC positive for CCR5 and CXCR4, and gMFI of CCR5 and CXCR4 
on pDC were comparable between both groups. After Ficoll-isolation of PBMC, percentage 
pDC positive for CCR7, CCR5 and CXCR4, and expression of CCR7, CCR5 and CXCR4 on pDC 
were higher (p<0.05) in KTx recipients than in healthy individuals. After cryopreservation 
the percentage pDC positive for CCR7, CCR5 and CXCR4, and expression of CCR7, CCR5 and 
CXCR4 on pDC were comparable between the two groups.
DISCUSSION
In the present study, we demonstrate that Ficoll-Paque separation and subsequent 
cryopreservation of PBMC induces higher pDC/mDC ratios than the pDC/mDC ratio in fresh 
blood samples. Additionally, the biovariability within 3 weeks of the BDCA method shows 
that the CV of percentage pDC ranged between 3.0% and 17.9%, and percentage mDC 
demonstrates a CV always lower than 12%. The higher variability in pDC can be explained 
by the lower number of pDC present in fresh blood compared to the higher mDC numbers. 
These results are in line with a study of Hackstein et al.23 who found an average CV of 3.8% 
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for mDC and 2.9% for pDC, only for pDC we found higher CV. 
The result of our study demonstrated that blood manipulations such as Ficoll-
isolation and subsequent cryopreservation of PBMC influenced the proportion of both pDC 
and mDC. The relative large increase in pDC compared to mDC result in higher pDC/mDC 
ratio after blood manipulation compared to unmanipulated blood cells. KTx recipients 
received immunosuppression which is known to influence DC numbers, and DC development 
and differentiation.20, 24, 25 To exclude that immunosuppression resulted in an additional effect 
on the pDC/mDC ratio, besides blood manipulations, the pDC/mDC ratio was measured in 
HF patients who did not receive immunosuppression. The results were comparable to those 
in KTx recipients, suggesting that higher pDC/mDC ratio in PBMC samples were caused by 
blood manipulations, and not by immunosuppressive drugs. 
In peripheral blood, BDCA-1 (CD1c) antigen is expressed on human mDC, but also 
on B cells. In fresh blood, the identification of CD14-CD19-BDCA-1+ mDC was performed 
as illustrated in Figure 1. However, Ficoll-isolation and cryopreservation of PBMC resulted 
in lower expression of CD19 on PBMC. As a consequence, B cells contaminated the CD14-, 
CD19- fraction, resulting in a complex distinction in the identification of mDC compared to 
unmanipulated cells. In addition, lower CD14 expression on monocytes was observed after 
Ficoll-isolation and cryopreservation of PBMC in comparison to fresh blood cells, which made 
the analyses of DC subsets even more complicated. Therefore, in comparison to fresh blood 
cells, blood manipulation of PBMC resulted in an altered proportion of pDC and mDC not 
corresponding to the in vivo situation in healthy individuals and transplant recipients, thus 
causing incorrect interpretation of the results.
Recent studies showed a relation between the number of pDC and age in healthy 
individuals.18, 23, 26 High numbers of pDC were found in individuals from 0-10 years of age, 
resulting in higher pDC/mDC ratio for young people.18, 23, 26 Vuckovic et al.18 showed that 
young individuals (<10 years) also have high number of mDC. In our study, all individuals 
tested were more than 24 years of age. Healthy individuals were younger than KTx recipients 
as well as HF patients, but all groups demonstrated comparable results with higher pDC/
mDC ratio after blood manipulations. This suggests that age in this study probably did not 
affect the pDC/mDC ratio.
It has been suggested that the pDC/mDC ratio in peripheral blood might be useful 
for immunological monitoring in disease and organ transplantation.17 For such monitoring 
purposes, we recommend that fresh blood cells should be used, because only this reflects 
the in vivo immune-status of transplant recipients. In multicenter trials, and trials with 
many patients, one has to keep in mind that only reliable results in pDC/mDC ratios will 
be obtained when using fresh blood cells. Similarly, other studies have also shown that 
lymphocyte subsets determination was more reliable in fresh blood than in Ficoll-isolated 
PBMC.27, 28 The number of B cells and CD8+ cells were lower in Ficoll-isolated PBMC than 
in fresh blood cells, and the number of NK cells was higher after Ficoll-isolation of PBMC. 
Therefore, our results support the idea that both DC, as other lymphocyte subsets, should 
be measured in fresh blood for immunological monitoring purposes.
DC require signals to induce their differentiation and activation.1 We examined the 
influence of Ficoll-isolation and cryopreservation of PBMC on maturation markers based on 
CKR. Those blood manipulations resulted in a shift towards mature DC by higher %CCR7+ 
mDC and %CCR7+ pDC. Additionally, lower %CCR5+, CXCR4+ mDC and %CCR5+, CXCR4+ pDC 
were found, suggesting that Ficoll-isolation and cryopreservation affects DC differentiation.
Costantini et al.29 analysed the effect of cryopreservation on lymphocyte 
immunophenotype in healthy individuals and HIV-infected individuals. They found that 
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cryopreservation and Ficoll-isolation of PBMC decreased the %CCR5+ T cells compared 
to fresh whole blood. In contrast, cryopreservation and Ficoll-isolation did not affect the 
expression of CXCR4+ T cells. A study of Shalekoff and Tiemessen30 reported higher 
%CXCR4+ cells and lower expression of CCR5 on leukocytes after overnight incubation with 
fluorescent-monoclonal antibody than after staining within 6 hours. This also suggests that 
most CKR are sensitive to small blood manipulations, and should therefore be measured in 
fresh blood samples within 4 h of blood sampling. 
Recent studies analysed the DC maturation status after cryopreservation.31, 32 John 
et al.31 showed that CD83 expression was higher after cryopreserved cultured immature DC 
compared to fresh cultured immature DC, suggesting a phenotypically mature DC. On the 
other hand, Hori et al.32 found no differences in the percentage CD83 either in cryopreserved 
cultured mature DC or in freshly cultured mature DC. We did not find differences between 
CD83 expression on DC after cryopreservation and CD83 expression after fresh blood 
samples (data not shown).
In conclusion, the current study shows that determination of pDC/mDC ratio and 
DC subset maturation status based on CKR expression is strongly influenced by Ficoll-Paque 
separation and subsequent cell cryopreservation. We recommend that only fresh blood 
samples should be used for monitoring purposes in both patient and control subjects.
Acknowledgment: This study was supported by grant C02.2002 from the Dutch Kidney 
Foundation.
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ABSTRACT
Background: A major goal in organ transplantation is to define the optimal immunosuppressive 
dose. Recently, we demonstrated that the frequency of cytotoxic T lymphocytes (CTLpf) 
identifies patients in whom the immunosuppressive load can be safely reduced. However, 
in peripheral blood mononuclear cells (PBMC) from HLA-identical living-related (LR) kidney 
transplant patients, no donor-specific CTLpf can be measured. The determination of the 
functional activity of cytotoxic T lymphocytes (CTL) could be an alternative method for the 
CTLpf. Granzyme B (GrB) is present in the granules of CTL and is involved in the direct 
lethal hit of donor target cells. Therefore, we wondered whether the GrB Elispot assay 
is an alternative method to determine the activity of CTL after HLA-identical LR kidney 
transplantation. 
Methods: We measured the number of GrB producing cells (pc) against donor PBMC 
and 3rd-party PBMC in PBMC from HLA-identical patients who were reduced in their 
immunosuppression from 100% to 50% AZA with 5 to 10 mg/day prednisone.
Results: We found low numbers of GrB pc before reduction of immunosuppression, as only 
20% of the patients’ PBMC responded to donor cells, whereas 57% of the patients’ PBMC 
responded to donor cells after reduction of immunosuppression. After 3rd-party stimulation, 
the number of GrB pc increased after tapering the immunosuppressive load (p=0.03).
Conclusion: Our results demonstrate that the GrB Elispot assay might be used as an 
alternative for the CTLpf after HLA-identical LR kidney transplantation.
Granzyme B Elispot assay determines the cytotoxic T-lymphocyte precursor frequency 
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INTRODUCTION
After organ transplantation most patients receive a standard dose of immunosuppression 
to prevent acute rejection. However, the chronic use of immunosuppression may result 
in several side-effects, such as infection, cancer, and diabetes mellitus.1 Therefore, it is 
warranted to minimize the immunosuppressive load, provided this is not accompanied by 
acute rejection.
In the HLA-identical living-related (LR) kidney transplant setting, the HLA molecules 
are identical between patient and donor. However, differences may exist in the expression of 
minor histocompatibility antigens (mHAgs). mHAgs are peptides derived from polymorphic 
intracellular proteins presented in the context of HLA molecules that can be recognized by the 
immune system.2 The clinical relevance of mHAgs after clinical transplantation is not known. 
After HLA-identical LR kidney transplantation, mHAgs might be responsible for alloreactivity 
as has been shown for graft-versus-host after identical bone marrow transplantation.3
Recently, we showed that kidney transplant patients with low donor-specific 
cytotoxic T lymphocyte precursor frequencies (CTLpf) could be safely reduced in their 
immunosuppression without the occurrence of rejection.4 However, in HLA-identical LR 
kidney transplant patients, no donor-specific CTLpf can be measured. The functional activity 
of cytotoxic T lymphocytes (CTL) might be an alternative for the CTLpf that determines the 
cytolytic activity of CTL.5 Granzyme B (GrB) is a relevant surrogate marker for functional 
activity of CTL. GrB is present in the granules of CTL and is involved, together with perforin, 
in inducing cell death in donor target cells through cleavage at specific aspartate residues 
resulting in mitochondrial damage.6 We wondered whether the GrB Elispot assay is an 
alternative for determining the functional activity of CTL after HLA-identical LR kidney 
transplantation. In a pilot study, we determined the number of GrB pc in peripheral blood 
mononuclear cells (PBMC) from HLA-identical LR kidney transplant patients who were reduced 
from 100% azathioprine (AZA) in two steps to 50% AZA in combination with standard dose 
prednisone.
MATERIALS AND METHODS
Patients and PBMC sampling
GrB Elispot assays were performed in PBMC from seven patients who were more than 2 
years post HLA-identical LR kidney transplantation (median, 4.6 years; range, 2.4-10.1). 
The patients were tapered from 100% AZA (median, 1.7 mg/kg; range, 1.1-1.8) in two 
steps to 50% AZA (median, 0.7 mg/kg; range, 0.5-1.1) in combination with 5 to 10 mg/
day prednisone (Pred). Not enough PBMC were present in two patients to determine the 
number of GrB pc at 100% AZA. PBMC were isolated from heparinised blood by density 
gradient centrifugation using Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden) 
as described before4 and stored at –140oC until use.
Proliferation assay
The phytohemagglutinin (PHA) proliferation assay was performed to control viability of 
PBMC.7 Only viable cells, according to this stimulation assay (stimulation index: ratio of the 
counts per minute obtained in the presence of PHA to the count per minute in the absence 
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of PHA ≥ 50), were analysed in the described results.
GrB Elispot assay
In a 96-well round bottom plate, 100 µl of 2x105 patients’ PBMC in complete culture medium7 
was added to 100 µl of 2x105 irradiated (40 Gy) PBMC derived from the donor. In addition, 
100 µl of 1x105 patients’ PBMC was added to 100 µl of 1x105 irradiated (40 Gy) 3rd-party 
PBMC. To control the influence of irradiation on cytokine production, 1x105 patients’ PBMC 
were incubated with 1x105 irradiated (40 Gy) patients’ PBMC. If responses were found in this 
control, it was subtracted from the donor-reactive and 3rd-party response. The GrB Elispot 
assay was performed according to manual from the Elispot kit (Sanquin, Amsterdam, The 
Netherlands).
Statistical analysis
The Mann Whitney U-test was used to compare the patients who received 100% AZA with 
those who received 50% AZA. Two sided p-values ≤ 0.05 were considered significant.
RESULTS AND DISCUSSION
As shown in Figure 1A, before reduction of immunosuppression a median frequency of 0 GrB 
pc/106 PBMC (range: 0-80) was found after stimulation with donor PBMC. After tapering the 
immunosuppression to 50% AZA, a median frequency of 35 GrB pc/106 PBMC was found 
(range: 0-150; p=0.27). Interestingly, before the reduction of immunosuppression, only 
one of five (20%) of the HLA-identical patients responded against donor PBMC, whereas four 
of seven (57%) PBMC from those patients responded against donor PBMC after reduction of 
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Figure 1: Number of donor-reactive (A) and 3rd-party (B) reactive granzyme B (GrB) producing cells 
(pc) in PBMC from HLA-identical living-related kidney transplant patients. Reactivity was measured before 
(100% AZA; n=5) and after (50% AZA; n=7) tapering of immunosuppression by using a GrB Elispot assay.
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immunosuppression.
We also observed before reduction of immunosuppression, that three of five (60%) 
of the patients’ PBMC responded to 3rd-party PBMC. The median frequency of the whole group 
before tapering of immunosuppression was 5 GrB pc/106 PBMC (range: 0-15) (Figure 1B). 
After tapering of immunosuppression, six of seven (86%) of the patients’ PBMC responded 
to 3rd-party PBMC. The median of the whole group after tapering of immunosuppression was 
90 GrB pc/106 PBMC (range: 0-230; p= 0.03). 
 Our results demonstrate that after HLA-identical LR kidney transplant patients, GrB 
pc can be determined mainly after reduction of immunosuppression. We assume that these 
responses are directed toward the mismatched donor mHAgs, and that the GrB Elispot assay 
can be used as an alternative for the CTLpf after HLA-identical LR kidney transplantation. 
Other groups used the interferon-g (IFN-g) Elispot assay as marker for the number of CTL.8, 
9 Recently, we demonstrated that IFN-g pc specific for donor mHAgs can also be found after 
HLA-identical LR kidney transplantation.7 In the future, we will determine the number of 
IFN-g pc and GrB pc after tapering immunosuppression in HLA-identical LR kidney transplant 
patients to validate the clinical relevance of both Elispot assays.
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ABSTRACT
Background: Human leucocyte antigen (HLA)-identical living-related (LR) kidney transplant 
recipients often receive the standard regimen of immunosuppression. We wondered whether 
these patients should be exposed to the side effects of these drugs any longer. Safe 
tapering of immunosuppression should not result in rejection and high donor-directed T-cell 
responses. In the present study, we investigated the effect of tapering azathioprine (AZA) 
on T-cell reactivity. 
Methods: Fifteen HLA-identical LR kidney transplant recipients receiving a median of 150 
mg/day AZA and 5-10 mg/day prednisone were tapered to a median of 50 mg/day AZA. 
Donor, 3rd-party, and tetanus toxoid (TET)-reactivity were determined in interferon (IFN)-g 
and interleukin (IL)-13 Elispot assays, which reflects the T-helper (Th)1 and T-helper (Th)2 
response.
Results: After tapering of AZA, none of the patients developed acute rejection and the renal 
function remained stable, even at 1-year follow-up. The frequency of donor-reactive IFN-
g and IL-13 producing cells (pc) was low. Tapering of AZA did not influence the frequency 
of both IFN-g and IL-13 pc. Also, the reactivity against 3rd-party cells and TET remained 
unchanged.
Conclusions: The AZA dose can be safely reduced in recipients of an HLA-identical LR 
kidney transplant without affecting kidney function and without increasing T-cell responses 
directed against donor or other antigens. 
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INTRODUCTION
Organ transplantation has become the preferred treatment for end-stage kidney function. 
To prevent graft rejection, transplant recipients receive immunosuppressive drugs to 
suppress immune responses directed to the foreign organ. Generally, lifelong administration 
of immunosuppressive drugs after transplantation is deemed necessary. However, chronic 
use of immunosuppression in transplant recipients is associated with several serious side 
effects, such as infections, osteoporosis, diabetes mellitus, and cancer.1, 2 Consequently, 
discontinuation of immunosuppression is warranted, provided this is not accompanied by 
rejection.3-5
In the human leucocyte antigen (HLA)-identical living-related (LR) kidney 
transplant setting, the major HLA molecules A, B, C, DR, DQ, and HLA-DP are identical. 
However, mismatches may exist in minor histocompatibility antigens (mHAgs). The mHAgs 
are peptides derived from polymorphic intracellular proteins presented in the context of HLA 
molecules, which can be recognized by the immune system.6-10 The expression of mHAgs is 
ubiquitous or specific on haematopoietic cells.11
In humans, mismatches in mHAgs have been shown to induce graft-versus-host 
disease (GVHD) after HLA-identical bone marrow transplantation (BMT). Goulmy et al. 
demonstrated that one or more disparities of HA-1, HA-2, HA-4, and HA-5 were associated 
with the development of GVHD.12 After BMT, male recipients who received an HLA-identical 
graft from a female donor are more at risk in developing GVHD than those who received 
a graft matched for gender.13 This risk is due to an enhanced activity against mHAgs HY 
encoded on the Y chromosome. Studies have shown the existence of HY specific cytotoxic T 
lymphocyte (CTL) after gender-mismatched BMT.14
The role of mHAgs in clinical solid organ transplantation is yet not known. Recently, 
Opelz described an association between the presence of panel reactive antibodies (PRA) in 
kidney transplants from HLA-identical sibling donors and long-term graft loss.15 Theoretically, 
after HLA-identical LR kidney transplantation, mHAgs, but also other non-HLA antigens15, 
16, might be responsible for the induction of acute or chronic rejection of the transplant. 
Therefore, HLA-identical LR kidney transplant recipients still receive immunosuppression. 
Considering the adverse effects of immunosuppression, we questioned whether these 
patients should be exposed to the severe side effects of immunosuppression.
After HLA-mismatched kidney transplantation, some studies reported a relation 
with increased T-cell reactivity in mixed lymphocyte culture (MLC), CTL precursor frequency 
(CTLpf), helper T lymphocyte precursor frequency (HTLpf), and acute rejection after tapering 
of immunosuppression.17-20 However, in the HLA-identical LR kidney transplant setting, no 
donor-reactive responses can be measured in CTLpf, HTLpf and MLC. Recently, we have 
shown that a sensitive method as the Elispot assay can be used to determine the reactivity 
against non-HLA antigens in the first period after HLA-identical LR kidney transplantation.21 
The Elispot assay can be used to determine the frequency of pro-inflammatory cytokines 
(e.g. IFN-g) and anti-flammatory cytokines (e.g. IL-13) directed to donor antigens. Both 
types of cytokines have been associated with acute rejection22, 23, while Th2-cytokines also 
have been suggested with graft acceptance.24, 25
In the current study, HLA-identical LR kidney transplant recipients, more than 
2 years after transplantation, were safely tapered to at least 50% of their azathioprine 
(AZA) dose. We questioned whether tapering the immunosuppressive load would result in 
increased T-cell reactivity in peripheral blood mononuclear cells (PBMC) from HLA-identical 
LR kidney transplant recipients. T-cell reactivity against donor, 3rd-party, and tetanus toxoid 
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(TET) antigens was retrospectively measured in IFN-g and IL-13 Elispot assays.
SUBjECTS AND METHODS
Patients
HLA-identical LR kidney transplant recipients, treated with AZA and prednisone, were 
asked to participate in this study. They were at least 2 years after transplantation, had 
no acute rejection in the last 6 months, had stable renal function, and no clinical relevant 
proteinuria (≥ 0.5 g/l). Fifteen patients agreed to participate. Characteristics of the patients 
are described in Table 1. At inclusion of the study, the patients received a median dose of 
150 mg/day AZA (range, 100-175 mg/day; ‘high AZA’) in combination with a median dose 
of 10 mg/day prednisone (range, 5-10 mg/day; Pred). The AZA dose was tapered twice with 
a four months interval to a median dose of 50 mg/day AZA (range, 50-100 mg/day; ‘low 
AZA’). The prednisone dose remained unchanged. Peripheral blood samples were analyzed 
at inclusion and 4 months after the last mentioned AZA dose reduction. Renal function was 
closely monitored.
PBMC Sampling
PBMC were isolated from heparinized blood by density gradient centrifugation using Ficoll-
Paque (Amersham Biosciences, Uppsala, Sweden) as described before.21 Thereafter, PBMC 
were stored in RPMI-1640-DM (BioWhittaker, Verviers, Belgium) containing 15% fetal calf 
serum (FCS) and 10% dimethyl sulfoxide (MERCK, Germany) at –140oC until use.
IFN-g and IL-13 Elispot assay
The phytohemagglutinin (PHA) proliferation assay was performed to control the viability of 
the PBMC as described before.21 The mean counts per minute (cpm) were determined, and 
the stimulation index (SI) was calculated by the ratio of the cpm obtained in the presence of 
PHA to the cpm in the absence of PHA. Only results of viable cells (SI ≥ 50) were analyzed 
in the described results.
Before the first tapering of the immunosuppressive medication, we received 35 
ml heparinized peripheral blood from 15 patients. Four months after the last AZA dose 
reduction, we received again 35 ml blood from those patients to perform Elispot assays. 
The IFN-g and IL-13 Elispot assays (U-CyTech Biosciences, Utrecht, The Netherlands) were 
performed as described before.21 Briefly, in a 96-well round bottom plate (Nunc, Roskilde, 
Denmark), 100 µl of 2x105 patients’ PBMC in culture medium was added to 100 µl of 2x105 
irradiated (40 Gy) PBMC derived from the donor. As control, unstimulated responder cells 
were used and subtracted from donor-reactive responses. PBMC from the patient were also 
stimulated with 1 µg/ml PHA (Murex Biotech), 3rd-party cells and 30 lf/ml tetanus toxiod 
(TET, RIVM, Bilthoven, The Netherlands). PHA was used as a positive control and showed in 
all experiments more than 100 spots per well. The 3rd-party PBMC used did not share HLA 
antigens with donor and patient. Both before and after tapering of immunosuppression, the 
same 3rd-party PBMC were used. TET stimulation was used to test the immune response 
to nominal antigens. After 40 h of incubation, the non-adherent cells were transferred to a 
96-well plate pre-coated with anti-human IFN-g or IL-13 monoclonal antibodies. The cells 
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were incubated for 5 h at 37oC to allow the formation of spots. The spots were counted 
automatically by using a Bioreader 3000 Elispot reader (BioSys, GmbH, Karben, Germany). 
Minor histocompatibility antigens typing after HLA-identical living-related kidney 
transplantation
Patient PBMC and donor PBMC were typed for 10 known mHAgs: H-Y, HA-1, HA-2, HA-3, 
HA-8, HB-1, BCL2A1 [encoded by two separate single nucleotide polymorphisms (ACC-1 and 
ACC-2) on a single gene], HwA-9, and UGT2B17 (Table 2). DNA from the selected couples 
(Table 1) was isolated using the QIAamp® DNA Mini Kit. The polymerase chain reaction 
(PCR-SSP) technique was used as typing method.26 This is a PCR-based technique with the 
use of Sequence Specific Primers, which shortens the post-amplification processing time to a 
simple gel electrophoresis detection step. Each tested mHAgs is a part of a di-allelic system. 
This means that each locus contains two alleles. We used a specific primer combination for 
each allele, to test the presence of this allele (Table 2).
Statistical analysis
Numerical data were compared using the Wilcoxon signed rank test. Two sided p-values ≤ 
0.05 were considered significant. For statistical analysis GraphPad statistical program was 
used (GraphPad Software Inc., San Diego, CA, USA).
RESULTS
Clinical results
After tapering the AZA dose to at least 50% of the original dose, none of the HLA-identical 
LR renal transplant recipients developed acute rejection. Their serum creatinine levels 
remained unchanged before and 4 months after halving the AZA dose (before tapering: 
median, 103 µmol/l; range, 63-128; after tapering: median, 102 µmol/l; range, 63-136). 
At 1-year follow-up, no clinical relevant increase in serum creatinine (median, 111 µmol/l; 
range, 67-138) and no proteinuria (≥0.5 g/l) had occurred. Additionally, haematological 
parameters [haemoglobline, haematocrite, mean cell volume (MCV), thrombocytes and 
leucocytes] remained normal during tapering of AZA (data not shown). 
IFN-g Elispot
Before tapering of AZA (‘high AZA’), and 4 months after AZA-reduction (‘low AZA’), 11 out 
of 15 (73%) HLA-identical patients responded to donor antigens (Figure 1A). The median 
frequency of IFN-g producing cells (pc) directed to donor antigens after reduction of AZA 
(median, 1 IFN-g pc/2x105 PBMC; range, 0-110; p=0.99) was comparable with before dose 
reduction (median, 2 IFN-g pc/2x105 PBMC (range, 0-88).
 Before reduction of AZA, 13 out of 15 (87%) patients responded to HLA-mismatched 
3rd-party PBMC. After tapering to low AZA, 15 out of 15 (100%) patients responded to 
3rd-party antigens (Figure 1B). The median frequency of IFN-g pc directed to 3rd-party 
antigens after tapering of AZA (median, 12 IFN-g pc/2x105 PBMC; range, 2-324; p=0.95) 
was comparable with before tapering (median, 14 IFN-g pc/2x105 PBMC; range, 0-305). The 
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response to HLA-mismatched 3rd-party antigens was significantly higher than the response 
to donor antigens (p<0.01). 
Before tapering AZA dose, we found that 13 out of 15 (87%) patients responded to TET. 
The median frequency of IFN-g pc directed to TET antigens before tapering AZA was 7 IFN-
g pc/2x105 PBMC (range, 0-1200). After tapering to low AZA, 11 of the 15 patients (73%) 
responded to TET, and tapering of AZA did not influence the number of IFN-g pc (median, 3 
IFN-g pc/2x105 PBMC; range, 0-1200; p=0.38).
Some of the HLA-identical patients had high responses against donor-PBMC in the 
IFN-g Elispot assay (≥ 10 IFN-g pc/2x105 PBMC; high responders). We analyzed whether 
other parameters could clarify the differences between high responders and nonresponders 
(0 IFN-g pc/2x105 PBMC). Haematological parameters, transaminases, and renal function 
(proteinuria and creatinine clearance) were comparable between high responders and 
nonresponders.
After 3rd-party stimulation, we observed in four patients (patient 3, 4, 7 and 15) 
high frequencies of IFN-g pc before and/or after tapering of AZA (> 45 IFN-g pc/2x105 PBMC; 
Figure 1B). The response against donor antigens in two of the four patients (patient 4 and 
7) remained low and stable after tapering of AZA (Table 3). This could indicate that before 
and after tapering the AZA dose, the Th1 cells in those patients are still able to recognize 
foreign antigens other than those of the donor antigens of the kidney. It was remarkable 
that one of those four patients (patient 3) showed high 3rd-party responses and donor-
reactive responses after tapering of AZA (Table 3). In this patient, renal function was stable 
during tapering of immunosuppression. Two patients (patient 6 and 15) demonstrated a 
decrease in 3rd-party antigens. The donor-reactive response also decreased significantly in 
one patient (patient 6), and slightly in the other patient (patient 15). Both patients showed 
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Figure 1: Number of IFN-g producing cells (pc) reactive to donor cells (A) and 3rd-party cells (B) deter-
mined in PBMC from HLA-identical living-related kidney transplant recipients before and after tapering 
of AZA dose (n=15). (A) Donor-reactive response: during high AZA, median, 2 IFN-g pc/2x105 PBMC 
(range: 0-88); during low AZA, median, 1 IFN-g pc/2x105 PBMC (range: 0-110). (B) Third-party res-
ponse: during high AZA, median, 14 IFN-g pc/2x105 PBMC (range: 0-305); during low AZA, median, 12 
IFN-g pc/2x105 PBMC (range: 2-324). The Wilcoxon signed rank test was used to compare HLA-iden-
tical recipients before and after reduction of immunosuppression (donor, p=0.99; 3rd-party, p=0.95).
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no abnormalities in renal function, liver function or haematological parameters.
IL-13 Elispot
As shown in Figure 2A, before reduction of AZA a detectable frequency of IL-13 pc against 
donor cells was observed in 8 out of 15 (53%) patients. After reduction to low AZA, only 4 
out of 15 (27%) patients responded to donor antigens (p=0.26). The responses to donor 
antigens after tapering of AZA (median, 0 IL-13 pc/2x105 PBMC; range, 0-53; p=0.55) were 
comparable to before reduction (median, 1 IL-13 pc/2x105 PBMC; range, 0-30).
Before reduction of AZA, 12 out of 14 (86%) patients responded to 3rd-party 
antigens (Figure 2B). The median frequency of the whole group before tapering was 6 IL-
13 pc/2x105 PBMC (range, 0-32). After tapering to low AZA, 10 out of 14 (71%) patients 
responded to 3rd-party antigens. Reduction of AZA also did not increase the number of IL-
13 pc (median, 4 IL-13 pc/2x105 PBMC; range, 0-20; p=0.18). The response to 3rd-party 
antigens was significantly higher than the donor-reactive response (p=0.01).
Before and after reduction of AZA, 10 out of 14 (71%) patients responded to TET. 
No difference in the frequency of IL-13 pc to TET was found before (median, 2 IL-13 pc/2x105 
PBMC; range, 0-187) and after (median, 2 IL-13 pc/2x105 PBMC; range, 0-127; p=0.46) 
tapering of AZA.
Similar to the IFN-g Elispot result, patient 3 demonstrated high frequencies of IL-
13 pc against donor antigens before (30 IL-13 pc/2x105 PBMC) and after (53 IL-13 pc/
2x105 PBMC) tapering of AZA. Whether these high frequencies of IL-13 pc were caused by 
mismatches in mHAgs remains unknown, because no mismatches for known mHAgs were 
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Figure 2: Number of IL-13 producing cells (pc) reactive to donor cells (A) and 3rd-party cells (B) de-
termined in PBMC from HLA-identical living-related kidney transplant recipients before and after tape-
ring of AZA dose (n=15). (A) Donor-reactive response: during high AZA, median, 1 IL-13 pc/2x105 
PBMC (range: 0-30); during low AZA, median, 0 IL-13 pc/2x105 PBMC (range: 0-53). (B) Third-party 
response: during high AZA, median, 6 IL-13 pc/2x105 PBMC (range: 0-32); during low AZA, median, 
4 IL-13 pc/2x105 PBMC; range: 0-20). The Wilcoxon signed rank test was used to compare HLA-iden-
tical recipients before and after reduction of immunosuppression (donor, p=0.55; 3rd-party, p=0.18).
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found with the correct HLA-restriction element between donor and recipient (Table 3).
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) after HLA-identical LR kidney 
transplantation
Table 1 shows CMV and EBV serology of donor and recipient. Before transplantation, eight 
patients were CMV-positive and seven patients were CMV-negative. From the CMV-negative 
patients, 5 out of 7 received a CMV-positive graft. Those 5 patients (CMV-/+) were not 
different in their cytokine-profile of IFN-g and IL-13 from the other 10 patients (CMV +/+, 
CMV +/-, CMV -/-).
Eleven patients were EBV-positive and four patients were EBV-negative before 
transplantation. From the EBV-negative patients, 2 out of 4 received an EBV-positive graft, 
one patient received an EBV-negative graft, and from one patient the EBV serology was not 
documented. The donor-reactive cytokine profiles were comparable between those two ‘EBV-
negative patient EBV-positive donor’ (EBV-/+) combinations and 11 EBV-positive patients.
Minor histocompatibility antigens typing after HLA-identical LR kidney transplantation
Patient PBMC and donor PBMC were typed for 10 known mHAgs that could cause a T-
cell response (Table 2). We analyzed whether the IFN-g and IL-13 Elispot results could be 
explained by mismatches in known mHAgs expressed with the correct restriction element.
In 11 out of 14 patient-donor combinations, we found mismatches for mHAgs 
(Table 3). The correct HLA-restriction element was present in only four patients. In 2 of 
these 4 patients, positive Elispot responses were found. In 6 out of the 7 patients without 
the correct HLA-restriction element, also positive Elispot results were found. Three patient-
donor combinations were identical for the 10 determined mHAgs. Those patients had no 
significant response in the IFN-g and IL-13 Elispots.
DISCUSSION
In the present study, we show that the immunosuppressive medication of HLA-identical 
LR kidney transplant recipients, who were more than 2 years after transplantation, can be 
safely reduced. Four months after the last AZA reduction to at least 50% of the original 
dose, no acute rejection or decrease in renal function had occurred. Also, at 1-year follow-
up, the kidney function remained stable. Tapering of AZA did not increase the frequency of 
Th1 cells (IFN-g) as well as the frequency of Th2 cells (IL-13).
The Elispot assay becomes an attractive method to determine donor-reactive 
responses in kidney transplant recipients and may be used to monitor patients. A study of 
Gebauer et al.27 determined the frequency of IFN-g pc in 11 stable HLA-mismatched renal 
allograft recipients, who were more than 18 months after transplantation, and found low 
frequencies of donor-reactive IFN-g pc (1-45 IFN-g pc/3x105 PBMC). Hricik et al.28 found 
also low frequencies of alloreactive IFN-g pc (<10 IFN-g pc/3x105 PBMC) in renal allograft 
recipients with low serum creatinine levels within 6 months after kidney transplantation. Also 
after BMT with HLA-identical sibling donors, detectable IFN-g pc were found in 20% of the 
donor cells stimulated with irradiated recipients cells.29 During the current study, comparable 
frequencies of IFN-g pc were found in the HLA-identical setting (high AZA: median, 2 IFN-
g pc/2x105 PBMC; range, 0-88; low AZA: median, 1 IFN-g pc/2x105 PBMC; range, 0-110). 
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It seems that those frequencies of IFN-g pc are common in an immunological quiescence 
period after transplantation and is independent of HLA-matching. 
The number of IFN-g pc directed to HLA-mismatched 3rd-party cells and TET did 
not change after tapering of AZA, while those reactivities were significantly higher than the 
reactivity to donor antigens. This suggests that the immune response to nominal antigens, 
alloantigens as well as to donor antigens is not affected by the reduction of AZA. Therefore, 
our HLA-identical LR kidney transplant recipients are both clinically (stable kidney function, 
haematological parameters, and transaminases) and immunologically stable. These results 
are in line with our experience in patients who received a kidney transplant with one or more 
HLA-mismatches.30 In this study also no increase in T-cell reactivity was found.
 We also determined the Th2 response by using an IL-13 Elispot assay. IL-13 is 
an immunoregulatory cytokine secreted by activated Th2 cells.24, 31 The importance of Th2 
responses has been shown in several studies in acute as well as in chronic rejection.23, 32, 33 
In our study, we found that before and after tapering of AZA, 53% and 27%, respectively, 
of the patients’ PBMC made IL-13 after stimulation with donor cells. Those frequencies of 
IL-13 pc were comparable before and after reduction of AZA. This suggests that the donor-
reactive Th2 response, as well as the Th1 response, was not affected by reduction of AZA. 
The number of IL-13 pc after stimulation with 3rd-party PBMC and TET remained also in the 
same range before and after reduction of AZA, indicating that tapering does not affect both 
Th1 and Th2 reactivity towards foreign HLA and nominal antigens. Alternatively, the AZA in 
the given dose has no immunosuppressive effect on Th1 and Th2 response. In a pilot study, 
we found comparable frequencies of granzyme B (GrB) pc before and after tapering of AZA 
in PBMC from HLA-identical LR kidney transplant recipients, suggesting that the functional 
activity of CTL were also unaffected.34 Unfortunately, not enough cells were available to test 
the frequency of GrB pc in this patient cohort.
In the present study, we observed that some of the HLA-identical patients 
demonstrated detectable (>10 IFN-g pc/2x105 PBMC) frequencies of IFN-g pc against donor 
antigens, whereas other patients had undetectable frequencies (0 IFN-g pc/2x105 PBMC). 
No relation was found between IFN-g frequencies and proteinuria, serum creatinine, CMV or 
EBV serology. Recently, Opelz et al.15 showed an association of PRA-reactivity with long-term 
graft loss in kidney transplants from HLA-identical sibling donors. Those lymphocytotoxic 
antibodies could reflect high B-cell responsiveness and alternatively could be directed 
to mHAgs expressed on donor cells, but also to other non-HLA antigens.16 Autologous 
responses are unlikely, because no difference was found between donor responses corrected 
for unstimulated patients’ PBMC and donor responses corrected for the autologous control. 
Accordingly, in our study the donor-reactive Elispot responses could be directed to mismatches 
in mHAgs, but also to other non-HLA antigens. 
Animal studies have shown that mHAgs are involved in the development of allograft 
arteriosclerosis, GVHD, and skin graft rejection.35-38 In humans, the influence of mHAgs on 
transplant outcome have mostly been seen after BMT.12, 39 Therefore, in our HLA-identical 
LR kidney transplant setting, mHAg disparities between patient and donor may theoretically 
trigger T-cell mediated rejection after tapering of immunosuppression. In our study, 14 
patients were typed for 10 known mHAgs, which could give a T-cell response. Four of those 
patients had mismatches for mHAgs and the correct HLA restriction molecule. Only PBMC 
from 2 of the 4 patients had a T-cell response after donor stimulation. We also found that 
PBMC from 6 of the 7 patients with mismatches for known mHAgs, but not with the correct 
restriction element, had a donor-reactive T-cell response in the IFN-g and/or IL-13 Elispot. 
A possibility for the response in those patient-donor combinations with mHAgs mismatches, 
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but not the correct HLA restriction, is that other HLA molecules can present the specific 
mismatched mHAgs. Therefore, not only mHAgs could be unknown, but also their HLA-
restriction molecule. In theory, all genetic polymorphic proteins presented in MHC could give 
peptides recognized as mHAgs, but not all mHAgs are potential for inducing strong T-cell 
responses. The hierarchy of mHAgs could clarify the variety of the donor response. When a 
high donor response was found, immunodominant mHAgs could be present.39, 40 Recently, 
Mori et al.41 found that there is a hierarchy of immunodominance among mHAgs in mice, 
which is dependent on mHAgs density on host cells and the repertoire of donor T cells 
capable of responding to mHAgs. However, this phenomenon is unknown in humans. Mori 
et al.41 suggested that GVHD is a consequence of activation of multiple T-cell populations 
against multiple mHAgs. In contrast, we found low numbers of IFN-g and IL-13 pc towards 
multiple donor-mHAgs, and those were insufficient to induce rejection of the graft. This 
could indicate the presence of low affinity T cells recognizing donor mHAgs or that these 
mHAgs were not immunodominant. Therefore, these patients could be tolerant for the donor 
mHAgs. The last possibility could be that these patients are still over-immunosuppressed. 
After tapering of AZA, the patients received a median of 1.1 mg/kg AZA and 5-10 mg 
prednisone, and this may still be sufficient to prevent cytokine production of lymphocytes 
after donor-stimulation, and therefore rejection.
Some mHAgs as HA-1, HA-2 and BCL2A1 are only expressed on haematopoietic 
cells, while HA-3, HA-8, and H-Y are ubiquitously expressed.14 Therefore, theoretically, T-cell 
responses could be found directed to those mHAgs only expressed on haematopoietic cells, 
while epithelial cells were not affected. Unfortunately, epithelial cells from the graft were not 
available in our laboratory.
In conclusion, this study shows that in HLA-identical living-related kidney transplant 
recipients the AZA dose can be safely reduced without the occurrence of acute rejection. 
Tapering of AZA showed no effect on kidney function, even at 1-year follow-up. No increase 
in T-cell reactivity directed to donor antigens is found. Therefore, we think that these patients 
are still over-immunossuppressed, and we suggest to reduce the immunosuppressive 
medication even further.
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ABSTRACT
Introduction: Living-related (LR) human leukocyte antigen (HLA)-identical renal 
transplant (RTx) recipients often receive standard immunosuppression, despite the absence 
of mismatched major HLA-antigens and the known complications of long-term use of 
immunosuppression. No data are available on the need for immunosuppression for these 
specific patients. We wondered whether their immunosuppressive load could be radically 
reduced.
Method: Between November 1982 and November 2005, 83 living-related HLA-identical 
RTx were performed in our center. Their unadjusted graft survival was 74% at 10 years. 
In 29 patients (median time after transplantation 5.6 (range 1.0-21.4) years) with stable 
uncompromised renal function, we tapered their immunosuppression from triple or dual 
therapy to prednisolone 5 mg/day.  Follow up on prednisolone monotherapy was at least 24 
months. 
Results: In 27 of 29 patients reduction of immunosuppression to prednisolone monotherapy 
was uneventful. One patient, using dual therapy, developed JC-virus nephropathy resulting 
in graft loss. One refused further discontinuation of his medication. Four (15%) of the 27 
patients on monotherapy developed-biopsy proven recurrence of their original disease. Only 
one of them showed a transient decline in renal function. One additional patient developed 
minor proteinuria and a rise in serum creatinine level, as a result of chronic urinary tract 
infections. The remaining 23 of 27 (85%) patients had an uneventful follow up during 24 
months prednisolone monotherapy. 
Conclusion: We conclude that HLA-identical LR RTx recipients who are at least 1 year after 
transplantation might be treated with low-dose steroid monotherapy. Close surveillance of 
patients for recurrence of their original disease is recommended to allow for potential early 
therapeutic intervention. 
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INTRODUCTION
After human leukocyte antigen (HLA)-identical living-related (LR) renal transplantation 
(RTx) there is less acute rejection and better graft survival compared with nonidentical 
renal transplant recipients. These superior results are because HLA-identical LR transplants 
are less immunogenic than nonidentical renal transplants, because in HLA-identical LR 
RTx all major (class I and II) HLA molecules are identical and only mismatches in minor 
histocompatibility antigens (mHAgs) or non-HLA antigens may exist. In animal models, the 
importance of mHAgs has been shown after cardiac transplantation and allogeneic bone 
marrow transplantation.1-5 In humans, mismatches in mHAgs have been shown to induce 
graft-versus-host disease after HLA-identical bone marrow transplantation, but minor HLA 
mismatches had no influence on 5-year graft outcome after RTx.6, 7
Nevertheless, recipients of HLA-identical LR donor kidney generally receive the 
same immunosuppressive regime as HLA-mismatched renal transplant recipients. Therefore, 
they remain at risk for cardiovascular disease, metabolic complications, infections, and 
malignancies, all known side effects of immunosuppressive medication and familiar risk 
factors for poor patient and graft survival after RTx.8
Insufficient data are available about immunosuppression after HLA-identical 
LR RTx.9-13 Even less data are available of the possibility to reduce or discontinue their 
immunosuppressive medication.14 Considering this, we designed a study to reduce the 
immunosuppressive load dramatically in this specific patient group.
MATERIALS AND METHODS
Patients
Between November 1982 and November 2005, 83 LR HLA-identical RTx were performed in 
our center. Molecular HLA typing was performed on DNA obtained from blood by polymerase 
chain reaction (PCR)/sequence-specific oligonucleotide using a reverse dot-blot method.15 Al 
study patients who were transplanted before this technique was available were retyped with 
this PCR technique to be sure they were really HLA-identical with their donor. A transplant 
was classed as HLA-identical if donor and recipient were reported to have identical HLA A, 
B, Cw, DR, DP and DQ antigens. All patients had negative cross matches with their donor 
prior to transplantation. Of these 83 patients, 43 (52%) were men and 40 (48%) were 
women. Their median age was 50 yrs (range 21-78 years) (Table 1). At time of observation 
(n=83), the median time after transplantation was 7.0 years (range 0.8-23.8 years). Their 
unadjusted graft survival was 74% at 10 years, compared to 61% after LR HLA-mismatched 
renal transplantation (Figure 1). 
Out of 83 HLA-identical LR RTx recipients, 54 patients could not be enrolled in our 
study (demographics see Table 1). Seven (13%) patients died before with a functioning 
kidney (median time after RTx was 9.6 years, range 0.9-15.6 years), as a result of cardio-
vascular disease (n=4), infection (n=1), malignancy (n=1), and suicide (n=1).
In 6 (11%) patients graft loss was observed, as a result of recurrence of the original 
disease (n=1), chronic rejection (n=2), tubular interstitial nephritis due to medication (n=1), 
surgical complication (n=1), and infection (n=1).
Two (4%) patients were less then 1 year after transplantation, 3 (6%) patients 
received a kidney from their identical twin sister, 1 (2%) patient already used monotherapy, 
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in 1 (2%) patient was transplanted for the fourth time, 11 (20%) patients were excluded for 
logistic reasons and 7 (13%) refused to participate in the present study. 
Seventeen (31%) patients could not be included because of proteinuria. Of these 
17 patients, 6 patients had a biopsy-proved recurrence of their original disease, 5 patients 
had a chronic allograft nephropathy (CAN), in 1 patient the proteinuria disappeared after 
nephrectomy of his native kidneys and in 5 patients, the cause of their proteinuria remained 
unknown. 
The ethical review committee of our center approved the protocol that was 
conducted according to local requirements. After informed consent, 29 LR HLA-identical 
renal transplant recipients who were more then 1 year after RTx, with stable renal function, 
without proteinuria (<0.2 g/L) and on triple or dual immunosuppression were enrolled in our 
immunosuppression reduction study. Their demographics are shown in Table 1. The median 
time after transplantation was 5.6 years. Only 5 patients were more than 10 years after 
transplantation.
Table 1: Baseline characteristics of the living-related HLA-identical renal transplant recipients transplan-
ted between November 1982 and November 2005.
HLA, human leukocyte antigen; RTx, renal transplantation.
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Figure 1: Unadjusted graft survival after living-related HLA-identical (green line) and HLA-mismatched 
(red line) renal transplantation.
Total HLA-
identical RTx
Not enrolled Study Group
Number of patients 83 54 29
Male: female 43:40 28:26 15:14
Age (median in yrs, range) 50 (21-78) 50 (26-78) 51 (21-66)
Male recipient, female donor
Female recipient, male donor
28/43 (65%)
17/40 (43%)
18/28 (64%)
11/26 (42%)
10/15 (67%)
6/14 (43%)
Time after RTx (median in yrs, range) 7.0 (0.8-23.8) 8.8 (0.8-23.8) 5.6 (1.0-21.4)
Original disease with potential to recur 42 (51%) 26 (49%) 16 (55%)
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Depending on the medication patients used at time of inclusion, we started tapering 
their calcineurin inhibitor (CNI), followed by mycophenolate mofetil (MMF) or azathioprine 
(AZA) and prednisolone dose with 2 months regular intervals to prednisolone monotherapy of 
5 mg/day. Serum creatinine levels and proteinuria were monitored. A renal biopsy was taken 
if patients developed a clinically relevant rise of serum creatinine or proteinuria (defined as 
>0.5 g/L). Blood was obtained for monotoring T-cell reactivity.16
Statistical methods
Data for this study were obtained by patient chart analysis. Survival curves were made 
using the Kaplan-Meier method, and the log-rank test was used to compare the survival 
rates. Continuous variables are reported as means ± SD and tested by paired Student’s 
t-test. Data that did not follow a normal distribution are presented as medians and tested 
by Wilcoxon signed rank test. Qualitative variables are reported as percentages and were 
tested by the Pearson’s chi-squared test. The SSPS statistical package version 12.0.1 was 
used. P-values <0.05 were considered significant
RESULTS
Twenty-nine HLA-identical LR RTx recipients were included in our immunosuppression 
reduction study. In 27 patients this was their first, for 1 patient it was his second, and for 1 
it was her third RTx. Their median panel reactive antibody (PRA) was 2% (range, 0-98%) 
before transplantation. 
Most of the patients used dual immunosuppressive therapy at inclusion. Nineteen 
(66%) used AZA combined with prednisolone, 4 (14%) patients used tacrolimus (Tacro) 
combined with mycophenolate mofetil (MMF), 3 (10%) patients used MMF combined with 
prednisolone, and 1 (3%) patient used cyclosporine (CsA) combined with prednisolone. Two 
patients (7%) used triple immunosuppression consisting of Tacro, MMF and prednisolone. 
Figure 2 shows the results of serum creatinine levels and proteinuria at time of inclusion 
Patient Serum
creatinine
(µmol/l)
Proteinuria
(g/l)
Medication Years
after
RTx
Diagnose
7 Stable
(102→103)
+
(1.5)
Pred mono for
16.8 months
4.6 Recurrence membranous
nephropathy
11 ↑
(108→126)
+
(0.74)
Pred mono for 2
months
3.3 Chronic urinary tract
infection
13 ↑
(87→213)
-
(0.02)
MMF 500 mg +
Pred 5 mg
1.1 JC-virus infection
24 Stable
(58→64)
+
(1.73)
Pred mono for
21.7 months
7.0 Recurrence membranous
nephropathy
21 Stable
(133→107)
+
(2.96)
Pred mono for
2.1 months
10.7 Recurrence diabetes
nephropathy
29 ↑
(111→203)
-
(0.09)
Pred mono for
13.3 months
7.8 Recurrence IgA
nephropathy
Table 2: Characteristics of patients who developed proteinuria or a rise in their serum creatinine 
during tapering of their immunosuppressive medication.
Clinical relevant proteinuria is defined as > 0.5 g/L. “Medication” is defined as the medication pa-
tients used at the moment their serum creatinine rise and/or they developed proteinuria. Diagnose 
is made on clinical grounds and confirmed by renal biopsy. Pred, prednisolone; MMF, mycophenolate 
mofetil; RTx, renal transplantation.
Chapter 9
114
(using different combinations of immunosuppressive medication), at the moment patients 
started with prednisolone monotherapy 5 mg/day and after they had been on prednisolone 
monotherapy for 12 and 24 months.       
One patient refused further discontinuation of his immunosuppressive medication after 
inclusion in the study. Another patient, still on dual therapy, developed a biopsy proved JC-virus 
nephropathy 13.3 months after transplantation. Despite reducing her immunosuppressive 
medication to prednisolone 10 mg/day, combined with leflunomide 30 mg/day, she had 
a progressive decline of her creatinine clearance resulting in graft loss 25.3 months after 
RTx. 
Four (15%) of the 27 patients showed a recurrence of their original disease in 
their renal biopsy, after being on monotherapy prednisolone 5 mg/day for 2, 13, 17 and 
22 months and 11, 8, 5 and 7 years after RTx, respectively. Despite proteinuria, serum 
creatinine levels remained stable in three of them. The other showed a transient rise in 
serum creatinine level, due to IgA nephropathy, which stabilized after reintroduction of MMF 
2 g/day and raising the prednisolone dose to 10 mg/day. Another patient showed a rise in 
serum creatinine level because of a chronic urinary tract infection after several urological 
procedures (Table 2).
In 23 (85%) of the 27 patients, the immunosuppression could be successfully 
reduced to prednisolone monotherapy 5 mg/day. No significant changes in serum creatinine 
levels, 99 µmol/L (range 66-196) vs. 93 µmol/L (range 68-196), or protein excretion, 0.08 
(range 0.02-0.19) vs. 0.10 (range 0.04-0.38) g/L, were observed between time of inclusion 
and after 24 months of prednisolone monotherapy 5 mg/day. There were no significant 
changes in systolic-, diastolic blood pressure, the number of antihypertensive drugs taken, 
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Figure 2: Serum creatinine levels and proteinuria at time of inclusion (using different combinations of im-
munosuppressive medication), at the moment patients started with prednisolone monotherapy 5 mg/day 
and after they had been on prednisolone monotherapy for 12 and 24 months.
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serum total-, low-density lipoprotein (LDL)- or high-denstity lipoprotein (HDL) cholesterol 
levels, haemoglobulin, thrombocytes, or leucocytes between time of inclusion and after 24 
months of prednisolone monotherapy. 
DISCUSSION
With the current results of patient and graft survival after RTx, we are confronted with the 
inherited complications of long-term use of immunosuppressive medication. Therefore, we 
have the obligation to investigate the possibilities of tapering this medication without reducing 
the short- and long-term graft and patient survival. A lot of our study patients were treated 
with azathioprine and prednisolone, by many classified as “light immunosuppression”. These 
patients were probably at low risk for rejection after tapering immunosuppression and this is 
exactly what we showed. Moreover, we should keep in mind that even maintenance therapy 
with so-called “light immunosuppression” is accompanied with serious side effects. 
In our opinion, in LR HLA-identical RTx recipients monotherapy with low-dose 
steroids, although not devoid from all side effects, is preferred above monotherapy with 
low-dose AZA, MMF or CNI, with regard to infections and malignancies. This also holds true 
for recently described protocols with antithymocyte globulin, total lymphoid irradiation, and 
hematopoietic-cell transplantation.17 In our LR HLA-identical RTx study group, dramatically 
tapering of their immunosuppressive medication to low dose prednisolone monotherapy 
is well tolerated, without the occurrence of acute rejections during a follow up of 2 years. 
Acute rejection episodes after identical sibling RTx have been reported. However, most of 
them were described in the AZA era in a time class II match was not perfect and BK-virus 
nephropathy was an unrecognized entity. Nevertheless, mismatches in minor HLA-antigens 
has been found relevant in the context of bone marrow transplantation and might theoretical 
induce immunological reactivity against minor mismatched solid organs. Recently, Gerrits et 
al. described in vitro reactivity against donor cells after HLA-identical LR RTx, but could not 
prove that this was the result of mismatches in minor HLA-antigens.18 Thus, acute rejection 
after tapering immunosuppression could be immunologically explained. However, it did not 
occur in our study, which is in line with the observation of Heinold et al., who did not find a 
clinical relevant role of minor HLA mismatches after solid organ transplantation.7 Differences 
in non-HLA antigens could be an alternative explanation for donor reactivity after HLA-
identical RTx.19, 20
After tapering their immunosuppressive medication, recurrence of original disease 
occurred in 15% (4 of 27) of the patients of the total study group, or otherwise specified, in 
25% (4 of 16) of the group of patients who had an original disease with potential to recur. 
After 2 years follow up, none of their renal grafts had failed. It should be mentioned that one 
of these four patients had a diabetes nephropathy. We wondered whether the recurrence 
of primary glomerulonefritis in the other three patients could be related to the tapering of 
their immunosuppressive load or that this just reflects the natural course of recurrence of 
a primary glomerulonephritis after RTx. In 1999, Andresdottir et al.21 described a biopsy 
proven prevalence of recurrence of original disease after LR HLA-identical RTx of at least 
27%, with a graft failure due to recurrence of 15%, with a mean time after transplantation 
of 7.7 ±6.1 years.
Before we embarked on the present study, we screened our LR HLA-identical 
population under full dose immunosuppression. There was a prevalence of 17% (7 out of 
42) of biopsy-proven recurrence of original disease, in the group of patients who had that 
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potential. In five patients with proteinuria, no histology was available, so the true incidence of 
recurrence could have been as high as 35%. This suggest that the prevalence of recurrence 
after tapering immunosuppressive medication in our study group was comparable to that 
described before in LR HLA-identical RTx recipients who used full-dose immunosuppression 
and is in line with earlier observation. 
In conclusion, the immunosuppressive medication can be safely reduced to low-
dose steroid monotherapy of 5 mg/day in HLA-identical LR renal transplant recipients 
provided that they have stable renal function, without proteinuria and they are at least 
1 year after transplantation. Close surveillance of patients for recurrence of their original 
disease is recommended to allow for potential early therapeutic intervention. 
Acknowledgment: This study was supported by grant C02.2002 from the Dutch Kidney 
Foundation. 
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ABSTRACT
Background: In many transplant centers, human leukocyte antigen (HLA)-identical living-
related (LR) renal transplant recipients receive standard maintenance immunosuppression 
from 1 year after transplantation. We questioned whether discontinuation of azathioprine 
(AZA) or mycophenolate mofetil (MMF) influenced T-cell reactivity, circulating DC subsets 
numbers, and their maturation status.
Methods: Twenty-nine HLA-identical LR renal transplant recipients were withdrawn from AZA 
or MMF. Thereafter, the patients received only prednisolone. T-cell reactivity was determined 
by interferon (IFN)-g (n=23), interleukin (IL)-10 (n=16), and granzyme B (GrB; n=10) 
Elispot assays. Circulating DC subset numbers and their maturation status determined by 
CCR2, CCR5, CCR7 and CD83 expression were measured by flow cytometry (n=12).
Results: The number of donor, 3rd-party, and tetanus toxoid (TET)-reactive IFN-g and GrB 
producing cells (pc) was not affected after withdrawal of immunosuppression. Discontinuation 
of AZA or MMF resulted in significant increased numbers of 3rd-party (p=0.003) and TET-
reactive (p=0.008) IL-10 pc, and a trend in higher numbers of donor-reactive IL-10 pc 
(p=0.06). No effect was found on the number of circulating DC subsets, but DC were shifted 
towards a more mature phenotype. 
Conclusions: In HLA-identical LR renal transplant recipients, therapy with AZA and 
MMF suppress the IL-10 production and the maturation of DC. This suggests that these 
immunosuppressants may hinder downregulation of immune responses in general, including 
allogeneic responses.
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INTRODUCTION
After human leukocyte antigen (HLA)-identical LR renal transplantation, mismatches only in 
minor histocompatibility antigens (mHAgs) and other non-HLA antigens may exist between 
donor and recipient.1, 2 mHAgs are genetic inherited peptides derived from polymorphic 
intracellular proteins presented in the context of HLA class I and II molecules and can be 
recognized by T cells. In humans, the clinical relevance of mHAgs has been reported after 
bone marrow transplantation2, and even after solid organ transplantation a role of mHAgs 
and non-HLA antigens has been suggested.3-5 Theoretically, both mismatches in mHAgs 
and other non-HLA antigens between donor and recipient might induce graft rejection. 
Consequently, HLA-identical LR renal transplant recipients still receive immunosuppression. 
However, the necessity for long-term use of immunosuppression in this patient group is 
yet unknown. We wondered whether HLA-identical LR renal transplant recipients should 
be exposed to the severe side effects of immunosuppression such as nephrotoxicity, 
malignancies, cardiovascular disease and diabetes mellitus.6, 7
Previously, we demonstrated that donor-reactive cytokine responses can be found 
after HLA-identical LR renal transplantation.8 Additionally, we showed that HLA-identical LR 
renal transplant recipients, who received azathioprine (AZA) in combination with prednisone, 
could be tapered to 50% of their original AZA dose without the occurrence of acute 
rejection. Furthermore, renal function and donor-reactive responses remained unaffected 
after tapering the AZA dose.9, 10 Therefore, we speculate that those patients are still over-
immunosuppressed and that the immunosuppressive dose could be reduced further.
Increased donor reactivity could occur after discontinuation of immunosuppression 
in transplant recipients after HLA-mismatched renal transplantation.11-14 Complete 
discontinuation of immunosuppression has been reported in a minority of renal transplant 
recipients long after transplantation with stable graft function and without clinical signs of 
rejection.15-20 In general, a decreased T-cell response was reported in those studies compared 
to patients with chronic allograft nephropathy.15, 16, 19, 20
In addition to immunological monitoring of donor-reactive T-cell responses in 
transplant recipients, it has been suggested that monitoring of circulating myeloid dendritic 
cells (CD11c+CD123lowBDCA-1+ mDC) and plasmacytoid DC (CD11c-CD123highBDCA-2+ pDC)21 
numbers in peripheral blood might be an useful tool for identifying transplant recipients in 
whom the immunosuppressive load can be safely tapered.22, 23 mDC produce high levels 
of interleukin (IL)-12 and induce T-helper 1 (Th1) and cytotoxic T-cell  (CTL) responses, 
whereas pDC produce interferon (IFN)-a in response to viruses and induce T-helper 2 (Th2) 
responses.24 Furthermore, it has been suggested that pDC are involved in the induction 
of peripheral T-cell tolerance after organ transplantation.23, 25 According to their surface 
immunophenotype, DC subsets can be identified as immature DC and mature DC.24, 26 In 
peripheral blood and tissues, DC resides as immature DC where they may internalize antigens. 
On antigen capture, immature DC differentiates into mature DC that are highly specialised to 
stimulate T cells efficiently.27 Several studies reported the influence of immunosuppressive 
drugs on DC subset numbers, differentiation, and their maturation status.23, 28-33 Furthermore, 
Mazariegos et al.23 reported that the proportion of pDC in peripheral blood mononuclear cells 
(PBMC) was higher in stable liver transplant recipients who could be successfully weaned 
from their immunosuppressive load.
In the present study, we discontinued the AZA and mycophenolate mofetil (MMF) 
dose. Thereafter, all patients received steroid monotherapy for at least 1 year. We questioned 
whether discontinuation of AZA or MMF influenced T-cell reactivity determined by Elispot 
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assays. This assay was used to determine the frequency of pro-inflammatory cytokine IFN-g 
and anti-inflammatory cytokine IL-10 that have been associated with allograft rejection or 
suppression of the immune response, respectively.34, 35 Granzyme B (GrB) was used as a 
marker of activity of cytotoxic T-lymphocytes (CTL).10, 36 CTL plays a crucial role in allograft 
rejection.37 Additionally, we wondered whether discontinuation of immunosuppression 
affected the circulating DC subsets numbers and their maturation status determined by flow 
cytometry.
MATERIALS AND METHODS
HLA-identical LR renal transplant recipients
The ethical review committee of our center approved the protocol that was conducted 
according to local requirements. Between November 1982 and November 2005, 83 LR HLA-
identical renal transplants were performed in our center. Out of those 83 patients, 54 patients 
could not be enrolled in our study: seven patients died with a functioning kidney (n=4: 
cardio-vascular disease; n=1: infection; n=1: malignancy; n=1: suicide), in six patients 
graft loss was observed (n=1: recurrence of original disease; n=2: chronic rejection; n=1: 
tubular intestinal nephritis due to medication; n=1: surgical complication; n=1: infection), 
two patients were less than 1 year after transplantation, three patients received a kidney 
from their HLA-identical twin sister, one patient already used monotherapy, one patient 
was transplanted for the fourth time, 11 patients were excluded for logistic reasons, seven 
patients refused to participate in the present study, and 17 patients could not be included 
because of proteinuria (n=6: recurrence of their original disease; n=5: chronic allograft 
nephropathy; n=1 proteinuria disappeared after nephrectomy of his native kidneys, n=5: 
cause of proteinuria is unknown).38 After informed consent, 29 HLA-identical LR renal 
transplant recipients agreed to participate in this study. Characteristics of the patients are 
described in Table 1. The patients had stable serum creatinine levels and no proteinuria (<0.5 
g/L) were more than 1 year after transplantation, and on triple or dual immunosuppressive 
therapy. From the 29 patients, 19 patients used AZA in combination with prednisolone and 
three patients used MMF in combination with prednisolone. The other seven patients (n=4, 
Tacro+MMF; n=1, CsA+prednisolone; n=2, Tacro+MMF+prednisolone) were converted 
to MMF (500 mg/day) in combination with prednisolone (5 mg/day). Then, the AZA or 
MMF dose was gradually discontinued over a period of 4 months and patients were kept 
on prednisolone (5 mg/day) monotherapy. The follow-up of the patients on prednisolone 
monotherapy was 1 year (Figure 1). Our laboratory analysis on T-cell reactivity started at 
dual therapy and 1 year monotherapy (Figure 1). 
Blood sampling
We received 35 ml heparinized peripheral blood at dual therapy and monotherapy to perform 
Elispot assays (33 ml peripheral blood), and to measure DC subset numbers and their 
maturation status (2 ml peripheral blood). PBMC from recipient and donor were isolated 
from heparinized blood by density gradient centrifugation using Ficoll-Paque (Amersham 
Biosciences, Uppsala, Sweden) and stored at –140oC as described before.9
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IFN-g, IL-10, and GrB Elispot assays
The phytohemagglutinin (PHA; Murex Biotech, Kent, UK) proliferation assay was performed 
to control the viability of the PBMC as described before.9 The mean counts per minute (cpm) 
were determined, and the stimulation index (SI) was calculated by the ratio of the cpm 
obtained in the presence of PHA to the cpm in the absence of PHA. Only results of viable cells 
(SI ≥ 50) were analyzed in the described results.
The IFN-g, IL-10, and GrB Elispot assays (U-CyTech Biosciences, Utrecht, The 
Netherlands) were used to determine the number of cytokine producing cells (pc) reactive 
to donor, 3rd-party, and tetanus toxoid (TET) antigens.39 Briefly, in a 96-wells round bottom 
plate (Nunc, Roskilde, Denmark), patients’ PBMC were stimulated with donor PBMC, 3rd-party 
PBMC, and TET. The 3rd-party PBMC did not share HLA antigens with donor and patient, and 
the same 3rd-party PBMC was used at dual therapy and steroid monotherapy. TET stimulation 
(RIVM, Bilthoven, The Netherlands) was used to determine the memory immune response to 
nominal antigens. As negative controls, we used patients’ PBMC stimulated with irradiated 
patients’ PBMC (autologous response; to control the influence of irradiation), and patients’ 
PBMC in culture media alone (unstimulated patients’ PBMC). The autologous response was 
subtracted from the donor and 3rd-party reactive response. The response of unstimulated 
patients’ PBMC was subtracted from the TET response. After 40 hr of incubation, non-
adherent cells were harvested and transferred in triplicate to a flat-bottom plate (Nunc, 
Roskilde, Denmark) precoated with IFN-g, IL-10, or GrB monoclonal antibodies (U-CyTech 
Biosciences) and post-coated with phosphate-buffered saline (PBS) supplemented with 1x 
Blocking stock solution B (U-CyTech Biosciences). Cells were incubated for 5 hr at 37oC for 
IFN-g and GrB Elispot assays, and overnight for IL-10 Elispot assay. Detection of spots was 
performed as described before.39 The spots were counted automatically by using a Bioreader 
3000 Elispot reader (BioSys, GmbH, Karben, Germany).
Antibodies for mDC and pDC staining
Fluorescence-activated cell sorter (FACS) analysis was performed using the following mouse 
anti-human monoclonal antibodies: allophycocyanin (APC)-conjugated BDCA-1 (clone: AD5-
AZA (50 mg/day) or
MMF (500 mg/day)
50% AZA/MMF Stop AZA/MMF
T=16
months
T=0 months T=4
months
T=2
months
Prednisolone (5 mg/day)
Dual therapy MonotherapyTiming of blood sampling
Start of
the study
Figure 1: Schematic overview of discontinuation of immunosuppressive medication in HLA-identical 
living-related renal transplant recipients and time of blood sampling (dual therapy and 1-year steroid 
monotherapy).
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8E7) and APC-conjugated BDCA-2 (clone: AC144) (Miltenyi Biotec, GmbH, Germany), peridinin 
chlorophyll protein (PerCP)-conjugated CD14 (clone: mφP9) and PerCP-conjugated CD19 
(clone: 4G7; Becton Dickinson Biosciences, San Jose, CA, USA), fluorescein isothiocyanate 
(FITC)-conjugated CD83 (clone: HB15A17.11; DPC, Serotec, Oxford, UK), phycoerythrin 
(PE)-conjugated CCR2 (clone: 48607.211) and PE-conjugated CCR7 (clone: 150503; R&D 
Systems Europe, Abingdon, UK), FITC-conjugated CCR5 (clone: 2d7; Becton Dickinson), 
and FITC-conjugated IgG2a (clone: X39) and PE-conjugated IgG2b (clone: X39) isotype 
control monoclonal antibodies (Becton Dickinson).
Immunofluorescence staining and flow cytometric analysis of dendritic cell subsets and their 
maturation status
Analysis of DC numbers and maturation status was performed as described before.40 Briefly, 2 
ml fresh heparinized blood was obtained from 12 HLA-identical LR renal transplant recipients 
(patient: 2, 5, 6, 7, 8, 9, 10, 14, 17, 19, 22, 28; Table 1) and processed within 4 hr. Whole 
blood samples were incubated with the abovementioned monoclonal antibodies for 30 min in 
the dark at room temperature. Cells that stained negative for CD14 and CD19 were gated and 
analyzed for BDCA-1 and BDCA-2 expression. mDC and pDC were identified as CD14-CD19-
BDCA-1+ cells and CD14-CD19-BDCA-2+ cells, respectively. Immature mDC were defined 
as CD83-CCR7 -CCR5+CCR2+, and mature mDC as CD83+CCR7+CCR5-CCR2-. Immature pDC 
were defined as CD83-CCR7+CCR5+CCR2+, and mature pDC as CD83+CCR7++CCR5-CCR2-. 
The proportion of mDC and pDC positive for CD83, CCR7, CCR5, and CCR2 was determined 
by comparison to their respective isotype control antibodies. From each tube, 500,000 
events were acquired on a FACScalibur flow cytometer using CELLQUEST PRO software 
(Becton Dickinson). 
 The absolute counts for each DC subset was calculated by multiplying the proportion 
of mDC and pDC within the total leukocyte population by the absolute number of white 
blood cells determined on an automatically cell counter (Casey®, Schärfe System, GmbH, 
Rentlingen, Germany). The absolute counts for total DC was calculated by the sum of the 
absolute counts of mDC and pDC. The pDC/mDC ratio was determined by dividing the 
absolute number of pDC with the absolute number of mDC.
Statistical analysis
The Wilcoxon signed rank test was used to compare the frequency of cytokine pc, the 
absolute number of total DC (mDC+pDC), mDC and pDC numbers, and the pDC/mDC ratio 
at dual therapy and monotherapy. The same test was used to compare the percentage 
positive of CD83, CCR7, CCR2 and CCR5 on DC subsets before and after discontinuation 
of AZA or MMF. The Fischer’s Exact test was used to compare the number of patients who 
responded to TET antigens before and after withdrawal of AZA or MMF. Two sided P-values 
≤0.05 were considered significant. For statistical analysis, SPSS 11.5 for Windows was used 
(SPSS, Inc., Chicago, IL, USA).
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RESULTS
Clinical results
After inclusion (dual therapy), 2 of 29 (7%) HLA-identical LR renal transplant recipients did 
not reach steroid monotherapy because to JC-virus infection (patient 13) and one patient 
(patient 1) refused to discontinue his immunosuppressive medication after inclusion in the 
study (Table 1). None of the patients had an acute rejection episode. A detailed description 
of the clinical results of this study is described by Van de Wetering et al.38.
Patient 11, 21, 26 and 29 (n=4) were not tested in the cellular assays, because we 
were unable to receive patient and donor PBMC, respectively (Table 1).
We received 35 ml heparinized blood during dual therapy and during monotherapy. 
The PBMC yield is variable after transplantation. From all patients described below, PBMC 
samples were tested during dual and after 1 year on monotherapy. We could perform an 
IFN-g Elispot assay in 23 patients, from 16 patients enough cells were available to perform 
the IL-10 Elispot, and even from 10 patients we also could perform a GrB Elispot.
In 2003, it was reported that monitoring of circulating DC would be a good tool 
to identify transplant recipients in whom the immunosuppressive medication can be safely 
discontinued.23 Then, we observed that cryopreservation of PBMC significantly effects 
chemokine receptor markers on DC.40 In other words, we could only determine the DC 
subsets and their chemokine receptors in fresh whole blood. Our inclusion of patients was 
from the beginning of 2003. Therefore, we have monitored the DC in 12 patients before and 
after withdrawal of AZA or MMF.
    
The frequency of IFN-g, IL-10 and GrB producing cells
The frequency of donor-reactive IFN-g pc did not increase after discontinuation of AZA or 
MMF (dual therapy: median, 2 IFN-g pc/2x105 PBMC [range, 0-13]; monotherapy: median, 
0 IFN-g pc/2x105 PBMC [0-16]; p=0.21; Figure 2A). The donor response was significantly 
lower than the 3rd-party response (dual therapy, p<0.001; monotherapy, p<0.001). The 
3rd-party reactivity was comparable between dual therapy (median, 33 IFN-g pc/2x105 PBMC 
[5-333]) and monotherapy (median, 31 IFN-g pc/2x105 [4-322]; p=0.59; Figure 2B). 
 From 16 patients, we were able to perform IL-10 Elispot assays. The number of 
donor-reactive IL-10 pc was low on dual therapy (median, 1 IL-10 pc/2x105 PBMC [range, 0-
4]) and tended to be higher after discontinuation of AZA or MMF (median, 1 IL-10 pc/2x105 
[0-80]; p=0.06; Figure 2C). No significant difference was found in donor and 3rd-party 
reactive IL-10 pc  (dual therapy, p=0.18; monotherapy, p=0.06). The frequency of 3rd-party 
reactive IL-10 pc was significantly higher during monotherapy (median, 13 IL-10 pc/2x105 
PBMC [0-208]; p=0.003; Figure 2D) than during dual therapy (median, 2 IL-10 pc/2x105 
PBMC [0-8]).
 We were able to perform GrB Elispot assays from 10 patients. No difference was 
observed between the number of donor-reactive GrB pc at dual therapy (median, 2 GrB 
pc/2x105 PBMC [range, 0-40]) and at monotherapy (median, 0 GrB pc/2x105 [0-6]; p=0.18; 
Figure 2E). The donor-reactive GrB pc was significantly lower than the 3rd-party reactive 
GrB pc (dual therapy, p=0.008; monotherapy, p=0.007). At dual therapy, the frequency 
of 3rd-party reactive GrB pc (median, 17 GrB pc/2x105 PBMC [0-49]) was comparable with 
monotherapy (median, 16 GrB pc/2x105 PBMC [0-47]; p=0.84; Figure 2F).
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Tetanus toxoid reactivity
The TET reactivity was not affected after withdrawal of AZA or MMF in IFN-g Elispot assays 
(dual therapy: median, 6 IFN-g pc/2x105 PBMC [0-217] vs. monotherapy: median, 4 IFN-g 
pc/2x105 PBMC [0-179]; p=0.74), and GrB Elispot assays (dual therapy: median, 5 GrB 
pc/2x105 PBMC [0-112] vs. monotherapy: median, 8 GrB pc/2x105 PBMC [0-115]; p=0.44).
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Figure 2: Number of IFN-g, IL-10 and granzyme B (GrB) pc reactive to donor cells (A, C, E) and 3rd-party 
cells (B, D, F) before (dual therapy) and after (1-year monotherapy) discontinuation of AZA or MMF in 
PBMC from HLA-identical living-related renal transplants determined by IFN-g, IL-10 and GrB Elispot as-
says.
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The total number of TET-reactive IL-10 pc was comparable during dual and monotherapy 
(dual therapy: median, 3 IL-10 pc/2x105 PBMC [0-77] vs. monotherapy: median, 10 IL-10 
pc/2x105 PBMC [0-102]; p=0.32). However, the number of patients that could respond to 
TET antigens (≥5 cytokine pc/2x105 PBMC) in the IL-10 Elispot assay was significantly higher 
at monotherapy than at dual therapy (dual therapy, 5/20 [25%] vs. monotherapy, 13/18 
[72%]; p=0.008; Fisher’s Exact test). No differences were found in IFN-g (p=0.57) and GrB 
(p=0.43) Elispot assays.
Dendritic cell subsets and maturation status
Discontinuation of AZA or MMF had no effect on the total DC numbers (dual therapy: median, 
14.6 DC/µl [range, 5.5-31.1]; monotherapy: median, 14.4 DC/µl [3.5-26.2]; p=0.52), the 
number of mDC (dual therapy: median, 10.7 µl mDC [4.0-23.7]; monotherapy: median, 
10.0 µl mDC [2.6-20.8]; p=0.62, Figure 3A) and pDC (dual therapy: median, 4.7 µl pDC 
[1.6-8.8]; monotherapy; median, 3.0 µl pDC [0.93-11.3]; p=0.62, Figure 3E), nor on the 
pDC/mDC ratio (dual therapy: median, 0.37 [0.23-0.82]; monotherapy: median, 0.33 
[0.16-0.96]; p=0.49).
 The percentage of CD83+ mDC was not affected after discontinuation of AZA or 
MMF (dual therapy: median, 0.49% [0-2.8]; monotherapy: median: 0.65% [0.08-1.45]; 
p=0.47). During monotherapy, the percentage of CCR7+ mDC (median, 22.3% [10.2-28.6]; 
p=0.007) was significantly higher than during dual therapy (median, 10.3% [5.3-20.9]; 
Figure 3B). During monotherapy, the percentage CCR2+ mDC (dual therapy: median, 87.6% 
[49.5-95.9]; monotherapy: median, 69.5% [50.3-91.4]; p=0.01; Figure 3C) and CCR5+ 
mDC (dual therapy: median, 91.2% [56.1-97.3]; monotherapy: median, 80.1% [53.4-
94.6]; p=0.04; Figure 3D) was significantly lower than during dual therapy. 
A similar pattern was found for pDC. No differences were observed in the percentage 
CD83+ pDC (dual therapy: median, 0% [0-0.6]; monotherapy: median, 0% [0-0.9]; p=0.31) 
during dual and monotherapy. The percentage CCR7+ pDC increased after discontinuation 
of AZA or MMF [dual therapy: median, 86.8% (81.3-94.7); monotherapy: median, 91.1% 
(86.6-96.9); p=0.12; Figure 3F]. The percentage CCR2+ pDC (dual therapy: median, 96.8% 
[92.5-98.5]; monotherapy: median, 94.2% [90.4-98.2]; p=0.04; Figure 3G) and CCR5+ 
pDC (dual therapy: median, 99.4% [98.3-100]; monotherapy: median, 98.9% [95.9-100]; 
p=0.02; Figure 3H) decreased after discontinuation of AZA or MMF.
DISCUSSION
After solid organ transplantation, life-long use of immunosuppression is deemed necessary to 
prevent graft rejection. However, after HLA-identical LR renal transplantation, the necessity 
for long-term use of immunosuppression is yet unknown. Considering the severe side effects 
of immunosuppression, minimizing of immunosuppression in these transplant recipients 
might be beneficial. Theoretically, discontinuation of immunosuppression in organ transplant 
recipients might result into an increased donor-reactive T-cell response.12-14, 41 This study 
showed that the number of donor, 3rd-party, and TET-reactive IFN-g pc or GrB pc did not 
increase after discontinuation of AZA or MMF. However, significantly increased numbers of 
3rd-party (p=0.003) and TET-reactive (p=0.008) IL-10 pc and a trend in more donor-reactive 
IL-10 pc (p=0.06) were found in HLA-identical LR renal transplant recipients. Additionally, no 
acute rejections occurred.38 We suggest that the suppressive function of IL-10 was hindered 
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by AZA and MMF. AZA and MMF are anti-proliferative agents, and may also have an effect on 
cytokine production of lymphocytes.42-44
IL-10 is an anti-inflammatory cytokine that have been associated with downregulation 
of the immune response.45 Several cells can secrete IL-10, such as B cells, monocytes, DC, 
activated Th2 cells, and regulatory T cells.45 In our assay, we assume that monocytes and 
Figure 3: Absolute numbers and their maturation status of mDC (A-D) and pDC (E-H) determined before 
(dual therapy) and after (1-year monotherapy) discontinuation of AZA or MMF in peripheral blood from 
recipients of an HLA-identical living-related renal transplant (n=12) by flow cytometry.
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DC did not produce IL-10, because only non-adherent cells were transferred to the IL-10 
Elispot plate. On activation by donor cells, both Th2 cells and regulatory T cells mainly 
produce IL-10.46 In the present study, we observed higher numbers of donor, 3rd-party, and 
TET reactive IL-10 pc after withdrawal of AZA or MMF, while the number of IFN-g and GrB pc 
remained stable. In agreement with our results, other studies also reported the presence of 
donor-reactive IL-10 that could reflect allograft tolerance in HLA-identical LR renal transplant 
recipients.20, 47
Renal transplant recipients who receive long-term immunosuppression are 
susceptible for infections.6 Therefore, tapering of immunosuppression may reduce the chance 
for infections in those patients. In our study, we observed that more patients could respond 
to TET antigens in IL-10 Elispot assays after discontinuation of AZA and MMF, suggesting an 
improvement of reactivity directed to nominal antigens.
Mismatches in mHAgs between donor and recipient in combination with the presence 
of the correct HLA-restriction molecule may trigger T-cell reactivity.2 We analysed whether 
donor-reactive T-cell responses could be a result of known mHAg disparities between donor 
and recipient. In the present study, we again found no relation between mHAg mismatches 
and the number of donor-reactive cytokine pc, which is in agreement with our previous 
studies.9, 39 Furthermore, Heinold et al.5 showed after cadaveric and LR renal transplantation 
that mHAgs mismatches between donor and recipients had no significant effect on death-
censored 5-year graft survival.
DC could play an important role in determining the balance between transplant 
tolerance and immunity.48 It has been suggested that immunological monitoring of 
peripheral blood DC subset numbers and their ratio might identify transplant recipients in 
whom the immunosuppressive load can be safely tapered.23 It is assumed that blood DC in 
healthy individuals display an immature phenotype and induce T cell unresponsiveness.49, 50 
Immature DC are specialised in the capture of antigens, and transport them from peripheral 
tissues to secondary lymph nodes. Both donor and recipient DC could play a role in allograft 
rejection. Donor DC are transferred with the graft and can directly interact with recipient 
T cells. Recipient DC in peripheral lymphoid organs can take up soluble donor antigens, 
infiltrate the graft, and present the antigens to T cells.51 Little is known about circulating 
DC after withdrawal of immunosuppression in kidney transplant recipients. Several studies 
reported interference of immunosuppressive drugs with DC numbers, differentiation and 
maturation of DC.23, 29-31, 33 Our study showed that withdrawal of AZA or MMF had no effect 
on the absolute numbers of total DC, mDC and pDC and their ratio. Although, several 
problems related to monitoring DC phenotype and subsets in peripheral blood were 
reported, for example, variability in technique, absence of reference standards, incomplete 
data regarding the influence of disease, medication, and patient-related factors on blood 
DC subsets.52 Additionally, some patients had mDC and pDC numbers that differed from the 
majority of patients. Nevertheless, interestingly, DC subsets shifted towards more mature 
DC phenotype after discontinuation of AZA or MMF, suggesting that AZA or MMF hinders the 
phenotypic maturation status of DC. In agreement with our data, it has been reported that 
MMF effects phenotypic DC maturation in both mice and in vitro models.53, 54 In MMF-treated 
DC, a lower expression of CD40, CD80, CD86, CD83, and CD54 was observed, suggesting 
an inhibitory effect of MMF on DC maturation.53 Also a dose-dependent inhibition of mixed 
lymphocyte reaction with AZA-treated DC was reported.55 MMF is an inhibitor of the enzyme 
inosine monophosphate dehydrogenase (IMPDH), which is involved in the novo synthesis of 
guanosine nucleotides. The inhibitory effect of MMF on DC maturation could be caused by an 
imbalance between cyclic guanosine monophosphate and cyclic adenosine monophosphate 
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(cAMP) in DC.56 Because both mDC and pDC circulate in peripheral blood57, those data 
support our results that after discontinuation of AZA and MMF DC shifted towards a more 
mature phenotype. 
In conclusion, recipients of an HLA-identical LR renal transplant can be safely 
withdrawn from AZA or MMF. The number of donor, 3rd-party, and TET-reactive IL-10 pc and 
maturation of DC was suppressed by AZA and MMF, suggesting that these immunosuppressive 
drugs may hinder downregulation of the general immune reactivity, including allogeneic 
responses.
Acknowledgment: This study was supported by grant C02.2002 from the Dutch Kidney 
Foundation.
 
Chapter 10
132
REFERENCES
1. Gerrits JH, Weimar W, Van Besouw 
NM. Immune monitoring after 
kidney transplantation. Minerva 
Urol Nefrol 2007;59:367-72.
2. Goulmy E. Minor histocompatibility 
antigens: from transplantation 
problems to therapy of cancer. 
Hum Immunol 2006;67:433-8.
3. Opelz G. Non-HLA transplantation 
immunity revealed by 
lymphocytotoxic antibodies. Lancet 
2005;365:1570-6.
4. Joosten SA, van Kooten C. Non-
HLA humoral immunity and 
chronic kidney-graft loss. Lancet 
2005;365:1522-3.
5. Heinold A, Opelz G, Scherer S, et 
al. Role of minor histocompatibility 
antigens in renal transplantation. 
Am J Transplant 2008;8:95-102.
6. Halloran PF. Immunosuppressive 
drugs for kidney transplantation. N 
Engl J Med 2004;351:2715-29.
7. Soulillou JP, Giral M. 
Controlling the incidence of 
infection and malignancy by 
modifying immunosuppression. 
Transplantation 2001;72:S89-93.
8. van Besouw NM, Vaessen LMB, 
Zuijderwijk JM, et al. The frequency 
of interferon-g producing cells 
reflects alloreactivity against 
minor histocompatibility antigens. 
Transplantation 2003;75:1400-4.
9. Gerrits JH, van de Wetering 
J, Postma S, et al. Stable T-
cell reactivity after successful 
tapering of azathioprine in HLA-
identical living-related kidney 
transplant recipients despite 
minor histocompatibility antigen 
mismatches. Nephrol Dial 
Transplant 2007;22:353-61.
10. Gerrits JH, van de Wetering J, 
Ijzermans JNM, Weimar W, van 
Besouw NM. Granzyme B ELISPOT 
assay determines the cytotoxic T 
lymphocyte precursor frequency 
after HLA-identical living-related 
kidney transplantation. Transplant 
Proc 2005;37:752-4.
11. Beik AI, Higgins RM, Lam FT, 
Morris AG. Steroid withdrawal and 
donor-specific hyporeactivity after 
cadaveric renal allotransplantation 
on maintenance triple therapy. 
Nephrol Dial Transplant 
1997;12:1949-55.
12. Creemers P, Pascoe MD, Pontin 
AR, Kahn D. Rebound effect of the 
allogenic T-cell response to donor 
and third-party lymphocytes after 
cyclosporine withdrawal in renal 
transplant recipients. Transpl 
Immunol 1998;6:261-4.
13. Goulmy E, Bittner K, Blokland E, 
et al. Renal transplant patients 
with steroid withdrawal evaluated 
longitudinally for their donor--
specific cytotoxic T cell reactivity. 
Transplantation 1991;52:1083-5.
14. Mazariegos GV, Ramos H, Shapiro 
R, Zeevi A, Fung JJ, Starzl TE. 
Weaning of immunosuppression 
in long-term recipients of living 
related renal transplants: a 
preliminary study. Transplant Proc 
1995;27:207-9.
15. Kawai T, Cosimi AB, Spitzer 
TR, et al. HLA-mismatched 
renal transplantation without 
maintenance immunosuppression. 
N Engl J Med 2008;358:353-61.
T-cell reactivity during tapering of immunosuppression to low dose monotherapy 
prednisolone in HLA-identical living-related renal transplant recipients
133
16. Brouard S, Dupont A, Giral M, 
et al. Operationally tolerant and 
minimally immunosuppressed 
kidney recipients display strongly 
altered blood T-cell clonal 
regulation. Am J Transplant 
2005;5:330-40.
17. Louis S, Braudeau C, Giral M, et 
al. Contrasting CD25hiCD4+T 
cells/FOXP3 patterns in chronic 
rejection and operational drug-
free tolerance. Transplantation 
2006;81:398-407.
18. Roussey-Kesler G, Giral M, Moreau 
A, et al. Clinical operational tolerance 
after kidney transplantation. Am J 
Transplant 2006;6:736-46.
19. Strober S, Benike C, Krishnaswamy 
S, Engleman EG, Grumet FC. Clinical 
transplantation tolerance twelve 
years after prospective withdrawal 
of immunosuppressive drugs: 
studies of chimerism and anti-
donor reactivity. Transplantation 
2000;69:1549-54.
20. VanBuskirk AM, Burlingham WJ, 
Jankowska-Gan E, et al. Human 
allograft acceptance is associated 
with immune regulation. J Clin 
Invest 2000;106:145-55.
21. Dzionek A, Fuchs A, Schmidt P, et 
al. BDCA-2, BDCA-3, and BDCA-4: 
three markers for distinct subsets of 
dendritic cells in human peripheral 
blood. J Immunol 2000;165:6037-
46.
22. Mazariegos GV, Sindhi R, Thomson 
AW, Marcos A. Clinical tolerance 
following liver transplantation: long 
term results and future prospects. 
Transpl Immunol 2007;17:114-9.
23. Mazariegos GV, Zahorchak 
AF, Reyes J, et al. Dendritic 
cell subset ratio in peripheral 
blood correlates with successful 
withdrawal of immunosuppression 
in liver transplant patients. Am J 
Transplant 2003;3:689-96.
24. Penna G, Sozzani S, Adorini L. 
Cutting edge: selective usage 
of chemokine receptors by 
plasmacytoid dendritic cells. J 
Immunol 2001;167:1862-6.
25. Kuwana M, Kaburaki J, Wright TM, 
Kawakami Y, Ikeda Y. Induction of 
antigen-specific human CD4(+) 
T cell anergy by peripheral blood 
DC2 precursors. Eur J Immunol 
2001;31:2547-57.
26. Sallusto F, Schaerli P, Loetscher P, 
et al. Rapid and coordinated switch 
in chemokine receptor expression 
during dendritic cell maturation. 
Eur J Immunol 1998;28:2760-9.
27. Banchereau J, Steinman RM. 
Dendritic cells and the control of 
immunity. Nature 1998;392:245-
52.
28. Hackstein H, Thomson AW. 
Dendritic cells: emerging 
pharmacological targets of 
immunosuppressive drugs. Nat 
Rev Immunol 2004;4:24-34.
29. Athanassopoulos P, Vaessen 
LMB, Maat AP, et al. Preferential 
depletion of blood myeloid 
dendritic cells during acute cardiac 
allograft rejection under controlled 
immunosuppression. Am J 
Transplant 2005;5:810-20.
30. Hackstein H, Renner FC, Bohnert A, 
et al. Dendritic cell deficiency in the 
blood of kidney transplant patients 
on long-term immunosuppression: 
results of a prospective matched-
cohort study. Am J Transplant 
2005;5:2945-53.
31. Hesselink DA, Vaessen LMB, Hop 
WC, et al. The effects of renal 
transplantation on circulating 
dendritic cells. Clin Exp Immunol 
2005;140:384-93.
Chapter 10
134
32. Mazariegos GV, Zahorchak AF, Reyes 
J, Chapman H, Zeevi A, Thomson 
AW. Dendritic cell subset ratio in 
tolerant, weaning and non-tolerant 
liver recipients is not affected by 
extent of immunosuppression. Am 
J Transplant 2005;5:314-22.
33. Sordi V, Bianchi G, Buracchi 
C, et al. Differential effects of 
immunosuppressive drugs on 
chemokine receptor CCR7 in 
human monocyte-derived dendritic 
cells: selective upregulation 
by rapamycin. Transplantation 
2006;82:826-34.
34. Baan CC, Weimar W. Intragraft 
cytokine gene expression: 
implications for clinical 
transplantation. Transpl Int 
1998;11:169-80.
35. Le Moine A, Goldman M, 
Abramowicz D. Multiple pathways to 
allograft rejection. Transplantation 
2002;73:1373-81.
36. Trapani JA, Smyth MJ. Functional 
significance of the perforin/
granzyme cell death pathway. Nat 
Rev Immunol 2002;2:735-47.
37. Ouwehand AJ, Baan CC, Roelen DL, 
et al. The detection of cytotoxic T 
cells with high-affinity receptors for 
donor antigens in the transplanted 
heart as a prognostic factor for 
graft rejection. Transplantation 
1993;56:1223-9.
38. van de Wetering J, Gerrits JH, 
van Besouw NM, IJzermans JNM, 
Weimar W. Successful tapering of 
immunosuppression to low-dose 
monotherapy steroids after living-
related human leukocyte antigen-
identical renal transplantation. 
Transplantation 2009;87:740-4.
39. Gerrits JH, Wetering J, Drabbels JJ, 
Claas FH, Weimar W, Besouw NM. 
Donor-reactive cytokine profiles 
after HLA-identical living-related 
kidney transplantation. Nephrol 
Dial Transplant 2008;23:2016-23.
40. Gerrits JH, Athanassopoulos P, 
Vaessen LMB, Klepper M, Weimar 
W, van Besouw NM. Peripheral 
blood manipulation significantly 
affects the result of dendritic cell 
monitoring. Transpl Immunol 
2007;17:169-77.
41. Hricik DE, Heeger PS. Minimization 
of immunosuppression in 
kidney transplantation. The 
need for immune monitoring. 
Transplantation 2001;72:S32-5.
42. de Lathouder S, Gerards AH, 
de Groot ER, Valkhof M, Aarden 
LA. Mycophenolic acid and 
methotrexate inhibit lymphocyte 
cytokine production via different 
mechanisms. Eur Cytokine Netw 
2002;13:317-23.
43. Jonsson CA, Carlsten H. 
Mycophenolic acid inhibits inosine 
5’-monophosphate dehydrogenase 
and suppresses immunoglobulin 
and cytokine production of B cells. 
Int Immunopharmacol 2003;3:31-
7.
44. Kaminska D, Tyran B, Mazanowska 
O, et al. Mycophenolate mofetil but 
not the type of calcineurin inhibitor 
(cyclosporine vs tacrolimus) 
influences the intragraft mRNA 
expression of cytokines in human 
kidney allograft biopsies by in situ 
RT-PCR analysis. Transplant Proc 
2005;37:770-2.
45. Moore KW, de Waal Malefyt R, 
Coffman RL, O’Garra A. Interleukin-
10 and the interleukin-10 receptor. 
Annu Rev Immunol 2001;19:683-
765.
T-cell reactivity during tapering of immunosuppression to low dose monotherapy 
prednisolone in HLA-identical living-related renal transplant recipients
135
46. Roncarolo MG, Battaglia M. 
Regulatory T-cell immunotherapy 
for tolerance to self antigens and 
alloantigens in humans. Nat Rev 
Immunol 2007;7:585-98.
47. Cai J, Lee J, Jankowska-Gan E, et 
al. Minor H Antigen HA-1-specific 
Regulator and Effector CD8+ T 
Cells, and HA-1 Microchimerism, 
in Allograft Tolerance. J Exp Med 
2004;199:1017-23.
48. Morelli AE, Thomson AW. 
Tolerogenic dendritic cells and the 
quest for transplant tolerance. Nat 
Rev Immunol 2007;7:610-21.
49. Hawiger D, Inaba K, Dorsett Y, et 
al. Dendritic cells induce peripheral 
T cell unresponsiveness under 
steady state conditions in vivo. J 
Exp Med 2001;194:769-79.
50. Steinman RM, Nussenzweig MC. 
Avoiding horror autotoxicus: the 
importance of dendritic cells in 
peripheral T cell tolerance. Proc 
Natl Acad Sci U S A 2002;99:351-
8.
51. Ehser S, Chuang JJ, Kleist C, et al. 
Suppressive dendritic cells as a tool 
for controlling allograft rejection in 
organ transplantation: promises 
and difficulties. Hum Immunol 
2008;69:165-73.
52. Solari MG, Thomson AW. Human 
dendritic cells and transplant 
outcome. Transplantation 
2008;85:1513-22.
53. Mehling A, Grabbe S, Voskort M, 
Schwarz T, Luger TA, Beissert S. 
Mycophenolate mofetil impairs 
the maturation and function of 
murine dendritic cells. J Immunol 
2000;165:2374-81.
54. Colic M, Stojic-Vukanic Z, Pavlovic 
B, Jandric D, Stefanoska I. 
Mycophenolate mofetil inhibits 
differentiation, maturation and 
allostimulatory function of human 
monocyte-derived dendritic cells. 
Clin Exp Immunol 2003;134:63-9.
55. Liu HN, Wong CK. In vitro 
immunosuppressive effects of 
methotrexate and azathioprine on 
Langerhans cells. Arch Dermatol 
Res 1997;289:94-7.
56. Lagaraine C, Lebranchu Y. Effects 
of immunosuppressive drugs 
on dendritic cells and tolerance 
induction. Transplantation 
2003;75:37S-42S.
57. Blanco P, Palucka AK, Pascual V, 
Banchereau J. Dendritic cells and 
cytokines in human inflammatory 
and autoimmune diseases. 
Cytokine Growth Factor Rev 
2008;19:41-52.

Chapter 11
A multiplex bead array analysis to 
monitor donor-specific cytokine 
responses after withdrawal of 
immunosuppression in HLA-identical 
living-related kidney transplant 
recipients
Jeroen H. Gerrits, Jacqueline van de Wetering, Els van Beelen, 
Frans H.J. Claas, Willem Weimar, and Nicole M. van Besouw
Transplant Proc 2009;41(5):1577-1582
Multiplex bead array after HLA-identical 
living-related kidney transplantation
Chapter 11
138
ABSTRACT
Introduction: Immune reactivity after HLA-identical living-related (LR) kidney 
transplantation can be caused by minor histocompatibility antigen and non-HLA antigen 
mismatches between donor and recipient. In our center, HLA-identical LR kidney transplant 
recipients receive azathioprine (AZA) or mycophenolate mofetil (MMF) in combination with 
corticosteroids for one year after transplantation. Thereafter, AZA or MMF was withdrawn and 
the patients were treated with steroid monotherapy as maintenance therapy. We questioned 
whether withdrawal of AZA or MMF affected the donor-specific lymphocyte proliferation and 
cytokine production. 
Methods: Donor and 3rd-party T-cell reactivity were determined by mixed lymphocyte 
reactions and by cytokine production using multiplex bead array technique.
Results: The donor and 3rd-party proliferative capacity were not affected after withdrawal of 
AZA or MMF. Thirteen of 17 cytokines were detected by the multiplex bead array technique. 
No differences were observed after 3rd-party induced cytokine production after withdrawal 
of AZA or MMF. However, production of donor-specific IFN-g and MIP-1β increased after 
discontinuation of AZA or MMF, but no clinically relevant acute rejection was observed.
Conclusions: After HLA-identical LR kidney transplantation, donor-specific cytokine 
responses can be found when AZA or MMF therapy is discontinued. The clinical relevance of 
this phenomenon is still not evident.
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INTRODUCTION
After solid organ transplantation, patients receive life-long immunosuppressive medication to 
suppress immune reactivity directed to the transplanted organ.1 Considering the severe side 
effects of immunosuppressive medication, minimization of immunosuppression is warranted 
in transplant recipients without inducing rejection of the donor graft. It has been reported 
that only a minority of HLA-mismatched kidney transplant recipients could safely discontinue 
their immunosuppressive medication completely.2-4 Recently, we described the possibility 
that HLA-identical living-related (LR) kidney transplant recipients can be withdrawn from 
their AZA and MMF dose.5
Theoretically, after HLA-identical LR kidney transplantation, differences in minor 
histocompatibility antigens (mHAgs) between donor and recipient may induce an immune 
response that might lead to graft rejection. mHAgs are intracellular peptides derived from 
non-HLA-encoded gene products that are presented on the cell surface of HLA class I and 
class II molecules, and can be recognised by T cells.6 Those antigens are inherited according 
to the Mendelian segregation theory.7 Indeed, after HLA-identical sibling bone marrow 
transplantation, immune reactivity is caused by mismatches in mHAgs between recipient 
and donor that may result in graft-versus-host disease.8, 9 Therefore, discontinuation of 
immunosuppression in HLA-identical LR kidney transplant recipients may disturb the 
immunological balance and lead to rejection. Accurate monitoring of immune parameters is 
thus warranted (e.g. by measuring cytokine activity). Pro-inflammatory cytokines have been 
associated with increased immune reactivity and allograft rejection, while anti-inflammatory 
cytokines have been associated with downregulation of immune reactivity.10
Cytokines can be measured by several techniques, such as real-time polymerase 
chain reaction (PCR) for mRNA cytokine levels, and flow cytometry for intracellular cytokines, 
Elispot assays for frequency of cytokine producing cells, and enzyme-linked immunosorbent 
assays (ELISA) for cytokine concentrations.11, 12 A recent developed assay to measure cytokine 
levels is the multiplex bead array technique. The advantage of this assay is that it provides 
simultaneous detection of multiple cytokines in serum, plasma or cell culture supernatants. 
The multiplex bead array technique captures cytokines by spectrally distinct beads, and 
uses fluorescent-labeled antibodies for detection of cytokines; samples are analysed on a 
compact flow cytometer.13
So far, there is no data available after clinical organ transplantation on simultaneous 
detection of donor-specific cytokine production in cell culture supernatants using a multiplex 
bead array technique. In our transplant center, HLA-identical LR kidney transplant recipients 
receive AZA or MMF in combination with steroids for 1 year after transplantation. From 1 
year after transplantation, AZA or MMF are discontinued.5 In the present study, we wondered 
whether withdrawal of AZA or MMF in HLA-identical LR kidney transplant recipients affected 
the donor-specific and 3rd-party specific cytokine production and proliferation.
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MATERIALS AND METHODS
HLA-identical living-related kidney transplant recipients
The ethical review committee of our center approved the protocol that was conducted 
according to local requirements. After informed consent, we studied seven HLA-identical LR 
kidney transplant recipients, who were more than 2 years after transplantation with stable 
serum creatinine levels and no proteinuria (<0.5 g/L). At inclusion, patients received 50 mg/
day AZA (n=6) or 500 mg/day MMF (n=1) in combination with 5 mg/day prednisolone (dual 
therapy). Thereafter, AZA and MMF dose were gradually tapered over a period of 4 months 
and the patients were kept on steroid monotherapy for at least one year. The characteristics 
of the patients are described in Table 1.
Peripheral blood mononuclear cells sampling
At dual therapy and monotherapy, we received 35 ml peripheral blood to perform mixed 
lymphocyte reactions (MLR) and cytokine analysis. Peripheral blood mononuclear cells 
(PBMC) from recipient and donor were isolated from heparinized blood by density gradient 
centrifugation using Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden). PBMC were 
collected from the interphase, washed twice with RPMI-1640-DM (Cambrex, Verviers, 
Belgium) supplemented with 100 IU/ml of penicillin (Cambrex) and 100 µg/ml of streptomycin 
(Cambrex). Thereafter, PBMC were stored in RPMI-1640-DM containing 15% foetal calf 
serum (FCS) and 10% dimethyl sulphoxide (MERCK, Germany) at –140oC until use.
MLR and collection of supernatant
One hundred microliters of 5x104 patient PBMC in complete culture medium [(RPMI-1640-
DM (Cambrex, Verviers, Belgium) supplemented with filtered [0.20-µm sterile syringe filter, 
Corning Incorporated, Corning, NY) 10% heat inactivated pooled human serum, 100 IU/ml 
of penicillin (Cambrex) and 100 µg/ml of streptomycin (Cambrex)] were stimulated with 100 
µl irradiated (45 Gy) 5x104 PBMC derived from the donor or completely HLA-mismatched 
Table 1: Demographics of HLA-identical living-related kidney trans-
plant recipients
1Data are presented as: median (range); 2PRA, panel reactive antibodies
Patients (n=7)
Age (years) (at dual therapy) 53 (28-63)1
Gender (male/female) 5/2
Primary kidney disease Patient 1: Medullary cystic disease
Patient 2: Acute tubular necrosis
Patient 3: IgA nephropathy
Patient 4: Hypertension
Patient 5: Von Hippel Lindau
Patient 6: Meningococcal sepsis
Patient 7: Reflux nephropathy
Time after transplantation (years) 6.3 (2.5-8.3)
# kidney transplantation: 1st / 2nd 6 / 1
PRA 2 (%) 2 (0-71)
Immunosuppression AZA + prednisolone (n=6)
MMF + prednisolone (n=1)
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3rd-party PBMC in a 96-well round bottom plate (Nunc, Roskilde, Denmark) for 7 days. To 
control the influence of irradiation, patient PBMC were incubated with its own irradiated 
patient PBMC (autologous response). Proliferation was measured by incorporation of 3H-
thymidine added during the last 8 h of culture. At day 6, supernatants were harvested and 
stored at –80oC until use.
Cytokine analysis
MLR supernatants were simultaneously tested for 17 cytokines (interleukin [IL]-1β, IL-
2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, IL-17, interferon [IFN]-g, tumor 
necrosis factor [TNF]-a, granulocyte colony-stimulating factor [G-CSF], granulocyte-
macrophage colony-stimulating factor [GM-CSF], monocyte chemotactic protein [MCP]-1, 
and macrophage inflammatory protein [MIP]-1β) with the Bio-Plex Human Cytokine 17-
Plex Panel following the manufacturer’s description (Bio-Rad Laboratorius, Veenendaal, The 
Netherlands). MLR supernatants were analyzed using a Bio-Plex array reader equipped with 
Bio-Plex software (Bio-Rad Laboratories). Detection limit was determined according to a 
standard curve (cytokine [lower detection limit-upper detection limit]): IL-1β [3-10000 pg/
ml]; IL-2 [3-20000 pg/ml]; IL-4 [5-1000 pg/ml]; IL-5 [5-10000 pg/ml]; IL-6 [10-10000 pg/
ml]; IL-7 [5-10000 pg/ml]; IL-8 [2-30000 pg/ml]; IL-10 [10-8000 pg/ml]; IL-12(p70) [10-
20000 pg/ml]; IL-13 [5-400 pg/ml]; IL-17 [5-7000 pg/ml]; IFN-g [30-20000 pg/ml]; TNF-a 
[20-20000 pg/ml]; G-CSF [10-8000 pg/ml]; GM-CSF [20-10000 pg/ml]; MCP-1 [10-7000 
pg/ml], MIP-1β [10-9000 pg/ml]. First, we tested which day is representative for optimal 
cytokine production of most cytokines in an HLA mismatched setting. In MLR supernatant, 
by day 6 most cytokines were detectable. Thereafter, we analysed the MLR supernatants 
at day 6 from the HLA identical LR renal transplant recipients. Cytokine concentrations 
ranging between the lower and higher detection limit were only analysed. The autologous 
response was subtracted from donor and from 3rd-party response to control the influence of 
irradiation.
mHAgs typing after HLA-identical LR kidney transplantation
DNA from donor and recipient were isolated using the QIAamp® DNA Mini Kit.14 Patient and 
donor PBMC were typed for 11 known mHAgs: HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-
2, HwA-9, HwA-10, UGT2B17, and HY.
Statistical analysis
The Wilcoxon signed rank test (two-sided P-values) was used to compare differences between 
donor-reactive responses and 3rd-party reactive responses and to compare differences 
between dual therapy and monotherapy. For statistical analysis, GraphPad statistical program 
was used (GraphPad Software Inc., San Diego, CA, USA).
RESULTS
Clinical results
One year after withdrawal of AZA or MMF, HLA-identical LR kidney transplant recipients had 
stable serum creatinine levels (dual therapy: median, 108 µmol/L; range, 62-135 versus 
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monotherapy: median, 114 µmol/L; range, 63-141) and no proteinuria (<0.5 g/L). None 
of the patients experienced acute rejection episodes or infections with cytomegalovirus or 
Epstein-Barr virus.
MLR
No difference was observed in donor-reactive MLR before (median, 231 cpm [range, 86-
5527]) and after withdrawal of AZA or MMF (monotherapy: median, 164 cpm [77-6050]; 
p=0.99). The donor-reactive MLR was comparable to the autologous MLR during dual 
therapy (donor-reactive MLR: median, 231 cpm [86-5527]; autologous MLR: 113 cpm 
[58-3377]; p=0.30) and during monotherapy (donor-reactive MLR: median, 164 cpm [77-
6050]; autologous MLR: median, 165 cpm [76-3410]; p=0.30). Before (p=0.02) and after 
(p=0.02) withdrawal of AZA or MMF, donor-reactive MLR was significantly lower than the 
3rd-party reactive MLR. Discontinuation of AZA or MMF had no influence on the 3rd-party 
reactive MLR (dual therapy: median, 7760 cpm [603-42810]; monotherapy: median, 8067 
cpm [201-29869]; p=0.99). 
Cytokine analysis
MLR supernatants were analysed for the presence of 17 cytokines (IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, IL-17, IFN-g, TNF-a, G-CSF, GM-CSF, MCP-1 and 
MIP-1β). Donor and 3rd-party reactive IL-4, IL-7, IL-10 and IL-12(p70) were below detection 
limit before and after withdrawal of AZA or MMF, while donor and third-party IL-5 and IL-13 
levels were inconsistently detectable. Donor and 3rd-party reactive IL-8 production was too 
high to determine exact cytokine levels.
Table 2: Influence of AZA and MMF withdrawal on donor and 3rd-party specific responses1 in PBMC 
from 7 HLA-identical LR kidney transplant recipients
Data are presented as median (range). AZA, azathioprine; MMF, mycophenolate mofetil; PBMC, peripheral 
blood mononuclear cells; LR, living-related; IL, interleukin; IFN-g, interferon-g; TNF-a, tumor necrosis 
factor-a; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-sti-
mulating factor; MCP-1, monocyte chemotactic protein-1; MIP-1b, macrophage inflammatory protein-1b.
1IL-4, IL-7, IL-10, and IL-12(p70) production were nondetectable. IL-8 production was too high to deter-
mine exact cytokine levels. Donor and third-party IL-5 and IL-13 levels were inconsistently detectable.
Dual therapy Monotherapy steroids
Cytokine
Donor-specific
response (pg/ml)
3rd-party specific
response (pg/ml)
Donor-specific
response
(pg/ml)
3rd-party specific
response
(pg/ml)
IL-1β 3 (0-432)3 12(0-541) 1 (0-839) 0 (0-269)
IL-2 0 (0-23) 34 (0-78) 5 (0-21) 26 (0-51)
IL-6 30 (0-2092) 60 (0-2297) 0 (0-8475) 3 (0-1854)
IL-17 0 (0-31) 12 (0-130) 9 (0-35) 13 (0-31)
IFN-γ 0 (0-171) 121 (0-550) 11 (0-301) 100 (0-194)
TNF-α 0 (0-525) 165 (28-216) 17 (0-416) 93 (0-1085)
G-CSF 0 (0-719) 0 (0-1067) 0 (0-545) 0 (0-77)
GM-CSF 0 (0-102) 54 (0-119) 31 (0-105) 32 (0-90)
MCP-1 0 (0-357) 210 (0-824) 325 (0-1056) 121 (0-556)
MIP-1β 0 (0-269) 1033 (171-3317) 266 (0-3184) 961 (94-7990)
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The autologous response was subtracted from donor and from third-party responses. 
We detected 10 donor- and 3rd-party specific cytokine responses before and/or after 
discontinuation of AZA or MMF in all patients. These cytokines were IL-1β, IL-2, IL-6, IL-17, 
IFN-g, TNF-a, G-CSF, GM-CSF, MCP-1 and MIP-1β (Table 2).
Withdrawal of AZA or MMF had no influence on the production of donor and 3rd-
party specific IL-1β, IL-2, IL-6, IL-17, TNF-a, G-CSF, GM-CSF and MCP-1 (Table 2). The 
production of donor-specific IFN-g was higher during monotherapy (median, 11 pg/ml; range, 
0-301) than during dual therapy (median, 0 pg/ml; range, 0-171; p=0.06; Figure 1A). After 
withdrawal of AZA or MMF, we observed that in five of seven patients, the production of 
donor-specific IFN-g had increased. Donor-specific IFN-g responses were lower than the 3rd-
party specific IFN-g responses during dual therapy (p=0.06). No difference was observed for 
the 3rd-party specific IFN-g response (Table 2; Figure 1B).
In addition, the production of donor-specific MIP-1β was also higher after withdrawal 
of AZA or MMF (dual therapy: median, 0 pg/ml [0-269]; monotherapy: median, 266 pg/ml 
[0-3184]; p=0.06; Figure 1C). In five of the seven patients, the donor-specific MIP-1β 
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Figure 1: Donor (A, C) and 3rd-party (B, D) specific cytokine production of IFN-g and MIP-1b in MLR cul-
tures from PBMC of HLA-identical LR kidney transplant recipients (n=7) during dual therapy (AZA or MMF 
+ steroids) and during steroid monotherapy.
production had increased after withdrawal of immunosuppression. Donor-specific MIP-1β 
responses were lower than the 3rd-party specific IFN-g responses both during dual therapy 
(p=0.02) and during monotherapy (p=0.02). The production of 3rd-party specific MIP-1β 
was not affected (Table 2; Figure 1D).
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Relation between production of donor-specific 
cytokines and mHAg mismatches
We analysed whether the presence (≥1 pg/ml) 
of donor-specific IFN-g and MIP-1β production 
was related to mHAg mismatches determined 
between donor and recipient.
From the seven patient-donor 
combinations, five couples (patient 1, 2, 4, 5, 
7) demonstrated at least one mHAg mismatch 
(Table 3). Two out of these five couples 
(patient 4 and 5) had an mHAg mismatch in 
combination with the correct HLA-restriction 
molecule (i.e. the HLA molecule in which the 
donor mHAgs could be presented to T cells). 
Remarkably, in patient 4 and 5, positive donor-
specific MIP-1β responses were found both 
before and after withdrawal of AZA and MMF, 
while during monotherapy donor-specific MIP-
1β production was detectable in six patients 
independent of mHAg mismatches. We could 
not find differences between IFN-g and mHAg 
mismatches. Additionally, no relation was 
found between production of donor-specific IL-
1β, IL-2, IL-6, IL-17, TNF-α, G-CSF, GM-CSF, 
and MCP-1 and the presence of known mHAg 
mismatches (data not shown).
DISCUSSION
After kidney transplantation, life-long use of 
immunosuppression is deemed necessary to 
avoid rejection of the transplanted kidney.1, 
15 However, the necessity for long-term use 
of immunosuppression in HLA-identical LR 
kidney transplant recipients is yet unknown. 
Considering the severe side effects of 
immunosuppression, tapering or even 
withdrawal of immunosuppression in these 
transplant recipients might be beneficial. 
Theoretically, withdrawal of immunosuppression 
in solid organ transplant recipients might 
result into increased donor-reactive T-cell 
responses.16-19 In the present study, none of 
the patients had an acute rejection episode 
and renal function remained stable when AZA 
or MMF was discontinued. We determined the 
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donor-reactive MLR response after HLA-identical LR kidney transplantation; the donor-
reactive MLR response was not higher than the autologous response. Apparently, priming of 
mHAgs as detected by MLR did not occur.
From the 17 cytokines analysed, 13 cytokines could be detected from which IL-8 
was too high to determine exact cytokine levels, while donor and third-party IL-5 and IL-13 
levels were inconsistently detectable. We observed that withdrawal of AZA or MMF had no 
significant influence on eight out of the remaining 10 detectable donor and 3rd-party specific 
cytokines. Interestingly, the production of donor-specific IFN-g and MIP-1β was higher after 
withdrawal of AZA or MMF, while the production of 3rd-party specific responses remained 
stable. This suggests that AZA or MMF suppresses donor-specific production of IFN-g and 
MIP-1β. AZA and MMF are anti-proliferative agents that may have an effect on cytokine 
production.20, 21 We are aware of our small cohort of patients. Therefore, future studies are 
needed to confirm our results.
 Pro-inflammatory cytokines (IL-2, IFN-g, TNF-a, Regulated upon Activation, Normal 
T-cell Expressed, and Secreted [RANTES], MIP-1a and MIP-1β) have been associated with 
increased immune reactivity and allograft rejection, while anti-inflammatory cytokines (IL-4, 
IL-5, IL-10 and IL-13) have been postulated to downregulate immune responses.22 In the 
present study, we found higher donor-specific IFN-g and MIP-1β production after withdrawal 
of AZA or MMF. Both cytokines can be produced by T-helper (Th) 1 cells and natural killer 
(NK) cells.23-25 Apparently, the increase in IFN-g and MIP-1β production capacity did not 
result in rejection.
It has been suggested that the presence of panel of reactive antibodies (PRA)-
reactivity was associated with long-term graft loss in kidney transplants from HLA-identical 
sibling donors, which could reflect immune reactivity directed to non-HLA antigens or 
mHAgs.26 In the present study, we found no correlation between PRA before HLA-identical 
LR kidney transplantation and increased donor-specific IFN-g and MIP-1β production during 
withdrawal of AZA and MMF. Additionally, the presence of PRA before transplantation did not 
result in acute rejection after discontinuation of AZA and MMF.
Donor-specific MIP-1β during dual therapy was related with mHAg mismatches in 
combination with the correct HLA-restriction molecule, suggesting that those responses were 
caused by those specific mHAg mismatches. This observation needs to be confirmed in a 
larger cohort of HLA-identical LR kidney transplant recipients. Apparently, AZA or MMF does 
not suppress the donor-specific MIP-1β production caused by mHAg mismatches presented 
in the correct HLA-restriction molecule, but again, this did not result in rejection.
In conclusion, donor reactivity can be detected in HLA-identical LR kidney transplant 
recipients using multiplex bead array technique. AZA and MMF suppress donor-specific IFN-g 
and MIP-1β production in HLA-identical LR kidney transplant recipients. However, the clinical 
relevance of this finding remains unclear.
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After HLA-identical living-related (LR) kidney transplantation, less acute rejection and better 
graft survival occur compared to recipients of an HLA-mismatched kidney transplant.1 This 
is explained that all major HLA molecules are identical between donor and recipient and only 
mismatches in minor histocompatibility antigens (mHAgs) and other non-HLA antigens may 
exist. The clinical relevance of mHAgs on transplant outcome has been demonstrated after 
bone marrow transplantation.2, 3 However, their relevance is yet not known after solid organ 
transplantation. Theoretically, both mismatches in mHAgs and other non-HLA antigens 
between donor and recipient may induce graft rejection. Consequently, HLA-identical LR 
renal transplant recipients still receive immunosuppression.
In Chapter 1, we provide a general introduction on immune monitoring after kidney 
transplantation. Non-invasive cellular assays using patients’ PBMC to determine immune 
reactivity directed to donor antigens could be helpful to identify transplant recipients in 
whom the immunosuppressive load can be safely reduced. Donor-reactive responses were 
determined by mixed lymphocyte reaction (MLR), CTL precursor frequency (CTLpf), helper 
T-lymphocyte precursor frequency (HTLpf) and Elispot assays before and during tapering of 
immunosuppression. In addition, a short overview concerning the development and side-
effects of immunosuppressive drugs are given.
The Aim of this thesis was to clarify the clinical relevance of donor-reactive 
T-cell responses directed to mHAgs and non-HLA antigens after HLA-identical LR kidney 
transplantation and during tapering of immunosuppression in this patientgroup (Chapter 
2).
In Part I, we studied donor-reactive T-cell responses during the first year after HLA-
identical LR kidney transplantation. After HLA-mismatched organ transplantation, studies 
showed that the donor-reactive T-cell responses, determined by either MLR, CTLpf, HTLpf 
or IFN-g Elispot assays, decrease during the first year after transplantation.4-8 In Chapter 
3, we demonstrated that, during immunological quiescence, donor-reactive IFN-g and GrB 
producing cells can be found in peripheral blood mononuclear cells (PBMC) from recipients 
of an HLA-identical LR kidney transplant both before and after HLA-identical LR kidney 
transplantation. We found no decrease in the number of donor and 3rd-party reactive IFN-g 
and GrB producing cells. These results were comparable with our previous data in a smaller 
cohort of HLA-identical LR kidney transplant patients.9 In addition, the number of donor-
reactive IFN-g and GrB producing cells were not related with known mHAg mismatches 
(HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-2, HwA-9, HwA-10, UGT2B17 and HY) between 
donor and recipient. 
Subsequently, we questioned whether the number of cytokine producing cells (IFN-
g, GrB, IL-13 and IL-10) directed to alloantigens in PBMC was different between HLA-identical 
LR kidney transplant recipients and HLA-mismatched LR kidney transplant recipients, who 
were approximately one year after transplantation. Healthy individuals served as controls. 
Chapter 4 showed that alloreactive cytokine responses (IFN-g, GrB and IL-13) from healthy 
individuals were higher compared to HLA-mismatched and HLA-identical LR kidney transplant 
recipients. Additionally, only the number of donor-reactive GrB producing cells was higher in 
the HLA-mismatched group compared to the HLA-identical group. Interestingly, in the HLA-
identical group, the number of donor-reactive IL-10 producing cells was significantly higher 
than their autologous control. These frequencies were also higher than the frequencies in 
the HLA-mismatched group and in healthy individuals. Additionally, donor-reactive cytokine 
responses could not be related to known mHAg mismatches between donor and recipient. 
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IL-10 is an anti-inflammatory cytokine that have been associated with downregulation of 
immune responses and may play a role in preventing graft rejection.10-12 After HLA-identical 
LR kidney transplantation, several studies showed the presence of donor-reactive IL-10 that 
could reflect allograft tolerance.13, 14 Several cells produce IL-10 after stimulation with donor 
antigens, such as monocytes, B cells, activated Th2 cells and T regulatory 1 (Tr1) cells.10 
Monocytes do not interfere in our Elispot assays, because only non-adherent cells were 
used. Also B cells played no role in our assays, because no difference in donor-reactive IL-10 
response was found between PBMC depleted for B cells and PBMC not depleted for B cells 
(data not shown). Beside IL-10, activated Th2 cells can also secrete IL-4, IL-5 and IL-13, and 
Tr1 cells produce transforming growth factor (TGF)-β.15, 16 Because high numbers of donor-
reactive IL-10 producing cells were found in combination with low numbers IFN-g, IL-13 
and GrB producing cells, we assume that not Th2 cells, but Tr1 cells could play a role after 
HLA-identical LR kidney transplantation. We suggests that IL-10 might play a beneficial role 
in active downregulation of immune reactivity against donor antigens during immunological 
quiescence.
In Chapter 5, the expression profile of 42 cytokines was screened by protein-array analysis 
in supernatant from donor-stimulated mixed lymphocyte cultures from PBMC of HLA-identical 
LR kidney transplant recipients. We observed that in 38 out of 42 (90%) proteins, donor-
reactive response was higher than autologous control. We assumed that those responses 
could be directed to mismatched mHAgs or other non-HLA antigens.
In addition to immunological monitoring of donor-reactive T-cell responses in transplant 
recipients, it has been suggested that monitoring of circulating DC subsets [myeloid DC 
(mDC) and plasmacytoid DC (pDC)] and their ratio in peripheral blood of transplant recipients 
might be an useful tool for identifying transplant recipients in whom the immunosuppressive 
load can be safely tapered.17 Because, it is practical and probably more accurate to measure 
sequential blood samples of one patient in one flow cytometric session, we studied the 
influence of cryopreservation on pDC/mDC ratio in healthy individuals and kidney transplant 
recipients (Chapter 6). We observed in both study groups that manipulation of PBMC 
by Ficoll isolation and cryopreservation affected the pDC/mDC ratio compared to fresh 
blood samples. Several studies demonstrated that immunosuppression may influence DC 
numbers.18-20 Therefore, we compared our results with PBMC from heart failure patients who 
did not receive immunosuppressive medication. The pDC/mDC ratio was also higher after 
cryopreservation of PBMC from heart failure patients compared to fresh blood cells, suggesting 
that the affected ratio was caused by blood manipulations, and not by immunosuppression. 
In addition, Ficoll isolation and cryopreservation of PBMC affected the maturation status of 
DC towards a more mature phenotype. These data imply that fresh blood samples should be 
used for monitoring purposes.
Considering the severe side effects of immunosuppression, minimizing of immunosuppression 
in transplant recipients might be beneficial. Theoretically, discontinuation of 
immunosuppression in organ transplant recipients might result into an increased donor-
reactive T-cell response.21-24 Complete discontinuation of immunosuppression was reported 
in a few renal transplant recipients long after transplantation with stable graft function and 
without clinical signs of rejection.25-27 However, after HLA-identical LR kidney transplantation 
there is no literature available about the necessity of immunosuppression in these patients 
and whether tapering of immunosuppression affected donor-reactive T-cell responses (Part 
Chapter 12
152
II). Therefore, we tapered the azathioprine (AZA) dose to 50% of the original dose in 
HLA-identical LR kidney transplant recipients, more than 2-years after transplantation, 
and studied the effect on renal function and T-cell reactivity (Chapter 7 and 8). After 
tapering the AZA dose, HLA-identical LR kidney transplant recipients remained free from 
acute rejection episodes and renal function was unaffected. We found that before tapering 
of AZA, the number of donor-reactive GrB producing cells was comparable to the number of 
GrB producing cells after tapering the AZA dose. Interestingly, before reduction of AZA dose, 
only 20% of the patients’ responded to donor antigens, whereas 57% of the patients’ PBMC 
responded to donor antigens after tapering of AZA. After 3rd-party stimulation, the number 
of GrB producing cells was increased after tapering the AZA dose (Chapter 7). Tapering 
of AZA did not increase the number of donor, 3rd-party and tetanus toxoid (TET)-reactive 
IFN-g and IL-13 producing cells (Chapter 8). In addition, donor-reactive cytokine responses 
measured before and after tapering of AZA could not be related to the number of known 
mHAg mismatches between donor and recipient. 
Because none of those patients experienced an acute rejection episode and renal 
function remained unaffected and no increase in the donor-reactive T-cell response was 
observed after tapering of the AZA dose, we assumed that the immunosuppressive dose 
could be reduced further (Chapter 9 and 10). We observed that withdrawal of AZA or MMF 
was successful in 85% (23/27) of the patients (Chapter 9). None of those patients had an 
acute rejection episode and renal function remained unaffected during a 24-months follow-up 
period. Also other clinical parameters, such as systolic, diastolic blood pressure, the number 
of antihypertensive drugs taken, serum total, LDL or HDL cholesterol levels, haemoglobulin, 
thrombocytes or leukocytes, showed no significant changes between inclusion and 24-
months on monotherapy prednisolone. 15% (4/27) of the patients developed recurrence 
of their original disease. This percentage was comparable to the recurrence of disease 
described elsewhere in HLA-identical LR kidney transplant recipients who used full dose 
immunosuppression.28
We observed no significant differences in the number of donor, 3rd-party and TET-
reactive IFN-g and GrB producing cells after withdrawal of AZA or MMF therapy (Chapter 
10). Remarkably, higher numbers of donor, 3rd-party and TET-reactive IL-10 producing cells 
were found during monotherapy prednisolone. Apparently, IL-10 was suppressed by AZA and 
MMF. AZA and MMF are anti-proliferative agents, and may also have an effect on cytokine 
production of lymphocytes.29, 30 Furthermore, discontinuation of AZA or MMF had no influence 
on the absolute numbers of total DC, mDC and pDC, and their ratio. The maturation status 
of DC subsets was shifted towards a more mature phenotype, suggesting that AZA and MMF 
affected phenotypic maturation of DC. In agreement with our results, studies have reported 
that AZA and MMF may affect phenotypic maturation of DC.31-33
Thereafter, we wondered whether we could detect differences in donor reactivity 
after discontinuation of AZA and MMF in lymphocyte proliferation and cytokine production 
using multiplex bead array technique (Chapter 11). We found that donor and 3rd-party 
proliferative capacity were not affected after withdrawal of AZA or MMF. Thirteen out of 
17 donor and 3rd-party reactive cytokines were detected during dual therapy and during 
monotherapy prednisolone. Four cytokines were not detectable. Only the production of donor-
reactive IFN-g and MIP-1β was higher after withdrawal of AZA or MMF, while the production 
of 3rd-party reactive responses remained stable. We concluded that donor reactivity can 
be detected in HLA-identical LR kidney transplant recipients using multiplex bead array 
technique. AZA and MMF suppressed the production of donor-reactive IFN-g and MIP-1β in 
HLA-identical LR kidney transplant recipients, and not the 3rd-party reactive response. The 
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clinical relevance of this finding is yet unclear.
Considering the successful clinical and laboratory results after tapering and even 
discontinuation of AZA or MMF in HLA-identical LR kidney transplant recipients, we propose 
to withdrawal the immunosuppressive medication (calcineurin inhibitors [CNI], AZA or MMF) 
to prednisolone 5 mg/day in these patients who are at least one year after transplantation. 
Low dose steroid monotherapy should be sufficient provided that they have stable renal 
function and no proteinuria. Close surveillance of patients for recurrence of their original 
disease is recommended for potential early therapeutic intervention. Whether complete 
withdrawal of corticosteroids may be possible in HLA-identical LR kidney transplant recipients 
remains to be investigated. Interestingly, in our study group, two HLA-identical LR kidney 
transplant recipients are also withdrawn from corticosteroid for more than 3 years. They did 
not develop acute rejection and have stable graft function (data not shown).
In summary, this thesis demonstrated that donor-reactive T-cell responses can be found 
after HLA-identical LR kidney transplantation, but those responses were not related to 
known mHAg mismatches (HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-2, HwA-9, HwA-
10, UGT2B17 and HY) (Chapter 3, 4, 8, 10, 11). In line with our study, Heinold et al.34 
reported that mHAg mismatches between donor and recipient after cadaveric and living-
related kidney transplantation had no significant influence on the 5-years death-censored 
allograft survival. Other studies reported an association with mHAgs and acute rejection, 
chronic allograft nephropathy and graft failure. However, they analysed these associations 
in patients who received a deceased kidney and not in HLA-identical siblings.35-38 So, one 
cannot exclude the possibility that the association was caused by HLA mismatches, as HLA-
Cw, HLA-DQ and DP, rather than mHAg mismatches in those patients.39-42
Proinflammatory cytokines, such as IFN-g, IL-2 and TNF-α, have been postulated to promote 
allograft rejection, while anti-inflammatory cytokines, IL-4, IL-5, IL-10 and IL-13, have 
been associated with downregulation of the immune response.43-45 In our studies, donor-
reactive T-cell responses could be detected in PBMC from HLA-identical LR kidney transplant 
recipients using Elispot assays during immunological quiescence (Chapter 3, 4, 7, 8, 10). 
Interestingly, we found a negative correlation (rs=-0.41; p=0.03) between the number of 
donor-reactive IL-10 producing cells and time after HLA-identical LR kidney transplantation 
before tapering of immunosuppression (Figure 1), while this was not observed for IFN-g 
and GrB (data not shown). Withdrawal of AZA or MMF resulted in higher numbers of donor-
reactive IL-10 producing cells in PBMC from HLA-identical LR kidney transplant recipients 
(Chapter 10). This suggests the presence of immune reactivity against donor antigens 
during the first year after transplantation and during withdrawal of immunosuppression, 
which was actively downregulated by donor-reactive IL-10 in these patients. Several other 
studies showed also the presence of donor-reactive IL-10 in recipients of an HLA-identical 
LR kidney transplant that could reflect allograft tolerance.13, 14, 46 
 We felt reassured that none of the patients had an acute rejection episode during 
withdrawal of AZA and MMF. Therefore, the clinical relevance of the Elispot assay to predict 
acute rejection could not be demonstrated in this specific patient group.
 
In conclusion, in peripheral blood, donor-reactive T-cell responses can be found in PBMC 
from recipients of an HLA-identical LR kidney transplant. These responses are not related 
with the number of known mHAgs mismatches between donor and recipient. High numbers 
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of donor-reactive IL-10 producing cells were found. This may reflect active downregulation of 
immune reactivity against mHAgs and non-HLA antigens. HLA-identical LR kidney transplant 
recipients can be safely discontinued from their CNI, MMF and AZA dose after one year 
posttransplantation. Low dose corticosteroids is sufficient for stable graft function.
Figure 1: Relation between the number of donor-reactive IL-10 producing cells (pc) in PBMC from HLA-iden-
tical LR kidney transplant recipients and time after transplantation during high dose of immunosuppression.
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Niertransplantatie is de beste behandeloptie voor patiënten met niet functionerende nieren. 
Hierbij wordt de zieke nier van de patiënt vervangen door een gezonde nier van de donor. Na 
transplantatie ontvangen patiënten medicijnen (immunosuppressiva) die het afweersysteem 
onderdrukken. Deze medicijnen worden gegeven om afstoting van de getransplanteerde 
nier te voorkomen. In het algemeen zal de patiënt zijn of haar hele leven deze medicijnen 
moeten innemen om acceptatie van de nier te handhaven. Langdurig gebruik van deze 
immuunsuppressieve geneesmiddelen kan echter leiden tot ernstige bijwerkingen, zoals 
infecties, nier- en leverfalen, suikerziekte, tumoren en hart- en vaatproblemen. Het is 
daarom wenselijk deze medicijnen in een minimale hoeveelheid voor te schrijven, zonder 
dat dit leidt tot afstoting van de getransplanteerde nier.
Transplantatie van een nier tussen individuen die genetisch niet identiek zijn, leidt tot afstoting 
wanneer de patiënt geen immunosuppressieve geneesmiddelen krijgt. Dit wordt veroorzaakt 
door een afweerreactie tegen lichaamsvreemde weefselantigenen op het celmembraan van 
de getransplanteerde nier. Deze weefselantigenen worden humane leukocyten antigenen 
(HLA; Human Leucocyte Antigens) genoemd. Wanneer alle HLA moleculen tussen ontvanger 
en donor identiek zijn, wordt de kans op afstoting aanzienlijk kleiner. Na HLA-identieke 
familieniertransplantaties zijn alle belangrijke HLA moleculen (HLA-A, B, Cw, DR, DP en DQ) 
tussen donor en ontvanger gelijk.
Ondanks dat bij HLA-identieke familieniertransplantaties alle HLA antigenen 
tussen donor en ontvanger gelijk zijn, kunnen er wel verschillen zijn in niet-HLA antigenen, 
zoals minor histocompatibiliteitsantigenen (mHAgs). mHAgs zijn genetisch overgeërfde 
peptiden (kleine stukjes eiwit) die afkomstig zijn uit polymorfe, intracellulaire eiwitten. 
Deze peptiden kunnen alleen worden gepresenteerd in het HLA molecuul, dat zich op het 
celoppervlak bevindt. mHAgs kunnen worden herkend door T cellen van de ontvanger en 
zij kunnen daarom een immuunrespons induceren. De klinische relevantie van mHAgs met 
betrekking tot afstotingsreacties is met name beschreven na beenmergtransplantatie.1, 2 
Hieruit bleek dat verschillen in mHAgs tussen ontvanger en donor tot een afweerreactie 
kan leiden, gericht tegen de ontvangercellen. De klinische relevantie van mHAgs na 
HLA-identieke familieniertransplantatie is echter nog onbekend. Gezien de resultaten bij 
beenmergtransplantaties, zou kunnen worden verondersteld dat verschillen in mHAgs of 
andere niet-HLA antigenen bij deze patiënten leiden tot afstoting van de getransplanteerde 
nier. Daardoor ontvangen deze patiënten nog steeds een onderhoudsdosering aan 
immunosuppressieve medicatie.
Vanwege de ernstige bijwerkingen van immunosuppressie, is het belangrijk om patiënten 
te identificeren bij wie de immunosuppressieve medicatie op een veilige manier kan worden 
verminderd. Dit kan door het monitoren van aanwezige immunologische reactiviteit gericht 
tegen donorcellen. Hoofdstuk 1 beschrijft een algemene introductie over het monitoren 
van immunologische reactiviteit na niertransplantatie. Er worden niet-invasieve cellulaire 
testen beschreven die gebruik maken van patiënten- en donorcellen. Donorreactiviteit werd 
bepaald met ‘gemengde lymfocyten kweek’ (mixed lymphocyte reaction: MLR), frequentie 
van donorspecifieke helper (HTLpf) of cytotoxische T-lymfocyten (CTLpf), of Elispot testen. 
Deze technieken werden beschreven vóór de transplantatie en tijdens het verminderen van 
immunosuppressieve medicatie. Verder wordt in dit hoofdstuk een kort overzicht gegeven 
over de ontwikkeling van de medicatie en over bijwerkingen van immunosuppressiva.
 Het hoofddoel van dit proefschrift was het onderzoeken van de klinische relevantie 
van donorgerichte T-cel reactiviteit tegen mHAgs na HLA-identieke familieniertransplantatie 
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en tijdens vermindering van immunosuppressie bij deze patiënten (Hoofdstuk 2).
In het eerste deel hebben we de T-cel reactiviteit gericht tegen donorantigenen gedurende 
het eerste jaar na HLA-identieke familieniertransplantatie onderzocht. Studies na niet-HLA-
identieke orgaantransplantatie hebben laten zien dat de T-cel reactiviteit gericht tegen 
donorcellen, gemeten met behulp van MLR, CTLpf en HTLpf, dalen gedurende het eerste 
jaar na transplantatie.3-6 In Hoofdstuk 3 wordt aangetoond dat donor-reactieve IFN-g en 
GrB producerende cellen kunnen worden gemeten in perifere bloed mononucleaire cellen 
(PBMC) van ontvangers van een HLA-identieke familieniertransplantaat, zowel voor als na 
transplantatie. De donor- en de 3e-partij reactiviteit daalden niet gedurende het eerste jaar 
na transplantatie. Deze resultaten kwamen overeen met eerder gevonden resultaten bij 
een kleinere groep van HLA-identieke familieniertransplantatiepatiënten.7 We vonden echter 
geen relatie met bekende mHAg verschillen (HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-
2, HwA-9, HwA-10, UGT2B17 and HY) tussen donor en ontvanger en het aantal donor-
reactieve IFN-g en GrB producerende cellen.
Daarna vroegen we ons af of er een verschil bestaat in het aantal cytokinen 
producerende cellen (IFN-g, GrB, IL-13 en IL-10) gericht tegen alloantigenen tussen HLA-
identieke en niet-HLA-identieke familieniertransplantatiepatiënten. Gezonde individuen 
dienden hierbij als controle. Hoofdstuk 4 laat zien dat alloreactieve cytokinen responsen 
(IFN-g, GrB en IL-13) van gezonde individuen hoger waren vergeleken met beide 
patiëntengroepen. Ook vonden we dat het aantal GrB producerende cellen bij de niet-HLA-
identieke groep hoger was dan de HLA-identieke groep. Opmerkelijk was dat het aantal 
donor-reactieve IL-10 producerende cellen bij de HLA-identieke groep significant hoger was 
dan de autologe reactiviteit. Deze frequentie was ook hoger dan de frequentie in de niet-
HLA identieke groep en gezonde individuen. Er werd opnieuw geen relatie gevonden met 
het aantal cytokinen producerende cellen in PBMC van HLA-identieke patiënten en bekende 
mHAg verschillen tussen donor and ontvanger.
Vanuit de literatuur wordt beschreven dat IL-10 een anti-inflammatoir cytokine is 
dat immuunreactiviteit kan onderdrukken en mogelijk zelfs een rol speelt bij het voorkomen 
van afstoting van een donororgaan.8-10 Studies na HLA-identieke familieniertransplantatie 
hebben laten zien dat de aanwezigheid van donorreactief IL-10 mogelijk tot tolerantie kan 
leiden.11, 12 Verscheidene cellen produceren IL-10 na stimulatie met donorantigenen, zoals 
monocyten, B cellen, T helper (Th)-2 cellen en T regulatoire type 1 (Tr1) cellen.8 Monocyten 
beïnvloedden de Elispot testen niet, omdat bij deze test alleen niet-adherente cellen 
waren gebruikt. Ook B cellen hadden geen invloed op de testen, omdat er geen verschil is 
gevonden in donor-reactieve IL-10 respons tussen PBMC zonder B cellen en PBMC met B 
cellen (data niet getoond). Naast IL-10 kunnen geactiveerde Th2 cellen ook IL-4, IL-5 en IL-
13 produceren, terwijl Tr1 cellen transforming growth factor (TGF)-β produceren.13, 14 Omdat 
hoge aantallen donor-reactieve IL-10 producerende cellen worden gevonden in combinatie 
met lage aantallen IFN-g, GrB en IL-13 producerende cellen, wordt aangenomen dat niet Th2 
cellen, maar Tr1 cellen een rol kunnen spelen na HLA-identieke familieniertransplantatie. 
Onze resultaten suggereren dat IL-10 een rol speelt bij het actief onderdrukken van 
immuunreactiviteit gericht tegen donorantigenen tijdens immunologische rust.
In Hoofdstuk 5 hebben we met behulp van een eiwit-array in het supernatant van 
donorgestimuleerde MLR het expressieprofiel van 42 cytokinen onderzocht. We vonden bij 38 
van de 42 (90%) eiwitten een hogere donor- dan de autologe reactiviteit. We veronderstellen 
dat deze responsen zijn gericht tegen mHAgs of andere niet-HLA antigenen.
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In de literatuur wordt beschreven dat monitoren van circulerende dendritische cellen 
(DC) [myeloide DC (mDC) en plasmacytoide DC (pDC)] en de ratio pDC/mDC in het 
perifere bloed van transplantatiepatiënten mogelijk patiënten kan identificeren bij wie 
de immunosuppressieve geneesmiddelen kunnen worden verminderd.15 Omdat het 
praktisch en mogelijk ook nauwkeuriger is om sequentiële bloedmonsters van één 
patiënt in één flowcytometrische meting te bepalen, hebben we onderzocht of de pDC/
mDC ratio wordt beïnvloed door cryopreservatie van cellen van gezonde individuen en 
niertransplantatiepatiënten (Hoofdstuk 6). In beide groepen vonden we dat de pDC/mDC 
ratio werd beïnvloed door het manipuleren van PBMC, zoals Ficoll isolatie en cryopreservatie. 
Er bestaan verscheidene studies die laten zien dat immunosuppressiva een effect kan 
hebben op de aantallen DC.16-18 Daarom hebben we onze resultaten vergeleken met PBMC 
van patiënten met hartfalen die geen immunosuppressieve medicatie ontvangen. Ook bij 
deze patiënten was de pDC/mDC ratio hoger na cryopreservatie van PBMC vergeleken met 
de pDC/mDC ratio gemeten in verse bloedmonsters. De uitkomsten van deze studie tonen 
aan dat manipulatie van vers bloed door Ficoll isolatie en cryopreservatie een direct gevolg 
heeft op de pDC/mDC ratio en de maturatie status van DC. Dit wordt niet veroorzaakt door 
het gebruik van immunosuppressieve therapie. Deze resultaten laten zien dat bij voorkeur 
verse bloedmonsters moeten worden gebruikt voor het monitoren van DC.
In deel 2 hebben we het effect van vermindering van de immunosuppressieve medicatie 
bij ontvangers van een HLA-identieke familieniertransplantaat op de donor-reactieve T-cel 
respons onderzocht.
Het gebruik van immunosuppressieve geneesmiddelen kan leiden tot zeer ernstige 
bijwerkingen.19 Daarom is het wenselijk zo weinig mogelijk immunosuppressie te geven 
zonder dat dit leidt tot afstoting van het donororgaan. Volgens de literatuur leidt vermindering 
of stoppen van immunosuppressieve medicatie na orgaantransplantatie tot een toename in 
donorgerichte T-cel reactiviteit.20-23 Volledig stoppen van de immunosuppressieve medicatie is 
slechts beschreven in een klein aantal niertransplantatiepatiënten die lang na transplantatie 
een stabiele nierfunctie hadden en geen klinische tekenen van afstoting vertoonden.24-26 Er is 
echter geen literatuur beschikbaar over de noodzakelijke hoeveelheid immunosuppressieve 
medicatie bij ontvangers van een HLA-identieke familieniertransplantaat. Tevens is het 
onbekend of de donorgerichte T-cel reactiviteit wordt beïnvloed na het verminderen van 
immunosuppressie bij deze patiënten (Deel II). Op onze polikliniek wordt een groep 
HLA-identieke familieniertransplantatiepatiënten gecontroleerd die azathioprine (AZA) en 
corticosteroiden als immunosuppressieve onderhoudstherapie gebruikten. Allen waren meer 
dan 2 jaar na transplantatie. We hebben eerst de AZA dosering verminderd tot 50% van de 
originele dosering. Bij deze patiënten werd het effect van vermindering van de AZA dosering 
op de nierfunctie en de T-cel reactiviteit tegen donorcellen onderzocht (Hoofdstuk 7 en 
8). De HLA-identieke patiënten bleven vrij van acute afstoting en de nierfunctie bleef stabiel 
na vermindering van AZA. Zowel voor als na vermindering van AZA bleef het aantal donor-
reactieve GrB producerende cellen onveranderd. Opmerkelijk was dat vóór vermindering 
van de AZA dosering slechts 20% van de patiënten reageerde op donorcellen, terwijl dit 
na vermindering van de AZA dosering 57% van de patiënten besloeg. Het aantal GrB 
producerende cellen gericht tegen 3e-partij antigeen nam eveneens toe na vermindering 
van de AZA dosering (Hoofdstuk 7). Er werd echter geen toename geconstateerd in het 
aantal donor, 3e-partij en tetanus toxoid (TET)-reactieve IFN-g en IL-13 producerende 
cellen (Hoofdstuk 8). Daarnaast vonden we geen relatie tussen het aantal donorreactieve 
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cytokinen en het aantal bekende mHAg verschillen tussen donor en ontvanger.
 Omdat alle HLA-identieke patiënten vrij bleven van acute afstoting, de nierfunctie 
stabiel bleef en geen toename in donorreactiviteit werd gevonden na vermindering van 
de AZA dosering, vroegen wij ons af of de immunosuppressieve medicatie nog verder kon 
worden verminderd (Hoofdstuk 9 en 10). Daarom werden patiënten die tenminste 1 jaar 
na transplantatie waren eerst op AZA (50 mg/dag) of mycofenolaat mofetil (MMF; 500 
mg/dag) therapie gezet in combinatie met 5 mg/dag prednisolon. Het volledig stoppen van 
AZA of MMF was succesvol bij 85% (23/27) van de patiënten (Hoofdstuk 9). Alle patiënten 
bleven vrij van acute afstoting en de nierfunctie bleef stabiel, ook na 24 maanden follow-
up. Daarnaast lieten andere klinische parameters, zoals bloeddruk, serum lipiden (LDL, 
HDL en triglyceriden) concentraties, glucose, HbA1c en CRP, geen verandering zien vanaf 
inclusie tot 24 maanden op monotherapie steroïden. Wel ontwikkelde 15% van de patiënten 
(4/27) terugkeer van hun oorspronkelijke ziekte. Dit percentage was echter vergelijkbaar 
met de terugkeer van de oorspronkelijke ziekte uit een andere klinische studie bij HLA-
identieke familieniertransplantatiepatiënten die hun hoge dosering immunosuppressie 
bleven behouden.27 
In Hoofdstuk 10 hebben we aangetoond dat het stoppen van AZA of MMF 
geen significant effect had op de aantallen donor, 3e-partij en TET-reactieve IFN-g en GrB 
producerende cellen. Opmerkelijk was dat het aantal donor, 3e-partij en TET-reactieve IL-
10 producerende cellen steeg ten tijde van monotherapie steroïden. Blijkbaar onderdrukt 
AZA en MMF IL-10. AZA en MMF zijn anti-proliferatieve middelen en kunnen ook een effect 
hebben op de cytokinenproduktie van lymfocyten.28, 29 Tevens vonden we dat het stoppen 
van AZA of MMF geen effect had op de absolute aantallen mDC en pDC en de pDC/mDC 
ratio. De maturatie status van DC subsets was veranderd naar een meer matuur fenotype, 
hetgeen suggereert dat AZA en MMF de fenotypische maturatie van DC onderdrukt. In vitro 
studies hebben eveneens aangetoond dat AZA en MMF de fenotypische maturatie van DC 
beïnvloedt.30-32
 Vervolgens hebben we onderzocht of het stoppen van AZA of MMF een effect had op 
de donorreactiviteit gemeten in een MLR en cytokinenproductie door middel van de multiplex 
bead array test (Hoofdstuk 11). Onze resultaten laten zien dat de proliferatieve capaciteit 
van patiëntencellen gericht tegen donor en 3e-partij antigenen niet werd beïnvloed door AZA 
of MMF. Uit de multiplex bead array test bleek dat 13 van de 17 donor en 3e-partij reactieve 
cytokinen konden worden gemeten tijdens combinatietherapie (AZA of MMF + prednisolon) 
en monotherapie prednisolon. De overige 4 cytokinen waren niet detecteerbaar. Opmerkelijk 
was dat alleen de productie van donorreactief IFN-g en MIP-1β hoger was na het stoppen van 
AZA of MMF, terwijl er geen verschil werd gevonden in de productie van 3e-partij reactieve 
responsen. Hieruit concluderen we dat donorgerichte reactiviteit kan worden gemeten bij 
ontvangers van een HLA-identieke familieniertransplantaat met behulp van de multiplex 
bead array test. AZA en MMF onderdrukken de productie van donorreactief IFN-g en MIP-1β 
bij deze patiënten, maar niet de 3e-partij reactiviteit. Tot op heden is de klinische relevantie 
van deze bevindingen echter nog niet duidelijk.
Gezien de ernstige bijwerkingen van langdurig gebruik van immunosuppressiva en de 
goede klinische en laboratorium resultaten na afbouw van de AZA en MMF dosering en zelfs 
het volledig stoppen van AZA of MMF, stellen wij voor de immunosuppressieve medicatie 
(calcineurin inhibitors [CNI], AZA of MMF) 1 jaar na transplantatie stapsgewijs te stoppen bij 
HLA-identieke familieniertransplantatiepatiënten. Een lage dosering monotherapie steroïden 
(5 mg/dag) zou voldoende moeten zijn, op voorwaarde dat de patiënten een stabiele 
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nierfunctie hebben en geen eiwit in de urine vertonen. Hierdoor zullen deze patiënten niet 
meer langdurig worden blootgesteld aan de ernstige bijwerkingen van immunosuppressiva. 
Patiënten met een glomerulaire nierziekte als oorspronkelijk lijden, zullen regelmatig 
poliklinisch moeten worden gecontroleerd om indien nodig de immunosuppressieve therapie 
aan te passen om terugkeer van de oorspronkelijke ziekte te voorkomen. In de toekomst 
zou moeten worden onderzocht of het volledig stoppen van de corticosteroïden mogelijk 
is bij ontvangers van een HLA-identieke familieniertransplantaat. In onze studiepopulatie 
hebben we inmiddels 2 HLA-identieke patiënten die ook volledig gestopt zijn met hun 
corticosteroïden medicatie. Deze patiënten zijn nu 3 jaar geheel zonder medicatie, zijn vrij 
gebleven van afstoting en hebben een stabiele nierfunctie (data niet getoond).
Samenvattend hebben we laten zien dat T-cel reactiviteit tegen donorcellen kunnen worden 
aangetoond na HLA-identieke familieniertransplantatie. Deze responsen bleken echter niet 
gerelateerd te zijn aan de bekende mHAg verschillen (HA-1, HA-2, HA-3, HA-8, ACC-1, ACC-
2, HwA-9, HwA-10, UGT2B17 en HY) (Hoofdstuk 3, 4, 8, 10, 11). Deze resultaten komen 
overeen met een studie van Heinold et al.33 die laat zien dat bekende mHAg verschillen 
geen invloed hebben op de 5-jaars transplantaatoverleving na het ontvangen van een 
overleden of een levende familieniertransplantatie. Andere studies laten een associatie zien 
met mHAg verschillen en acute afstoting, chronische afstoting en transplantaatfalen.34-37 Zij 
analyseerden deze associaties bij patiënten die een niertransplantaat ontvingen van een 
overleden donor en niet bij HLA-identieke koppels. Daarom kan er niet worden uitgesloten 
dat de gevonden associatie werd veroorzaakt door HLA verschillen, zoals HLA-Cw, HLA-DQ 
en HLA-DP, in plaats van mHAg verschillen tussen donor en ontvanger.38-41
In de literatuur is beschreven dat pro-inflammatoire cytokinen, zoals IFN-g, IL-2 en TNF-
α, afstoting van het getransplanteerde orgaan bevorderen, terwijl anti-inflammatoire 
cytokinen, IL-4, IL-5, IL-10 en IL-13, met name geassocieerd zijn met het onderdrukken van 
de immuunreactiviteit.42-44 In onze studies konden met behulp van de Elispot test, tijdens 
immunologische rust, donorgerichte T-cel reactiviteit worden gedetecteerd in PBMC van 
HLA-identieke familieniertransplantatiepatiënten (Hoofdstuk 3, 4, 7, 8, 10). Opmerkelijk 
was dat er een negatieve correlatie (rs=-0.41; p=0.03) werd gevonden tussen het aantal 
donorreactieve IL-10 producerende cellen en tijd na HLA-identieke familieniertransplantatie. 
Dit was gemeten voor vermindering van immunosuppressie (Figuur 1). Voor IFN-g en GrB 
werd dit niet gevonden (data niet getoond). Daarna resulteerde het stoppen van AZA of 
MMF bij deze patiënten in een toename van het aantal donorreactieve IL-10 producerende 
cellen (Hoofdstuk 10). Deze resultaten suggereren dat er immuunreactiviteit aanwezig 
is gericht tegen donorantigenen tijdens het eerste jaar na transplantatie en tijdens 
het stoppen van immunosuppressiva. Dit zou kunnen betekenen dat de aanwezige 
immuunreactiviteit actief wordt onderdrukt door donorreactief IL-10 bij HLA-identieke 
familieniertransplantatiepatiënten. Een aantal andere studies heeft ook donorreactief IL-10 
bij ontvangers van een HLA-identieke familieniertransplantaat aangetoond, dat mogelijk tot 
tolerantie kan leiden.11, 12, 45
 Het grote pluspunt van onze studies is dat geen van de HLA-identieke patiënten 
een acute afstoting heeft doorgemaakt na het stoppen van AZA en MMF therapie. Daarom 
hebben we de klinische relevantie van de Elispot test in het voorspellen van acute afstoting 
niet kunnen aantonen voor deze specifieke patiëntengroep. 
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Concluderend kunnen we zeggen dat in het perifere bloed van ontvangers van een HLA-
identieke familieniertransplantaat T-cel reactiviteit tegen donorcellen kan worden aangetoond. 
Deze reactiviteit kan niet worden gerelateerd aan het aantal bekende mHAg verschillen tussen 
donor en ontvanger. Hoge aantallen donorreactieve IL-10 producerende cellen suggereert 
een actieve onderdrukking van immuunreactiviteit, gericht tegen mHAgs en andere niet-HLA 
antigenen. Bij deze patiënten kunnen de CNI, MMF en AZA doseringen stapsgewijs 1 jaar na 
transplantatie veilig worden stopgezet; een lage dosering corticosteroïden blijkt voldoende 
voor een stabiele nierfunctie.
 
Figuur 1: Het aantal donorreactieve IL-10 producerende cellen (pc) in PBMC van HLA-identieke familie-
niertransplantatiepatiënten in relatie tot de tijd na transplantatie voor afbouw van de immunosuppres-
sieve medicatie.
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Abbreviations
APC  antigen-presenting cells
AZA  azathioprine
BDCA  blood dendritic cells antigens
BMT  bone marrow transplantation
CAN  chronic allograft nephropathy
CKR  chemokine receptors
CNI  calcineurin inhibitor
CRYO  cryopreservation
CsA  cyclosporine A
CTL  cytotoxic T lymphocyte
CTLpf  cytotoxic T-lymphocyte precursor frequency
DC  dendritic cells
FB  fresh blood
GrB  granzyme B
GVHD  graft-versus-hose disease
HF  heart failure
HLA  human leucocyte antigens
HTLpf  helper T-lymphocyte precursor frequency
IFN  interferon
IL  interleukin
KTx  kidney transplantation
LDA  limiting dilution assay
LR  living-related
mAbs  monoclonal antibodies
mDC  myeloid DC
mHAgs  minor histocompatibility antigens
MHC  major histocompatibility antigens
MIP-1b  macrophage inflammatory protein-1b
MLR  mixed lymphocyte reaction
MMF  mycophenolate mofetil
mo  month
NFAT  nuclear factor of activated T cells
PBMC  peripheral blood mononuclear cells
pc  producing cells
PCR  polymerase chain reaction
pDC  plasmacytoid DC
PHA  phytohemagglutinin
Pred  predniso(lo)n(e)
RTx  renal transplantation
SI  stimulation index
Tacro  tacrolimus
TET  tetanus toxoid
Th  T helper cells
TNF  tumor necrosis factor
Tr1  Type-1 regulatory T cells
Tregs  regulatory T cells
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− European Society for Organ Transplantation Congress, Geneva, Switzerland Oct 16-19,  2005
− Annual Meeting NVVI, Noordwijkerhout, The Netherlands  Dec 8-9,  2005
− Annual Meeting NTV, Zeewolde, The Netherlands   March 15-17,  2006
− World Transplant Congress, Boston, USA    July 22-27,  2006
− Annual Meeting NVVI, Noordwijkerhout, The Netherlands  Dec 7-8,   2006
− Annual Meeting NTV, Zeewolde, The Netherlands   March 28-30,  2007
− Annual Meeting Dutch Society of Nephrology, Veldhoven, The Netherlands April 3-4,   2007
− European Society for Organ Transplantation Congress, Prague, Czech Republic Sept 30-Oct 3,  2007
− Annual Meeting Department of Internal Medicine Erasmus MC, Antwerp, Belgium Jan 10-11,  2008
1NVVI, Nederlandse Vereniging voor Immunologie (Dutch Society for Immunology)
2NTV, Nederlandse Transplantatie Vereniging (Dutch Transplantation Society)
Presentations
− Overimmunosuppression after HLA-identical living-related kidney transplantation.  Oral
   Annual Meeting Dutch Society of Nephrology, 2004 (Award for best abstract of session 
   ‘Scientific Session IV’)       
− Overimmunosuppression after HLA-identical living-related kidney transplantation.  Poster
    International Transplantation Society Congress, 2004    
− Stable donor-specific reactivity during tapering of immunosuppression after HLA- Oral
    identical living-related kidney transplantation. Annual Meeting NTV, 2005  
− Stable donor-specific reactivity during tapering of immunosuppression after HLA- Oral
    identical living-related kidney transplantation. Annual Meeting Dutch 
    Society of Nephrology, 2005      
− Stable donor-specific T-cell reactivity during tapering of azathioprine after HLA- Poster
    identical living-related kidney transplantation. American Transplant Congress, 2005
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− High frequencies of donor-specific IL-10 producing cells after HLA-identical living- oral
   related kidney transplantation. European Society for Organ Transplantation 
   Congress, 2005
− Cytokine-profiles after HLA-mismatched and HLA-identical living-related kidney  poster
    transplantation. Annual Meeting NVVI, 2005     
− T-cell reactivity during monotherapy of predisone after HLA-identical living-  oral
    related kidney transplantation. Molecular Medicine day, 2006   
− T-cell reactivity during monotherapy prednisone after HLA-identical living-related  oral
    kidney transplantation. Annual Meeting NTV, 2006 (Award for best presentation 
    of session ‘Plenary session II)
− Cytokine-profiles after HLA-mismatched and HLA-identical living-related kidney  oral
    transplantation. Annual Meeting NTV, 2006
− T-cell reactivity during monotherapy prednisone after HLA-identical living-related  poster
    kidney transplantation. World Transplant Congress, 2006
− Cytokine-profiles after HLA-mismatched and HLA-identical living-related kidney  poster
    transplantation. World Transplant Congress, 2006
− T-cell reactivity during prednisone monotherapy after HLA-identical living-related  poster
    kidney transplantation. Annual Meeting NVVI, 2006
− Donor-specific T-cell reactivity during steroid monotherapy after HLA-identical living- oral
    related kidney transplantation. Annual Meeting NTV, 2007
− Donor-specific T-cell reactivity during steroid monotherapy after HLA-identical living- oral
    related kidney transplantation. Annual Meeting Dutch Society of Nephrology, 2007
− Donor-specific T-cell reactivity during steroid monotherapy after HLA-identical living- poster
    related kidney transplantation. American Transplant Congress, 2007
− T-cell reactivity in HLA-identical living-related kidney transplantation during steroid  oral
    monotherapy. European Society for Organ Transplantation Congress, 2007
− T-cell reactivity in HLA-identical living-related kidney transplantation during steroid  oral
    monotherapy. Annual Meeting Internal Medicine, 2008
− Donor-reactive T-cell responses even after HLA-identical living-related kidney   poster
    transplantation. American Transplant Congress 2008
Seminars and workshops
- ‘Winterschool’ Dutch Kidney Foundation    Jan 7-10, 2004
- Clinical Review Symposium NTV, Utrecht, the Netherlands   Nov 25, 2004
- Seminar ‘New developments in medical immunology’,    Nov 23, 2005
  Rotterdam, the Netherlands
- 10th Molecular Medicine Day, Rotterdam, the Netherlands   Febr 1, 2006
- Clinical Review Symposium NTV, Utrecht, the Netherlands   Nov 23, 2006
2. Teaching activities
Lecturing
- Lecture for PhD students/Medical Doctors (ESOT course)   Nov 29, 2004
- Lecture for PhD students/Medical Doctors (ESOT course)   Oct 30, 2006
Supervising practicals
- 1st ESOT Hands-on-Course Laboratory Techniques         Nov 29-Dec 1, 2004
- 2nd ESOT Hands-on-Course Laboratory Techniques         Oct 30-Nov 2, 2006
